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Abstract 
Dupuytren’s disease (DD) is a fibromatosis of connective tissue within the palm of the 
hands. It is characterised by progressive collagen deposition that leads to hardening and 
thickening of the connective tissue and results in permanent contraction of affected fingers. 
The aetiology of Dupuytren’s disease is so far unknown and the pathogenesis is favoured by 
ageing, genetic predisposition, mechanic trauma and possibly other risk factors. Blood and 
tissue samples of over 850 German and Swiss DD patients were collected in order to analyse 
the genetics, gene expression patterns and the in vitro behaviour of disease tissue derived 
fibroblast in 2-D and 3-D models. 
A genome wide association study (GWAS) with 565 unrelated DD patients and 1,219 
controls was performed. Data for 5,204,451 single-nucleotide polymorphisms (SNPs; 186 
cases genotyped with Affymetrix Genome-Wide Human SNP Array 6.0 and 379 cases, 1219 
controls genotyped with Axiom CEU 1 Array; data imputed with HapMap CEU reference 
panel) were analyzed for association with DD. SNP rs2290221 on chromosome 7p14, 
showed the strongest association signal with a p-value of 2.2x10
-10
 and odds ratio of 2.13. 
SNP rs2290221 is located intronic of the genes secreted frizzled-related protein 4 (SFRP4) 
and ependymin related protein 1 (zebrafish) (EPDR1).  
In addition an integrative replication study with 2,325 Dutch, English and German DD cases 
and 11,562 controls was performed. It identified nine different susceptibility loci that 
showed genome-wide significance. Six of these loci contain genes known to be involved in 
the Wnt/β-catenin signalling pathway. Again the strongest association was seen for the 7p14 
locus.  
Consistent with GWAS findings, a whole genome expression analysis with 12 DD primary 
disease tissue samples and 12 normal fascia controls revealed upregulation of the Wnt/β-
catenin signalling pathway and also changes in mitochondrial function and oxidative stress 
response in disease tissue. The Wnt signalling pathway is therefore likely to be a key player 
in the fibromatosis process observed in DD. Primary disease tissue derived fibroblasts at 
least in part retained their disease associated characteristics in vitro, they exhibited higher 
proliferation rates and generated strong contraction forces in 3-D collagen gels, and thus 
present an excellent model for investigating the mechanisms of DD in the context of aging 
and aging associated diseases. 
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Zusammenfassung 
Bei der Dupuytren´schen Erkrankung (DD) handelt es sich um eine Fibromatose des 
Bindegewebes in der Handinnenfläche und der Innenseite der Finger. Im Verlauf der 
Krankheit verhärtet und verdickt sich das Bindegewebe aufgrund progressiver 
Kollagenablagerungen. Dies führt zu einer dauerhaften Kontraktion von betroffenen Fingern. 
Die Ursache des Morbus Dupuytren ist bisher unbekannt. Der Krankheitsverlauf wird durch 
Alter, genetische Veranlagung, mechanische Traumata und möglicherweise weitere 
Risikofaktoren begünstigt. Von über 850 deutschen und Schweizer DD-Patienten wurden 
Blut und Gewebeproben gesammelt, um die Genetik, Genexpression und das In-vitro-
Verhalten von Fibroblasten in 2-D und 3-D-Modelle zu analysieren. 
In einer genomweiten Assoziations-Studie (GWAS) wurden 565 DD-Patienten und 1.219 
Kontrollen miteinander verglichen. Dabei wurden 5.204.451 genetische Marker (single-
nucleotide polymorphisms (SNPs)) untersucht. SNP rs2290221 auf Chromosom 7p14, zeigte 
das stärkste Assoziationssignal mit einem P-Wert von 2,2x10
-10
 und eine Odds Ratio von 
2,13. SNP rs2290221 befindet sich im Intron der beiden Gene secreted frizzled-related 
protein 4 (SFRP4) und ependymin related protein 1 (zebrafish) (EPDR1).   
Parallel dazu wurde eine integrative Replikations-Studie mit 2325 Niederländisch, Deutsch 
und Englisch DD Patienten und 11.562 Kontrollen durgeführt. Diese identifizierte neun 
verschiedene Loci, die mit genomweiter Signifikanz mit DD assoziierten. Sechs dieser Loci 
enthalten Gene, die im Wnt/β-catenin-Signalweg eine Rolle spielen. 
In Übereinstimmung mit den GWAS Erkenntnisse ergab eine genomeweite Expressions-
Analyse, bei der 12 DD- und 12 Kontroll-Gewebeproben miteinander verglichen wurden, 
eine Hochregulation des Wnt/β-Catenin-Signalweges in den DD Proben. Außerdem wurden 
Veränderungen in der oxydative Stressreaktion festgestellt. Der Wnt-Signalweg stellte daher 
wahrscheinlich eine wichtige Komponente im Krankheitsprozess dar. Primäre Fibroblasten, 
die aus DD Gewebe gewonnen wurden, behielten zum Teil ihre mit der Krankheit 
verbundenen Eigenschaften in vitro. Sie zeigten eine höhere Proliferationsrate und erzeugt 
starke Kontraktionskräfte in 3-D Kollagengelen. Sie stellen somit ein hervorragendes Modell 
dar für die Untersuchung der Krankheitsmechanismen im Kontext des Alterns und alters-
assoziierter Krankheiten. 
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1 Introduction 
1.1 Aging and Aging Associated Diseases 
Aging is a progressive process that leads to death. It is characterised by decline in body 
functions and loss of fertility. Aging occurs in many organisms although bacteria and some 
multicellular organisms e.g. Hydra do not age. In general all organisms with clear separation 
of soma and germline are thought to undergo aging. On the cellular level the loss of 
replicative capacity is called senescence. 
There are several theories that try to explain aging from an evolutionary point of view. 
Kirkwood and Austad (2000) argued that animals in the wild mostly die early in life of 
extrinsic hazards, e.g. infection, predation or starvation and only very few animals live long 
enough to die of old age. Consequently evolutionary aging theories explain the aging process 
not as a trait under natural selection but as a by-product of life. In the “mutation 
accumulation” theory, first developed by P.B. Medawar (1952), delirious mutations that 
affect late stages in life but have no impact on the earlier phases (e.g. reproduction) 
accumulate over generations because there is no selection against them (Martin et al. 1996, 
Kirkwood and Austad 2000, Charlesworth 2001). One human example for this may be 
Huntington’s disease, which is caused by a dominant mutation that was not selected against 
because the disease manifests only after the onset of reproduction (Partridge and Gems 
2002). The “pleiotropy” or “trade-off” theory (Williams 1957) states that a mutation with 
positive effect early in life is favoured by selection regardless of possible deleterious effects 
the same mutation has late in life if the probability of surviving to be affected is small. 
Support for this theory is thought to come from experiments with Drosophila melanogaster 
where early reproducing flies were short lived compared to late reproducing ones (Partrigde 
and Gems 2002). One consistent observation in humans was that women who lived to the 
age of 100 years were four times more likely to have had children while in their forties than 
women who survived to age 73 (Perls et al. 1997). The “disposable soma” theory (Kirkwood 
1977), is based on optimal allocation of limited metabolic resources between somatic 
maintenance and reproduction. Because metabolic resources are limited investment in e.g. 
reproduction at the expense of repair allows damage to accumulate with age (Kirkwood and 
Austad 2000). 
All these theories are based on the observation that death in wild living animals is primarily 
caused by extrinsic factors at a young age. But looking at survival curves (Kirkwood and 
Austad 2000) may only reveal part of the age-structure of populations. Another point of view 
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is offered by mortality curves. Especially in larger animals (mammals) mortality by extrinsic 
hazards is high in newborn animals and may peak again when offspring leave their parental 
care and e.g. try to establish a territory. Only individuals that live beyond this point may 
reproduce. At the same time these individuals also have a higher chance to reach old age. 
Therefore the aging process may have a larger effect on the population subgroup that 
reproduces than on the whole population itself.  
Although aging is not an ordered process under natural selection like development, it is still 
a common process that is regulated through common mechanisms in different (model) 
animals (Partrigde and Gems 2002). That is because aging is affected by common 
genetically controlled processes, reproduction and damage repair that are conserved in 
animals. Several studies from Drosophila melanogaster and Caenorhabditis elegans show 
that fecundity and lifespan are inversely connected (Sgrò and Partridge 1999, Friedman and 
Johnson 1988). In humans extrinsic hazards have been greatly reduced in developed 
countries resulting in proportionately more and older old people. Aging associated diseases 
are therefore more common forming serious health and resource (cost) issues. The arising 
interest in aging and aging associated diseases results mainly from the questions how we 
age, and how healthy aging can be achieved. To answer these questions one has to study the 
mechanisms of aging on cellular and molecular level downstream of its evolutionary origin. 
1.1.1 Free Radical Theory of Aging 
Again several theories were developed that try to explain the molecular mechanisms that 
drive the aging process. Most prominent among these is the Free Radical Theory of Aging 
(also termed Mitochondrial Free Radical Theory of Aging (MFRTA) or Oxidative Stress 
Theory of Aging (OSTA)). It states that the damage of reactive oxygen species (ROS) 
accumulates over time and that this damage to macromolecules and cells underlies the aging 
process. Since it was first proposed (Harman 1956) this theory was much discussed because 
it remains difficult to prove. Long lived species show reduced ROS production compared to 
short lived species (Sanz et al. 2010, Lambert et al. 2007, Sohal et al. 1995, Ku and Sohal 
1993), with exceptions (Andziak et al. 2005). But experimental manipulations to reduce or 
increase ROS production rather did not result in increased or reduced lifespan, respectively 
(Sanz et al. 2010, Pérez et al. 2009, and Doonan et al. 2008). Nevertheless the production of 
ROS is a complex process whose disruption in disease and aging leads to oxidative damage 
(de Magalhães and Church 2006). Other theories were developed highlighting other 
important processes that get deregulated with age and that may be associated with 
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(disrupted) ROS production. The immune system may play an important role in the aging 
process. The Immune oxidation-inflammation theory of aging tries to link oxidative damage 
in cells of the immune system to aging (De la Fuente 2008). Most age-related diseases are 
associated with a low level of chronic inflammation (De la Fuente and Miquel 2009) and the 
immune system is a source of ROS. Neutrophils, macrophages, dendritic cells and 
monocytes release ROS (oxidative burst), as part of their innate immune function towards 
different pathogens (Cannizzo et al. 2011, Cathcart 2004, Park 2003). Another line of 
argument highlights that protein aggregates accumulated in aging cells. These are removed 
by autophagy and lysosomal degradation (Terman et al. 2006). Lysosoms are especially 
sensitive to ROS and may therefore also play an important part in the aging process. The 
mechanisms of ROS function in conjunction with oxidative stress shall be discussed in 
greater detail in chapter 1.3 of this introduction. 
1.1.2 Insulin/IGF Signalling and Aging 
The best studied signalling pathway involved in aging is the Insulin signalling pathway. C. 
elegans strains with mutations in components of this pathway have extended lifespans (Ogg 
et al. 1997, Kimura et al. 1997, Kenyon et al. 1993, Friedman et al. 1988). In the worm food 
stimulates the secretion of insulin-like hormones by chemosensory neurons. These bind to 
the neuronal receptor Daf-2. Upon receptor binding intracellular signalling leads to the 
inhibition of Daf-16, a transcription factor that regulates e.g. the transcription of genes 
involved in ROS reduction (superoxide dismutase (SOD2, SOD3) and catalase) (Honda and 
Honda 1999, Murphy et al. 2003, Lee et al. 2003). In mammals there are three related 
receptors: the insulin receptor (Insr), the insulin-like growth factor 1 (Igf1) receptor and the 
insulin receptor-related receptor (Insrr). A decrease in insulin/Igf1 signalling has been shown 
to extend longevity in mice (Brown-Borg et al. 1996, Coschigano et al. 2000, Flurkey et al. 
2001). Mutations in these mice affect the activities of the multiple components of these 
signalling pathways, i.e. phosphatidylinositol-3-phosphate (PI3K), Akt and Forkhead 
proteins (FOXO) (Blüher et al. 2003; Holzenberger et al. 2003) which are also targets of the 
ROS-mediated redox pathways (Papaconstantinou 2009). 
These last findings come from research on model organisms (yeast, worm, fly, and mouse). 
Another approach to access aging mechanisms is the study of aging associated diseases. In 
the developed countries aging was proposed to be the major risk factor for diseases and 
death in humans after the age of 28 (Harman 2006). Therefore studying aging associated 
diseases is one important approach to access healthy aging in humans. 
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1.2 Dupuytren´s Disease 
Dupuytren’s disease (DD) (OMIM 126900) is one of the most common genetic disorders of 
connective tissue (CT). Patients develop non-malignant (benign) CT tumours in the palm of 
the hand and in the fingers (fibromatosis). The fibromatosis is characterised histological by 
the proliferation of fibroblasts and the massive deposition of collagen. The tumour shows an 
aggressive clinical behaviour with frequent local recurrence. 
Connective Tissue (CT) is one of the four traditional classes of tissues (the others being 
epithelial, muscle, and nervous tissue). It is found throughout the body and consists mostly 
of extracellular matrix (ECM) that can be either loosely or densely packed. Collagen is the 
main component of connective tissue in animals and also the most abundant protein in 
mammals, making up about 25% of the total protein content. There are also specialised CT 
subtypes which include cartilage, bone, blood, adipose, haematopoietic and lymphatic tissue. 
A prominent CT structure in the palm of the hand that is affected by DD is the superficial 
palmar fascia (palmar aponeurosis), which forms a thin triangular layer of connective tissue 
underlying the dermis in the palm of the hand and extending into the fingers (see figure 1 
and 2). It is attached to the undersurface of the skin above it and the bones and muscle 
coverings below it. The superficial palmar fascia acts as scaffolding which anchors palm 
skin to the bones in the hand and maintains the shape of the skin. The fascia is a normally 
unnoticeable layer, with few resident cells. In DD it thickens and contracts causing 
permanent bending of affected fingers. 
 
Figure 1. Schematic representation of three main structures of the palmar fascia. 
a. normal anatomy, b. Dupuytren’s contracture. 
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Figure 2. Cross-section of the hand. Highlighted in yellow 
is the palmar aponeurosis that partly extends into the overlying 
dermis and underlying muscle layer. 
In the early stages DD affects the bands of aponeurotic fascial fibres that run longitudinally 
in the palm (Luck 1959) (figure 1). In the course of DD first one or more small tender lumps 
form in the palm of the hand, these are called nodules. These nodules are characterised by 
high content of proliferating fibroblasts and relatively low amounts of collagen. The skin can 
become attached to the nodules and invaginated (figure 4). In the progresses of the disease 
hard cords do form along the fascial fibres. These cords consist mostly of collagen fibres and 
few proliferating fibroblasts. As cords form or extent into fingers, these get contracted 
bending permanently towards the palm. Once contracture develops, the fingers get in the 
way affecting simple everyday tasks such as face washing (poking the eye with affected 
digit), combing hair, putting the hand in a pocket or glove, driving or playing sports. 
Dupuytren's disease often develops in both hands and most commonly affects the ring 
fingers and the little fingers, followed by the index, the middle fingers and the thumbs 
(Bayat and McGrouther 2006). Contractures often span several adjacent joints. For affected 
joints, if bending one joint allows the adjacent joint to be fully straightened and vice versa, 
the contracture is referred to as a "composite contracture". If an affected joint cannot be fully 
straightened in any hand position, the result is called a "fixed contracture". The disease may 
cause deformity of the affected hand, limiting hand function and diminishing the patient’s 
quality of life (figures 3 and 4). 
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Figure 3. Clinical photograph showing the hands of two patients with advanced stage DD showing severe 
deformity. First picture (white background) from: Couto-Gonzalez et al. 2010. Second picture (green 
background) from: Howard et al. 2003. 
 
Figure 4. Photograph showing a patients hand with 
Dupuytren’s disease in digit 4. Photo: Frank C. Müller. 
Three different stages of disease tissue can be defined: proliferative, involutional and 
residual (Luck 1959). The first stage in characterised by proliferating fibroblasts in the 
nodules. Cells, rather than collagen, make up a large portion of the tissue, and the nodules 
are likely to be vascular. In the involutional stage, fibroblasts within the nodules align along 
the major lines of stress, predominately in the longitudinal axes of the hand (Luck 1959). As 
the contracture progresses, the nodules become smaller and increasingly ill-defined. In the 
residual stage, the nodules disappear, leaving a hypocellular and tendon-like fibrous cord 
(Luck 1959). The progression through these stages varies greatly in different individuals 
(Shih and Bayat 2010) from an aggressive course were the disease progresses to severe 
contraction in a few years to mild progression with no apparent change over many years. 
Nodules and cords can be found simultaneously in affected tissue from one patient. 
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1.2.1 The Myofibroblast 
The myofibroblast is the celltype thought to be responsible for the contraction on cellular 
level. Myofibroblasts differentiate from fibroblasts. Myofibroblasts differentiate after tissue 
injury. They are involved in normal wound healing and organ development (Tomasek et al. 
2002). They synthesise ECM components, remodel the ECM and exhibit great contraction 
forces responsible for wound contraction leading to wound closure (Hinz et al. 2007). 
  
  
Figure 5. Immunohistological staining of a myofibroblast. 
The actin filaments arrayed in parallel sheets (stress fibers)  
are stained in red (phalloidin), the nucleus is stained in blue  
(DAPI) and αSMA is stained in green. 40x magnification. 
Unchallenged fibroblasts exhibit few or no actin-associated cell-cell and cell-matrix contacts 
and little ECM production (Tomasek et al. 2002). After tissue injury, they become activated 
to migrate into the damaged tissue by cytokines locally released from inflammatory cells 
(Werner and Grose 2003). Macrophages and T lymphocytes have been observed in DD 
tissue (Baird et al. 1993). Fibroblasts are normally shielded from mechanical stress through 
the ECM. Disruption of the ECM in tissue injury results in mechanic stress, which also 
activates fibroblasts. In response to mechanical challenge, fibroblasts produce contractile 
stress fibres. These are composed of cytoplasmic actins (Tomasek et al. 2002). Stress fibres 
are connected to fibrous ECM proteins at sites of integrin-containing cell-matrix junctions 
(Hinz 2006) and between cells via de novo established N-cadherin-type adherents’ junctions 
(Hinz et al. 2004). Additionally differentiated myofibroblasts are defined by their de novo 
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expression of alpha smooth muscle actin (αSMA) (figure 5), which localises to stress fibres. 
In culture fibroblasts generate stress fibres when grown on normal plastic or glass surface. 
To stimulate αSMA expression fibroblast must be additionally treated with transforming 
growth factor beta 1 (TGFβ1) (Hinz 2006, Hinz et al. 2007). In vitro αSMA positive 
fibroblasts show twofold stronger contraction forces than αSMA negative fibroblasts (Hinz 
et al. 2001). At the end of tissue repair, the reconstructed ECM again takes over the 
mechanical load and myofibroblasts are released from stress and disappear by massive 
apoptosis (Tomasek et al. 2002). 
1.2.2 History and Prevalence 
DD was first described by the Swiss physician Felix Plater in 1614 and was later named after 
Baron Guillaume Dupuytren, a French physician, who in 1831 extensively lectured on the 
subject (Brenner and Rayan 2003). DD is common in the north of Europe. It is present in 
Germany (Brenner et al. 2001, Loos et al. 2006), Scandinavia (Bergenudd et al. 1993), 
Iceland (Guğmundsson et al. 2000), the UK (Gerber et al. 2011), and Ireland and has also 
been described in white populations in Northern America and Australia and in parts of 
Japan. It is rare in other populations, e. g. from Africa were only sporadic cases without 
family history are reported (Mitra and Goldstein 1994), or Asia (except Japan) (Slattery 
2010). DD is significantly more frequent in the north than in the south of France (Maravic et 
al. 2005). 
DD is a common disease. Estimative more than 2.3% of the German population are affected 
(Brenner et al. 2001). In UK the prevalence is about 4% in men and 2% in women (Early 
1962). The prevalence of DD increases with age (Hindocha et al. 2009). In Iceland it 
increased from 7.2% in men aged 46-49 years to 39.5% in men >70 years old (Guğmundsson 
et al. 2002). Patients treated surgically for DD have an increased risk for cancer and cancer 
associated death (Wilbrand et al. 2000, Guğmundsson et al. 2002). 
1.2.3 Treatment 
There are a variety of classification systems (Rayan 1998, Woodruff et al. 1998, Falter et al. 
1991, Tubiana 1986) to group disease severity. Tubiana’s system (figure 6) grades the 
contracture into one of four stages based on the combined angles of contracture of the joints 
of the finger (metacarpal phalangeal (MCP) and proximal interphalangeal (PIP)). The 
contraction degree at each finder joint is measured and classified. Classifications from each 
finger can be added for one hand resulting in a maximal value of twenty. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker - 17 - 
 
Figure 6 Tubiana's classification. It grades the contracture into one of four stages based on the combined 
angles of contracture of the MCP and PIP joints, and may be applied to both composite and fixed 
contractures: This angle is illustrated by the blue lines in this diagram. MCP: metacarpal phalangeal; 
PIP: proximal interphalangeal. From www.handcenter.org. 
There is no cure for DD so far. When disease hampers finger movement corrective surgical 
treatment becomes necessary. Roughly two different approaches are frequently applied. The 
more non-invasive method involves the cutting across tight bands of diseased fascia, letting 
the edges gape apart and heal back at or closer to their natural length to restore the area's 
original flexibility (fasciotomy). This can be done without opening the affected area, by 
inserting a small-gauge needle through the skin along the length of the cord (needle 
fasciotomy). The cord is incised, using sweeping motions. Thus the cord is weakened and 
allows an extension force over the finger to rupture it (Desai and Hentz 2011). Most 
common is the surgical removal of affected tissue (limited fasciectomy) (figure 7). This 
procedure involves careful dissection and excision of the involved diseased fascia. After 
surgery, the hand is splinted, with the MCP and PIP joints in an extended position. Short- 
and long-term effectiveness of splinting following surgery was only poorly evaluated 
(Larson and Jerosch-Herold 2008). A resent non-surgical approach is based on the injection 
of collagenases into the affected tissue in order to resolve the collagen deposits (Hurst et al. 
2009). Collagenase is injected directly into a Dupuytren cord, leading to lysis of the collagen 
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found within the diseased tissue. The patient returns the following day for joint manipulation 
in an attempt to rupture the cord (Desai and Hentz 2011). 
Postoperative complications include haematoma, skin necrosis, infection, nerve injury, 
vascular injury, prolonged oedema, reflex sympathetic dystrophy and, rarely, finger loss. The 
most common complication is postoperative joint stiffness and loss of pre-operative flexion. 
Regardless of the technique, there is a high rate of recurrence following surgical correction 
(Bayat and McGrouther 2006, Denkler 2010). For needle fasciotomy it was in the range of 
65% after 33 months (van Rijssen et al. 2006). 
 
 
    
Figure 7. A. Exposure of Dupuytren’s cord in the palm of the hand. From Rozen et al. 2012. 
1.2.4 Genetics and other Risk Factors 
DD is clearly an aging associated disease with onset from the fourth and fifth decade of life. 
A strong risk factor is male gender. Women are less severe affected and develop the disease 
later in live. In men the time of first surgical treatment peaks around the fifth decade of live 
while women mostly present for surgery approximately one decade later. 
Frequent familial occurrence of DD indicates a genetic basis for the disease. Studies have 
determined a family predisposition in 12.5% (Brenner et al. 2001) and 27% of cases (Coert 
et al. 2006). Several extended pedigrees were identified particularly in Scandinavia, pointing 
to an autosomal dominant inheritance with reduced penetrance (Burge 1999). There is one 
report so far describing a whole genome approach to identifying an underlying gene in an 
extended Swedish family (Hu et al. 2005). They found linkage to an interval on chromosome 
16 with a lod score value of 3.2, assuming 90% penetrance in family members over 45 years 
of age. Another small genome wide association study (GWAS) has been conducted with 40 
cases and 40 controls (Ojwang et al. 2010). But no candidate genes have been identified so 
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far. Reduced penetrance in several pedigrees and the large number of apparently sporadic 
cases indicate that Dupuytren disease is a complex disease in which genetic and 
environmental risk factors are involved. Several environmental factors have been proposed 
to contribute to DD development. Smoking and alcohol consumption have been associated 
with DD (e.g. Burge et al. 1997, Godtfredsen et al. 2004, Guğmundsson et al. 2000). 
Elevated blood glucose levels, low body weight, and low BMI (body mass index) have also 
been associated with DD (Guğmundsson et al. 2000). Heavy manual labour and exposure to 
vibrations probably contribute to the disease (Liss and Stock 1996, Descatha et al. 2011). 
DD is common among diabetes mellitus type 2 patients, but they may be in general less 
severe affected (Noble et al. 1984). In a study with epilepsy patients 56% had DD (Critchley 
et al. 1976). The authors proposed that this association is probably due to epileptic drug 
intake and subsequent stimulation of tissue growth factors. DD is common in patients with 
frozen shoulder, another fibrotic disorder (Smith et al. 2001). DD is rare among patients with 
rheumatoid arthritis (Arafa et al. 1984) and DD patients had less frequently stiff joints and 
rheumatic disorders (Guğmundsson et al. 1999). 
1.2.5 Social Relevance and Civic Impact 
DD is a common complex disorder. High prevalence rates result in considerable economic 
burden for treatment of this disease (Maravic et al. 2005, Gerber et al. 2011). Although DD 
is not life threatening it affects a constantly used tool, the hand. Finger contraction hampers 
already small tasks in the daily routine e.g. handshake. And patients may additionally 
experience pain in the affected hand. There is no cure for DD. High reoccurrence rates are 
observed after surgical treatment and the risk of complications is even higher at repeated 
surgery (Denkler 2010). 
1.2.6 Other related Diseases 
There are a number of clinically related conditions that occur less frequent and manifest in 
different parts of the body. Patients that present with one of these conditions often also have 
DD. In some DD patients connective tissue depots form at the dorsum of the proximal 
interphalangeal finger joints, the so called knuckle pads. In plantar fibromatosis 
(Ledderhose´s disease, LD) the sole of the feet is affected. Often the fibromatosis manifests 
in the part of the sole that is not in contact with the ground and thus does not hamper 
walking but in extreme cases the toes can contract. 
Penile contracture (Peyronie's disease, PD) is characterized by the formation of thickened 
fibrous plaques on the dorsum of the penis. Comparison of gene expression profiles indicates 
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that Dupuytren´s disease and Peyronie's disease share a common pathophysiology (Qian et 
al. 2004). PD was described as a genetic disorder with autosomal dominant inheritance (Bias 
et al. 1982). It was also linked to trauma (Carrieri et al. 1998). In this study it will be 
evaluated how many DD patients additionally suffer from these related conditions. 
1.3 Mitochondrial Dysfunction and Oxidative Stress 
In the following section recent knowledge of mitochondrial dysfunction and oxidative stress 
in the context of aging is discussed briefly. Mitochondrial dysfunction was implicated in the 
aetiologies of type 2 diabetes (Patti et al. 2003, Petersen et al. 2004, Lowell and Shulman 
2005) and age related neurodegenerative disorders (Bowling and Beal 1995), e.g. 
Alzheimer's disease (Swerdlow and Khan 2004), Parkinson's disease (Langston et al. 1983, 
Schapira et al. 1989, Bindoff et al. 1989), and Huntington's disease (e.g. Kuwert et al. 1990, 
Kim et al. 2010). 
1.3.1 Mitochondrial Dysfunction 
The main function of mitochondria is ATP production, which occurs during mitochondrial 
oxidative phosphorylation. During oxidative phosphorylation, electrons from reduced 
substrates are transferred to O2 through a chain of respiratory electron transporters including 
the complex I, III, and IV proton (H
+
) pumps, which in turn generate a proton gradient across 
the mitochondrial inner membrane. The electrochemical energy of this gradient is then used 
by the ATP synthesis (complex V) which couples H
+
 reuptake with ADP phosphorylation in 
the matrix to generate ATP (Feissner et al. 2009). Proteins of the electron transport chain are 
downregulated with aging (Ghosh et al. 2011). Electrons leak from reduced sites in the 
respiratory chain and react with oxygen to form reactive oxygen species (ROS) which play 
an important role in cell signalling, but are better known for creating oxidative stress 
(Brookes et al. 2002). In mitochondria ROS cause mutations of mitochondrial DNA 
(mtDNA) which affect the electron transport chain function triggering increased ROS 
generation and accumulation of mtDNA damage over time (Mammucari and Rizzuto 2010). 
During aging, giant non-functional mitochondria, defective in ATP production together with 
aberrant macromolecules, accumulate especially in post-mitotic organs, such as the nervous 
system and the cardiac and skeletal muscle. These are removed by autophagy, which also 
declines with aging (Bergamini et al. 2007) accelerating the accumulation of these large 
aggregates with age (Mammucari and Rizzuto 2010). 
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1.3.2 ROS Production in Mitochondria 
ROS is implied in the aetiology of a number of diseases such as diabetes (Newsholme et al. 
2007) and hypertension (Paravicini and Touyz 2006). In the mitochondrial respiratory chain, 
the transport of electrons is coupled with the formation of ROS. In particular, the redox 
reactions at respiratory complexes I and III generate superoxide (O2
•−
) (Rigoulet et al. 2011). 
Under physiologic conditions, the superoxide production is around 0.1% of the respiratory 
rate (Tahara et al. 2009). O2
•−
 in solution is short lived and rapidly converted into 
hydrogenperoxid (H2O2) e.g. by the mitochondrial superoxide dismutase (SOD2). H2O2 is 
not a free radical (one or two unpaired electrons in the outer electron orbital) and is a more-
stable molecule that is able to diffuse across biologic membranes. By the so called Fenton 
reaction H2O2 generates the highly reactive hydroxyl radicals 
•
OH and H
•
 in the presence of 
metals such as Fe, which is a co-factor of many proteins. Other proteins in mitochondria are 
able to produce ROS, e.g. dehydrogenases, a-ketoglutarate dehydrogenase complex 
(aKGDHC) and glycerol-3-phosphate dehydrogenase (GPDH) and uncoupling proteins 
(UCPs) (Tahara et al. 2009) and monoamine oxidase (MAOA) in the outer mitochondrial 
membrane (Peña-Silva et al. 2009). 
1.3.3 ROS Production at the Plasma Membrane 
Mitochondria are the main side of ROS production. Another source of ROS are cells of the 
immune system. Neutrophils, macrophages, dendritic cells and monocytes release ROS in 
response to pathogens (Cannizzo et al. 2011). ROS in these cells is generated by NADPH 
oxidases (NOXs) located in the plasma membrane. They catalyze the production of 
superoxide by the one-electron reduction of oxygen, using NADPH as the electron donor 
(Babior 1999): . 
O2
•−
 is then converted into H2O2 by the cytosolic superoxide dismutase (SOD1) (Cannizzo et 
al. 2011). The NOX gene family includes seven members. They are expressed in a variety of 
different tissues (Krause 2004). NOX4 is most widely expressed and was associated with 
transforming growth factor β (TGFβ1) induced fibroblast to myofibroblast differentiation 
(Cucoranu et al. 2005). 
1.3.4 Mitochondrial Dysfunction without enhanced ROS Production 
The Mitochondrial Free Radical Theory of Aging predicts that a normal metabolism causes 
ROS production in mitochondria. ROS cause damage to lipids, proteins, and mtDNA. ROS-
induced mtDNA mutations lead to the synthesis of functionally impaired respiratory chain 
subunits, causing respiratory chain dysfunction which in turn enhances ROS production. 
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This cycle over time promotes aging (Harman 2006) and involves an exponential increase of 
mtDNA mutations over time. But the formation of ROS in the course of normal metabolism 
does not necessarily increase significantly with age (Barja 1999). Trifunovic et al. (2005) 
used a mouse model that accumulates mtDNA mutations over time because of a defect 
mitochondrial polymerase lacking proofreading 3’-exonuclease activity (Trifunovic et al. 
2004) and found no increase in ROS and oxidative damage and at the same time severely 
impaired respiratory chain function. The authors concluded from these findings that mtDNA 
mutations rather than ROS initially drive the aging process. But absolute mutation levels 
(deletions) have been argued to be too low to drive premature aging in these mice 
(Kraytsberg et al. 2009). 
1.4 WNT/β-catenin Signalling Pathway 
Wnts are secreted glycoproteins that act as short range signals in multiple processes. They 
are expressed in spatially restricted and dynamic patterns during development (Cadigan and 
Nusse 1997) and in the adult organism (Moon et al. 2004). Wnt signalling has been 
implicated in the pathogenesis of cancer (van de Wetering et al. 2002, Giles et al. 2003, 
Uematsu et al. 2003), cardiovascular disease (van Gijn et al. 2002), and Alzheimer's disease 
(De Ferrari and Inestrosa 2000) and upregulation of Wnt signalling was associated with 
aging (Marchand et al. 2011, Brack et al. 2007, Liu et al. 2007). The Wnt protein family 
comprises 19 members in mammals which can trigger different pathways in the signal 
receiving cell (Veeman et al. 2003, Sugimura and Li 2010). One extensively studied 
pathway involves the stabilisation of β-catenin which then translocates into the nucleus and 
acts on the expression of target genes. Wnt signalling is activated during fibroblast 
proliferation (Cheon et al. 2004) and elevated levels of β-catenin were found in pulmonary 
fibrosis (Chilosi et al. 2003), aggressive fibromatosis (Cheon et al. 2002), and also in DD 
(Varallo et al. 2003). Expression profile of human lung fibroblasts treated with Wnt3a 
revealed that among genes differentially expressed in response to Wnt stimulation, where 
genes that play a role in differentiation of fibroblasts to a myofibroblast or smooth muscle 
phenotype (Klapholz-Brown et al. 2007). 
1.4.1 Wnt/β-catenin Signalling 
In the absence of Wnt, β-catenin is targeted to a multimeric protein complex called the 
destruction complex, which includes the scaffolding protein axin and the tumour suppressor 
protein adenomatous polyposis coli (Apc). β-catenin is then phosphorylated by casein kinase 
1 (Ck1, CSNK1A1) and subsequent glycogen synthase kinase 3β (Gsk3β) (Liu et al. 2002). 
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This phosphorylation targets β-catenin for ubiquitination and subsequent degradation by the 
proteasome (figure 8). In the nucleus prospective target genes of the pathway are kept in a 
repressed state by T-cell factor (Tcf) and lymphoid enhancer-binding protein (Lef) 
transcription factors and associated co-repressors (Gordon and Nusse 2006, Logan and 
Nusse 2004). 
 
Figure 8 Model for the activation of the Wnt/β-catenin pathway. (A) In the absence of a Wnt signal, β-
catenin is phosphorylated and targeted for proteasome-mediated degradation by a destruction complex 
that contains axin and Gsk3β among other proteins. (B) On binding of Wnt to the receptors Fzd and 
LRP, Dvl binds to Fzd and recruits the destruction complex through interaction with axin. Subsequently, 
Gsk3β phosphorylates critical sites on LRP, which, together with residues phosphorylated by CkIγ, act 
as docking sites for axin. (C) Binding of axin to LRP leads to inhibition of the destruction complex and 
stabilization of β-catenin. CkIγ, casein kinase Iγ; Dvl, dishevelled; Fz, Frizzled; Gsk3β, glycogen synthase 
kinase 3β. From Fuerer et al. Wnt signalling in development and disease. Max Delbrück Center for 
Molecular Medicine meeting on Wnt signalling in Development and Disease. EMBO Rep. 2008 
Feb;9(2):134-8. 
Two cell-surface receptors cooperate to transmit Wnt signals across the plasma membrane to 
activate β-catenin signalling. Wnts bind to the seven transmembran domains containing 
receptor frizzeld (Fzd 1-10) and the low density lipoprotein receptor-related protein (Lrp 5 
and 6). Ternary ligand-receptor complexes form ribosome-sized aggregates in the cell 
membrane. The binding of Wnt to Fzd/Lrp leads to the phosphorylation of Lrp6 by Gsk3β 
and Ck1 (Rao and Kühl 2010). Axin and the phosphoprotein dishevelled (Dvl) then bind to 
the cytoplasmic tails of Lrp and Fzd, respectively. The destruction complex is disrupted and 
axin is degraded. The activation of Dvl also leads to the inhibition of Gsk3β. Both effects 
increase the post-translational stability of β-catenin. As the β-catenin level rise in the 
cytoplasma, β-catenin also translocates into the nucleus, where it interacts with DNA-bound 
Tcf and Lef family members to act on the transcription of target genes (Moon et al. 2004). 
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1.4.2 Wnt Signalling: Modifications, Antagonists and Activators 
Wnts are modified before secretion by the addition of two fatty acids, palmitic acid on the 
first conserved cysteine and palmitoleic acid on a highly conserved serine residue (Willert et 
al. 2003; Takada et al. 2006). These modifications render Wnt proteins hydrophobic and 
Heparan sulfate proteoglycans (Hspgs) prevent Wnts from aggregating in the extracellular 
matrix (Fuerer et al. 2010). Members of the Hspg family were shown to act as a reservoir or 
modulator for several growth factors and signalling molecules (e.g. Bernfield et al. 1999; 
Whitelock and Iozzo 2005). Sulphated proteoglycan levels were elevated in DD primary 
tissue (Tunn et al. 1988). 
Telomerase directly modulates Wnt/β-catenin signalling by serving as a cofactor in a beta-
catenin transcriptional complex. The telomerase protein component TERT (telomerase 
reverse transcriptase) interacts with BRG1 (also called SMARCA4), a SWI/SNF-related 
chromatin remodelling protein, and activates Wnt-dependent reporters in cultured cells and 
in vivo (Park et al. 2009). 
In addition to its function in the Wnt signalling pathway, β-catenin also binds tightly to the 
cytoplasmic domain of type I cadherins and plays an essential role in the structural 
organization and function of cadherins by linking cadherins through α-catenin to the actin 
cytoskeleton (Jamora and Fuchs 2002, Gumbiner 2000). 
There are several inhibitors and activators that either inhibit or promote Wnt signalling 
extracellular. One example for an inhibitor is the family of dickkopf proteins (DKK) (Glinka 
et al. 1998). DKK1 binds to LRP5/6 and the transmembrane protein Kremen (Mao et al. 
2002). This interaction inactivates LRP5/6. R-Spondins (RSPOs) promote Wnt signalling by 
antagonizing DKK1-mediated interaction with LRP and Kremen (Kim et al. 2008). 
Sclerosteosis (SOST) and sclerostin domain containing 1 (SOSTDC1) are also secreted Wnt 
inhibitors that bind to and inactivate LRP (Semënov et al. 2005, Itasaki et al. 2003). Wnt 
inhibitory factor (WIF) proteins and secreted frizzled related proteins (SFRP1,2-5) act by 
directly binding Wnt molecules and can function as Wnt inhibitors, but may also stabilize 
Wnt's and facilitate Wnt signalling (Hsieh et al. 1999, Hoang et al. 1996). Connective-tissue 
growth factor (CTGF) modulates Wnt signalling and interacts with LRP6 (Mercurio et al. 
2004). Dapper, antagonist of beta-catenin, homolog (DACT1-3) promotes Wnt/β-catenin 
signalling by binding intracellulary to Dvl (Gloy et al. 2002). 
In colorectal cancer Wnt/β-catenin is commonly dysregulated in colorectal cancer (Pálmer et 
al. 2001). Vitamin D acts protective against colorectal cancer (Garland et al. 1989).The most 
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active vitamin D metabolite, 1alpha,25-dihydroxyvitamin D3 (D3) inhibits β-catenin 
transcriptional activity by promoting vitamin D receptor (VDR) binding to β-catenin and the 
induction of E-cadherin expression. Vitamin D3 has been shown to regulate two genes 
encoding the extracellular Wnt inhibitors DKK-1 and DKK-4. By an indirect transcriptional 
mechanism, D3 increases the expression of DKK-1 RNA and protein, which acts as a tumour 
suppressor in human colon cancer cells harbouring endogenous mutations in the Wnt/beta-
catenin pathway (González-Sancho et al. 2005). In contrast, vitamin D3 represses DKK-4 
transcription by inducing direct VDR binding to its promoter. DKK-4 is a target of the 
Wnt/β-catenin pathway and is up-regulated in colorectal tumours (Pendás-Franco et al. 
2008). Several vitamin D target genes have been characterized including tenascin-C, 
fibronectin, laminin and its receptor, apolipoprotein D, insulin-like growth factor binding 
protein 3, cyclin C, and several members of the transforming growth factor family and their 
receptors (Freedman, 1999). 
Mice overexpressing SFRP4, aWnt inhibitor had significant higher serum and urine levels of 
vitamin D (Cho et al. 2010). The connection between Wnt/β-catenin signalling and viamin D 
signalling could be causative for the observed north-south decrease in the prevalence of DD. 
1.4.3 Wnt/β-catenin Signalling and Aging 
Wnt/β-catenin signalling is increased and leads to an enhanced fibrosis in aging muscle 
(Brack et al. 2007). During aging the regenerative potential of muscle declines (Goldspink et 
al. 1994). Muscle tissue is replaced by fibrous connective tissue and adipose tissue. Brack et 
al. (2007) examined muscle tissue and cells derived from muscles of young (~6-month-old) 
and aged (~24-month old) mice. Axin2 (target of Wnt/β-catenin signalling) transcript levels 
were increased in aged muscle and a progressive increase in Wnt signalling in myogenic 
cells during aging with an increase in β-catenin and decrease of GSK3β was noted. Increased 
β-catenin was also found in aged muscle tissue in response to injury compared with young 
tissue. The injection of Wnt3A into young muscle after injury resulted in increased 
connective tissue deposition phenotypically similar to regenerating aged muscle. Exogenous 
Wnt also reduced cellular proliferation in young regenerating muscles. Reduced fibrosis was 
seen in aged muscle after the injection of Wnt inhibitors (DKK1 and SFRP3). The authors 
concluded that the fibrotic aging phenotype in muscle is promoted by Wnt’s (or Wnt-like 
proteins) present in the aging serum (Brack et al. 2007). 
Liu et al. (2007) determined reduced number of stem cells in the klotho mouse, a model for 
accelerated aging (Kuro-o et al. 1997) that lacks klotho, a secreted protein found to decline 
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in the serum of mouse and human during aging (Xiao et al. 2004). Liu et al. noted that 
klotho and Wnt were co-expressed in transfected cells. They showed by 
immunoprecipitation that klotho binds to Wnt3A, Wnt1, Wnt4 and Wnt5A. In their cell-
culture model klotho inhibited Wnt-signalling and the mouse model lacking klotho 
expression had enhanced expression of Wnt target genes (Axin2). In cultured fibroblasts 
(mouse embryonic and human) continuous exposure to Wnt3A first increased proliferation 
(BrdU incorporation) but over time proliferation decreased while the level of apoptosis was 
not increased. The authors concluded that chronic Wnt stimulation may contribute to stem 
cell depletion and aging. 
Marchand et al. (2011) compared the expression profiles of middle old (43-60 years, N = 8) 
and older patients (75-83 years, N = 7) in mammary artery media and found target genes of 
the Wnt/β-catenin signalling pathway upregulated in the older group (e.g. SPP1, WISP1, 
versican and IGFBP2). Β-catenin mRNA was not significantly upregulated but β-catenin 
phosphorylation at serine 675 was significantly increased in the older group. This 
phosphorylation induces β-catenin nuclear localization and transcriptional activity, 
suggesting that β-catenin is activated during aging. Cyclin D2 mRNA and protein levels 
were unchanged as were mRNA levels of catalase and SOD2. Wnt3A treatment of vascular 
smooth muscle cells (VSMC) from old rats (8 month old) did not induce proliferation and 
cyclin D1 expression as it did in VSMCs derived from young rats (6 weeks old) while β-
catenin was activated in young and old cells. The authors concluded that β-catenin pathway 
is activated during human vascular aging but that the proliferative response to Wnt is altered 
downstream of β-catenin activation (Marchand et al. 2011). 
Together these findings hint that Wnt/β-catenin signalling plays an important role during 
aging and that its function in aged tissue differs from that of young tissue. 
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1.5 Objectives and Hypotheses 
Dupuytren´s disease is a complex disease with a strong genetic basis. The aim of this study 
was to identify loci in the human genome that are associated with Dupuytren´s disease. 
Therefore a genome wide association study (GWAS) was conducted with a case control 
study design. This study design should allow for the identification of some of the genetic 
factors that promote pathogenesis. Because DD is a complex genetic disease several genetic 
loci are expected to be associated, each contributing in small part to the susceptibility of this 
disease. 
Expression profiles of primary tissue and tissue derived fibroblasts differ between DD 
patients and matched controls (Pan et al. 2002, Qian et al. 2004, Rehman et al. 2008, Satish 
et al. 2008, Zang et al. 2008). A range of genes identified from these studies were proposed 
to play a causative role in the pathogenesis of DD. But no signalling pathways have been 
attributed to DD so far. A whole genome expression analysis was conducted in order to 
identify major signalling pathways involved in DD pathogenesis. Results from this 
experiment may possibly support and confirm findings from the GWAS. As DD is an aging 
associated disease identified pathways may lead to the identification of links between DD 
and aging. 
DD fibroblasts in vivo are characterised by high proliferative and contractile activity. 
Disease tissue derived primary fibroblasts were cultured and characterised in comparison to 
control tissue derived fibroblasts. These experiments should help to establish and 
characterise a simple in vitro model, desirable to test hypotheses from the GWAS in the 
future. 
A questionnaire based elevation of known risk factors and other parameters was conducted 
in order to characterise DD patients sampled for DNA and disease tissue epidemiologically.  
Integration of data from all these approaches should help to pave the way to a 
comprehensive understanding of the molecular pathology of this poorly understood aging-
related disease. 
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2 Materials and Methods 
2.1 Sample Collection, Storage and Handling 
2.1.1 Subjects 
Between 2007 and 2011 760 DD patients were recruited through the outpatient clinics of the 
plastic surgery departments of nine hospitals in Germany and one in Switzerland. 
Additionally a number of patients were recruited through the German Dupuytren Society 
(Dupuytren e.V.). 
Genotype data from 1618 German controls were already available, 1164 of these were part 
of the Popgen study (University of Kiel, Germany) (project number: BSP+SPC/110217/83), 
and 454 were from KORA (Helmholtz Center Munich, Neuherberg, Germany) (project 
number: K26/11). These samples were genotyped with the Affymetrix 6.0 chip. In addition 
genotype data for 1219 Popgen controls that were typed on the Affymetrix Axiom 2.0 chip 
was also available. Participants provided written informed consent and the study was 
approved by the Ethics Committee of the MathNat Faculty of the University of Cologne. 282 
control DNAs with European background were provided by the University of Essen. 
2.1.2 Questionnaire 
For each participant a one-sided questionnaire was completed by the attending physician. 
The recorded parameters are given in Table 1. The questionnaire was changed twice during 
the study, when minor adjustments or additional questions became eligible. All versions of 
the questionnaire are listed in figures 68-70 of the appendix. A separate questionnaire was 
used for control individuals, which is also given in the appendix. 
Table 1. Parameters enquired in questionnaire survey for DD patients 
parameter factors 
name  
date of birth  
gender male, female 
age at first surgery  
affected hand right, left, both 
degree after Tubiana 0, 1, 2, 3, 4 
recurrence recurrence, extension 
preceding complications trauma, sudeck dystrophy 
ectopic manifestations e.g. knuckle pads, plantar fibromatosis 
affected family members no, yes, who 
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Table 1 continued:  
  
parameter factors 
other diseases  diabetes mellitus, rheumatoid arthritis, epilepsy, other 
medication antiarrhythmia, antihypertensive, antiepileptic drugs, other 
for women:  
age at menopause  
hormone intake yes, no 
ovarian surgery yes, no 
profession  
smoking habits 0, <5, <20, >20 cigarettes per day 
year subject stopped smoking  
alcohol intake never, occasional, regular 
 
The age at first surgery is likely to reflect a combination of the age of onset and progression 
of disease. Both, patients with an early age of onset or an aggressive course of disease will 
potentially present earlier for surgery than patients who are affected late in life or are mildly 
affected. The age at first surgery was therefore selected as a variable to compare different 
patient subgroups. Two tailed student´s t-test was applied to test whether groups differed 
significantly in their ages at first surgery. Statistical analyses were done with excel. 
Associations were considered significant if the p-value was <0.05. 
2.2 DNA Extraction 
DNA was extracted for 565 patients from either whole blood samples or primary fibroblasts. 
2.2.1 DNA Extraction from Blood 
For DNA extraction peripheral blood was sampled in EDTA containing S-Monovette tubes 
(Sarstedt, Nümbrecht, Germany). Samples contained 2 to 10ml of whole blood. Blood 
samples were shipped at room temperature and frozen upon arrival at -20°C (short term 
storage) or -80°C (long time storage). 
A number of 12 to 24 samples were extracted simultaneously. For extraction the frozen 
blood sample was thawed at room temperature. The thawed sample was transferred to a 
50ml falcon tube (BD Bioscience, USA). Possible blood clots were solved by adding 500µl 
Proteinase K (10mg/ml) and 10 minutes incubation at room temperature. Blood volume was 
then recorded and four times the volume of cell lysis buffer (solution A: 0.01mol/l Tris, 
0.005mol/l MgCl2, 0.32mol/l saccharose, 1% Triton X 100; pH 8) was added. The sample 
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was incubated for 10 min at room temperature on a Stuart table tube roller (Bibby Scientific 
Limited, UK). The sample was then centrifuged at 2500rpm and 4°C for 10 minutes 
(Megafuge, rotor 8155). Subsequently the supernatant was carefully decanted without losing 
the cell nucleus pellet at the bottom of the tube. 
Then 2ml solution B (0.4mol/l Tris, 0.15mol/l NaCl, 1%SDS, 0.06mol/l EDTA; pH 8) was 
added and transferred with the pellet to a 15ml falcon tube. The sample was vortexed briefly 
for a few seconds then incubated at room temperature on the tube roller till the pellet was 
completely resolved. After that 500µl of solution C (5mol/l perchlorate) was added to the 
sample. The tube was inverted ten times and spun down briefly to collect the liquid at the 
bottom of the tube. 2ml of cold (4°C) chloroform was added and the sample mixed by 
shaking the tube. The sample was then spun at 4°C for 10 minutes. Phase separation resulted 
in upper aqueous layer containing the DNA and lower whitish phase containing halogen and 
coagulated proteins. The upper phase was transferred to new 15ml tube. Again a volume of 
500µl solution C or less was added and mixed with the sample followed by the addition of 
2ml chloroform and centrifugation as before. After centrifugation the upper phase was again 
collected in a fresh 15ml tube. If the upper phase was clear the sample was further processed, 
if not solution C and chloroform were added for a third time. As soon as the DNA containing 
phase was clear of proteins an equal amount of icecold isopropanol was added to the sample 
to precipitated the DNA. The tube was inverted slowly ten times till white strands of DNA 
were visible. The DNA coil was fished with a glass rod and transferred to a 1.5ml tube 
containing 1ml of 99% ethanol. The DNA was pelleted at 13000rpm in a refrigerable table 
microcentrifuge for 10 min at +4°C the ethanol was decanted and the DNA pellet air dried. 
When the pellet was dry 500µl of DNase free water were added to the sample and the DNA 
was resolved for days on a tube roller at 4°C. The solved DNA sample was stored at -20°C 
till further processing. 
2.2.2 DNA Extraction from primary Fibroblasts 
In some cases, where no blood sample existed, DNA was extracted from primary patient 
fibroblasts. Fibroblasts were cultured in 225cm
2
 cell culture flasks. Upon reaching 
confluence cells were harvested as described below (see chapter: Cell culture). The samples 
were centrifuged to pellet cells and the supernatant was aspirated. 
The cell pellets were stored at -20°C till further processing. To isolated DNA cell pellets 
were lysed in 1ml solution B (0.4mol/l Tris, 0.15mol/l NaCl, 1%SDS, 0.06mol/l EDTA; pH 
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8) and DNA was extracted as described above (see chapter: DNA extraction from blood). 
Extracted DNA was dissolved in DNase free water and stored at 4°C. 
2.2.3 DNA Quality control and Quantification 
1 to 10 dilutions of the DNA stocks were made. DNA dilutions were analysed with a ND-
1000 Spectrophotometer (Wilmington, USA). 1.5µl of well mixed DNA dilutions were 
loaded onto the ND-1000 Spectrophotometer. DNA light absorbance at 260nm and 280nm 
was measured trice for every sample and DNA concentration and purity were calculated 
directly by the provided software. 
2.3 Whole Genome Association Study 
Completion of the sequencing of the human genome in 2001 (Venter et al. 2001, Lander et 
al. 2001) and the International HapMap Project (International HapMap Consortium 2003 and 
2005), a catalogue of common genetic variants in humans, resulted in crucial insights into 
human genetic diversity (Hakonarson and Grant 2011). Genetic variants that are near each 
other tend to be inherited together. They are in linkage disequilibrium with each other. 
Individuals who carry a particular allele at one site often predictably carry specific alleles at 
other nearby variant sites. It is therefore possible to infer genotypes of genetic variants 
through linkage disequilibrium without genotyping them directly. The HapMap project aims 
to identify a set of common genetic variants (minor allele frequency (MAF) ≥ 5%) with 
which the other common variants can be inferred. 
Together with advances in single-base extension biochemistry and hybridization/detection to 
synthetic oligonucleotides these insights have made it possible to accurately and cost 
effectively genotype hundreds of thousands of single nucleotide polymorphisms (SNPs) 
(Steemers et al. 2006). 
In the first step genomic DNA is fragmented and amplified. Fragmentation can be 
accomplished for example with digestion enzymes or mechanically. Adapters are annealed to 
the fragments. The adapters function as primer binding sites for whole-genome amplification 
(WGA) which generates sufficient DNA for subsequent hybridization to the array chip. 
Amplified DNA is again fragmented ( 300–600 base pairs) and resuspended at low-
picomolar target concentration to drive hybridization to the array. The array contains beads 
that each carries copies of allele-specific oligonucleotides for one SNP. As the DNA 
fragments hybridise to the array the oligonucleotids bind to a 50bp sequence directly 
adjacent to the SNP. After hybridisation the oligo-probes are extended with labelled 
ddNTPs. Dependent on the present allele a different label is incorporated. Signals from 
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different labels are then amplified and captured with a bead array reader (Gunderson et al. 
2005, Steemers et al. 2006). 
2.3.1 DNA Sample Preparation for Affymetrix Chips 
DNAs with concentrations above 50ng/µl were transferred to 96-well plates, subsequent 
called mother plates. Mother plates were normalised to 50ng/µl with a Microlab starlet robot 
(Hamilton, Bonaduz, Switzerland). 100ng of each DNA sample was loaded onto 2% agarose 
gels to check for DNA integrity. 
2.3.2 Affymetrix 6.0 Chip 
In this study 186 patient DNA samples were analysed with the Genome-Wide Human SNP 
Array 6.0 (Affymetrix UK Ltd, UK), which features 1.8 million genetic markers, including 
more than 906,600 single nucleotide polymorphisms (SNPs) and more than 946,000 probes 
for the detection of copy number variation. Affymetrix’ GeneChip™ technology applies a 
combination of photolithography and combinatorial chemistry to directly synthesise 
oligonucleotides on a glass surface. Up to 6.5 million different oligonucleotides are 
synthesised on a 1.7 cm² surface. DNA samples (200–500ng) were processed and hybridized 
according to the manufacturer’s instructions by ATLAS Biolabs GmbH, Berlin. Data was 
then processed and analyzed by Prof. Dr. Michael Nothnagel, Christian-Albrechts 
University, Institute of Medical Informatics and Statistics, Kiel.  
2.3.3 Axiom CEU 1 Chip 
379 additional samples were genotyped with the Axiom Genome-Wide CEU 1 Array Plate 
which features more than 587,000 SNPs and 11,000 single base insertions/deletions (in/dels). 
SNP content and insertions/deletions (in/dels) for the Axiom™ Genome-Wide CEU 1 Array 
were selected from the Axiom Genomic Database. These validated markers were derived 
from various public sources, including the International HapMap Project (~464,000 SNPs), 
the Single Nucleotide Polymorphism Database (dbSNP), and 1000 Genomes Project content 
already in dbSNP (~122,000 SNPs and in/dels). 
The Axiom genotyping platform is a two color, ligation-based assay utilizing 30-mer 
oligonucleotide probes synthesized in situ on a microarray substrate, with automated, 
parallel processing of 96 samples per plate. Features are 3μm squares, at a pitch of 5μm 
center-to-center, with a total of ~ 1.38 million features available for experimental content. 
Each SNP feature contains a unique oligonucleotide sequence complementary to the 
genomic sequence flanking the SNP site on either the forward or reverse strand. Solution 
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probes bearing attachment sites for one of two dyes, depending on the 3' (SNP-site) base (A 
or T, versus C or G) hybridize to the glass probe/target complex, and are then ligated for 
specificity. Features are typically replicated twice on the array, so that each SNP is 
interrogated by two features; A/T and C/G SNPs require four features, because the two 
alleles match the same dye and therefore distinct probe sequences in different physical 
locations on the array are required to distinguish them. A maximum of ~ 690,000 SNPs may 
be accommodated by this format; this number is reduced if A/T or C/G SNPs are included, 
or if additional features are used to improve the resolution of specific SNPs, but may also be 
increased if high resolution SNPs are tiled with a single feature. The platform can be 
leveraged for designing arrays at previously unattainable levels of SNP density with respect 
to customization of variant selection. 
Sample preparation 
DNA samples were brought onto 96-well plates (mother plates) as described above. Plates 
were then normalized to 15ng/µl. 5µl were of each normalized sample was loaded onto 1% 
agarose gels (E-Gel® 48 1% Life Technologies) and run in EG mode on E-base devices 
(Life Technologies) for 12 minutes. Thus DNA integrity was visualized. Only samples with 
a distinct band directly below the gel pocket, which constitutes intact genomic DNA were 
used for whole genome genotyping (see figure 9 for an example). Degraded DNA samples 
were replaced. Four 96-well plates with 94 Dupuytren Patient DNA samples each were 
prepared. In addition each of the four plates contained a reference DNA sample (Axiom 
Reference Genomic DNA 103). 
 
Figure 9. Gel image of DNA samples for whole genome genotyping. 
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Axiom Genotyping 
20ul (~300ng) per sample were brought onto 96-deep-well plates (Beckman Deep Well 
Titer, polypropylene; P/N 267007). The Affymetrix Axiom version 2.0 assay was preformed 
as described in the user manual. The protocol consists of the following steps: 1. Whole 
genome amplification, 2. Fragmentation, 3. Resuspension and quality control step, 4. 
Hybridisation, staining and detection. All pipetting steps in the first three steps were carried 
out with Biomek FX robot (Beckman Coulter). Hybridisation and subsequent washing, 
staining and detection steps were carried out with the GeneTitan instrument (Affymetrix UK 
Ltd, United Kingdom). 
1. Whole Genome Amplification 
All reagents (Denaturation Solution, Neutralizing Solution, Amplification Solution and 
water) were thawed on the benchtop at room temperature for one hour. The 10x 
Denaturation solution was diluted with water and 20µl of the dilution were transferred to the 
sample. Genomic DNA samples were denatured 37°C for 10 min. 130µl of neutralizing 
solution was then added to each well. The amplification master mix was prepared from 
amplification solution and enzyme mix and 230µl of the mastermix were pipetted onto each 
sample. The samples were then incubated for 23±1 hours in an oven at 37°C. 
2. Fragmentation 
Enzymatic fragmentation was carried out. Axiom Frag Enzyme, Axiom 10X Frag Buffer, 
Axiom Precip Soln 1 and 2, Axiom Frag Diluent, Axiom Frag Rxn Stop solution and 
Isopropanol (99.5%) were used in this step. Axiom 10X Frag Buffer and Axiom Precip Soln 
2 were thawed to room temperature on the benchtop. In order to inactivate the amplification 
enzymes the sample plate was incubated at 65°C and then at 45°C for 20 min each. Then 
47.5µl of fragmentation buffer was added to the sample. Fragmentation enzymes and 
Fragmentation diluent was mixed and 11.3µl of the mixture added to each sample. The 
sample was then incubated for 30 min at 40°C. Then 19µl of stop solution were added to the 
sample. The precipitation solutions were mixed and 240µl of the solution and 600µl of 
isopropanol were added to the sample. The fragmented DNA was precipitated over night at -
20°C. 
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3. Resuspension and hybridization preparation and quality control 
On the following day the sample plate was centrifuged for 40 min at 4 °C at 3200xg in order 
to pellet the DNA. The plate was then inverted to remove the liquid and placed upside down 
on a tissue for 5 min. the plate was then dried in an oven at 37°C for 20 min. Axiom Hyb 
Buffer, Axiom Hyb Soln 1, Axiom Resusp Buffer and Axiom Hyb Soln 2 were used in the 
next step. The resuspension buffer was placed on the benchtop at room temperature for one 
hour prior to usage. 35µl of resuspension buffer was added to the sample and the sample was 
mixed by pipetting up and down. The hybridization mastermix was prepared from 
hybridization buffer and hybridization solutions 1 and 2. 80µl of the hybrisation mastermix 
was added to the sample. 115µl of the sample hybridization mixture were then transferred 
onto the hybridization reaction plate. The sample was diluted 1:5 by pipetting 5µl of sample 
in a plate with 55µl water. The diluted sample was the diluted further by adding 10µl of 
diluted sample to 90µl of water for optical density (OD) measurement of sample DNA 
concentration. Additionally 3µl of diluted sample were mixed with 120µl of TrackIt Gel 
Loading Buffer (diluted 1000-fold) in the gel QC plate. 
Quality control was then preformed. 4% agarose gels (E-Gel® 48 1% Life Technologies) 
were run in EG mode on E-base devices (Life Technologies). 20µl of sample from the gel 
QC plate and 15µl of diluted TrackIt 25bp ladder were loaded onto the gel. The gel picture 
was taken after 20 min. For an example see figure 10. Fragmentation should result in DNA 
fragments of 25 to 125 base pairs. 
                    
                       Figure 10. Gel image example of 48 fragmented samples. 
125bp 
25bp 
125bp 
25bp 
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For OD measurement at 260, 280 and 320nm a DTX 880 Multimode Detector with Genomic 
Filter Slide (Beckman Coulter) was employed. DNA concentrations were calculated by the 
provided software. Total sample concentrations should range between 1000 and 1600µg. 
4. Preparation for the GeneTitan Instrument Hybridisation, Staining and Scanning 
The hybridisation plate is covered with a metallic lid. The sample is then incubated in a 
thermal cycler (PTC200) at 95°C for 10 min and then at 48°C for 3 min to denature the 
samples. 105µl of the samples is then transferred to the hybridisation tray and loaded onto 
the GeneTitan instrument. The array plate is simultaneous loaded. Hybridisation lasts 23.5 
hours. 
On the following day the washing and staining solutions for the washing and staining of the 
hybridised array are prepared with the biomek instrument. Five different 96-well plates are 
prepared. One contains stabilising solution, two plates contain stain 1, one plate contains 
stain 2 and one plate contains ligate solution. All five plates are loaded onto the GeneTitan 
instrument after hybridisation. The samples on arrays are then ligated, washed, stained and 
stabilized during 5 hours. After this the array is scanned by the GeneTitan instrument during 
7.5 hours. The data is then imported into the Genotyping Console software (Affymetrix). 
Dish quality control (QC) and Genotype calling 
The Genotyping Console software (Affimetrix) software was used to perform dish QC and 
for subsequent genotype calling. Before performing genotyping analysis on any samples, the 
quality of each individual sample should be determined. Dish QC (DQC) is the 
recommended sample quality QC metric for the Axiom™ Arrays. DQC operates by 
measuring signal at a collection of non-polymorphic sites in the genome (i.e., sites that do 
not vary in sequence from one individual to the next). DQC monitors non-polymorphic 
locations where it is known which of the two channels in the assay represents the allele 
present in the genome; therefore, which channel should have a signal intensity above the 
background signal, and which channel’s signal should be indistinguishable from the 
background are known. DQC is a measure of the extent to which the distribution of signal 
values for the two channels are separated from the signal values for the background, with 0 
indicating no separation and 1 indicating perfect separation. Samples with a DQC value less 
than the default DQC threshold of 0.82 were dropped from the study. 
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DQC is a useful single-sample performance metric, and under normal circumstances it 
correlates well with genotyping performance. One exception to these circumstances is the 
case of sample mixing―a sample consisting of different individuals mixed together can still 
have a good DQC score since the signals at non-polymorphic locations will remain the same 
in a mixture. Such samples can generally be identified by having the combination of good 
DQC values and abnormally low sample call rates. No such samples were found. 
With the GTC software Dish QC was preformed per plate and the genotypes were called for 
all four patient and 13 control plates (Popgen controls genotyped on the same platform) 
together with the algorithm AxiomGT1: Axiom 2.0. The confidence threshold was set to 
0.15. The prior models file Axiom_GW_Hu_SNP.r4.AxiomGT1.models was used. Genotype 
data was then exported to PLINK format (Purcell et al. 2007). 
Data analysis 
Data analysis was conducted with the PLINK software package (version 1.07; 
http://pngu.mgh.harvard.edu/purcell/plink/) following protocols by Anderson et al. (2010) 
and Clarke et al. (2011). Data files were recoded in binary file format. Sex was imputed 
from the X chromosome genotypes with the “--impute-sex” option and checked against 
recorded gender information from the questionnaires. (This reference check was done in 
cases only.) 51 individuals with call rates below 97% were removed. Of these 7 were cases. 
For the remaining individuals the mean heterozygosity rate was calculated in order to 
identify samples with an excessive or reduced proportion of heterozygote genotypes, which 
may be indicative of DNA sample contamination or inbreeding, respectively. 10 samples 
were removed that had a heterozygosity rate greater than ± 3 standard derivations from the 
mean (see figure 11). Three duplicated control samples and two related cases were also 
excluded. For the remaining 359 cases and 1173 controls SNP quality control was 
preformed. 587,299 SNPs and small in/dels were genotyped. All markers with call rates of 
less than 97%, a minor-allele frequency of less than 0.01, or a deviation from Hardy-
Weinberg equilibrium (P>0.00001) were excluded. 
Multidimensional scaling analysis was conducted to identify genetic differences in cases and 
controls, as cases originated from different locations in Germany and Switzerland while all 
controls came from the north of Germany. The allele frequencies between cases and controls 
were compared with the use of a basic chi-square allelic test with 1 degree of freedom and 
the overdispersion factor of association test statistic (genomic control inflation factor, λgc; 
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Devlin and Roeder1999) was calculated with the use of observed versus expected values for 
all SNPs. In order to correct for population stratification association testing was conducted 
with logistic regression and the first four covariates. 
 
Figure 11. Genotype failure rate versus heterozygosity across all individuals genotyped with Axiom. 
N=1590 
 
Figure 12. Genotype failure rate versus heterozygosity across individuals with genotype call rates >97% 
and and/or a heterozygosity rate ± 3 s.d. from the mean. N=1559 
2.3.4 Imputation 
The data from 186 cases genotyped on the Affymetrix 6.0 chip and 379 cases and 1219 
controls genotyped on the Axiom genotyping platform were imputed with the Beagle v.3.3.2 
software (Browning and Browning 2009) using the HapMap Phase3 reference panel 
(including 180 Utah residents with Northern and Western European ancestry from the CEPH 
collection (CEU) genotyped for about 3.1 million SNPs) (The International HapMap 
Consortium 2010). Imputation was done by Prof. Dr. Michael Nothnagel and Dr. Sabine 
Siegert, Christian-Albrechts University, Institute of Medical Informatics and Statistics, Kiel. 
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5,204,451 SNPs were included in the subsequent association test with a Bonferroni level of 
9.6E-09 and an imputations score (Beagle’s r2) of >0.8. Data was adjusted for the first six 
components (covariates) of a multidimensional scaling (MDS) analysis in order to correct for 
genomic inflation (also see chapter 2.3.3).  
2.3.5 SNPstream Genotyping 
The Genome Lap SNPstream 48-plex Genotyping System (Beckman Coulter GmbH, 
Germany) was used to genotype selected SNPs in replication and verification of GWA 
results. The SNPstream Genotyping System is based on single nucleotide primer extension, 
where the 3’-ends of tagged extension primers are complementary to the sequence strictly 
adjacent to the SNP site (Denomme and Van Oene 2005). The extension primer binds to the 
afore amplified sequence and one of two different fluorescent labelled dideoxynucleotides is 
added to the primer sequence depending on which SNP allele is present in the sequence. The 
tagged extension primers can be directed toward a specific location in each well (containing 
a 4 x 4 oligonucleotide array) of the 384 SNPware plate, because of the presence of a tag at 
the 5’-terminus of the extension primer, complementary to the arrayed oligonucleotides. In a 
multiplex reaction 465 new patient samples and 282 controls (provided through the 
University of Essen) were analysed for 48 SNPs. 
The annotation of each SNP and its frequency in populations of European ancestry were 
assessed in dbSNP NCBI and ENSEMBL (http://www.ensembl.org/index.html) databases. 
Tagged SNPs were used when SNPs proofed incompatible with either primer panel. The 
liquid handling in all the reaction protocols was done with Biomek FX Workstation 
(Beckman Coulter, GmbH, Germany). 48 PCR primer pairs and 48 extension primers were 
designed with the online software of Beckman&Coulter (www.autoprimer.com). PCR 
primers were designed to amplify a short sequence (90–175bp) surrounding the polymorphic 
site for each SNP of interest. The single-strand tagged extension primers were designed to be 
complementary to a 30 nucleotide sequence flanking the SNP site. 
Multiplex PCR reaction and clean up 
Multiplex PCR was performed in a GeneAmp 9700 thermocycler (Applied Biosystems 
GmbH, Germany) according to the recommended PCR conditions: one denaturation cycle at 
94°C for 1min, 40 cycles with denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and 
extension at 72°C for 1 min, followed by cooling the reaction to 4°C. The reaction was 
performed in a final volume of 5µl with 6ng genomic DNA, 75µM dNTP mix, 50nM primer 
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pool, 5mM MgCl2, and 1U AmpliTaq Gold polymerase (Applied Biosystems GmbH, 
Germany) in water. PCR products were purified by Exo-Sap reaction (0.67U exonuclease I 
and 0.33U shrimp alkaline phosphatase in 3µl added to the 5µl PCP product), performed in a 
GeneAmp 9700 thermocycler to degrade unincorporated PCR primers and dNTPs, following 
the recommended conditions: first step at 37°C for 30 min and final incubation at 96°C for 
10 min. 
Primer extension reaction 
After SBE Clean-Up PCR products were divided to two 384 well plates by transferring 4μl 
of the original plate to a new 384 well plate. Extension protocol was performed using an 
appropriate mix containing TAMRA and Bodipy-fluorescein labelled dideoxynucleotides 
(ddNTPs) and a pool of allele-specific tagged extension primers. One of the 384 well plates 
was used for the TCAG primer extension reaction, whereas the other plate was used for the 
CGAT primer extension reaction. This separation is necessary because only two instead of 
four fluorescent dyes are used to label the four different dideoxynucleotides (ddNTPs). E.g. 
in the TCAG reaction SNPs with the allele combination T/C, A/G, and T/G can be 
distinguished because T and A are labelled with one dye and C and G with the other. For this 
reaction the extension primer panel includes only primer that bind to SNPs sequences with 
either T/C, A/G, or T/G allele combinations. The extension reaction was performed in a 
GeneAmp 9700 thermocycler according to the recommended extension conditions with a 
cycle at 96°C for 3 min, 60 cycles with a first step at 94°C for 20 sec and a second step at 
40°C for 11 sec, and final hold at 4°C. The reaction was performed in a final volume of 7.5µl 
with 1.50µl water, 1.88µl Extension Mix Diluent, 0.04µl each of the two extension mixes 
(containing the dye-labelled dideoxynucleotides) for each reaction (TC and AG for TCAG 
primer extension reaction, CG and AT for the CGAT primer extension reaction), 0.01µl of 
SNPware primer panel 1 (and 2 for the other reaction), and 0.01µl of DNA polymerase. 
Hybridisation 
After the primer extension the two reaction plates were pooled together again. 7μl 
Hybridization Solution were added into each well of one of the primer extension reaction 
plates, mixed and everything was transferred onto the second primer extension reaction 
plate. 16μl from each well of the pooled plate was then transferred to a prewashed SNPware 
plate. The SNPware plate with the hybridization mix was incubated at 42°C for 2 h in a 
humid chamber. Thereafter, the SNPware plate was washed three times, adding 1 x SNPware 
Wash Buffer II to each well to remove the probes not arrayed. The SNPware plate was 
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placed face down on a soft tissue in a centrifuge and spun for 2 min at 1.500 rpm to dry the 
plate. 
Data analysis 
The SNPware plate was analyzed with the GenomeLab SNPStream array imager. Blue and 
green lasers (488 and 532 nm, respectively) detected the fluorescent colour of the extended 
base for each spot. Genotype data were generated on the basis of the relative fluorescent 
intensities for each SNP with the GetGenos software. The software converted the numbers 
and sample position data into scatter plots which were then automatically separated into 
statistical genotype clusters. Graphical review and operator adjustment of the genotype 
clusters were performed to refine fluorescent cutoff values and the genotypes were exported 
into a result excel file. Data was analysed with PLINK v1.07 (Purcell et al. 2007) 
(http://pngu.mgh.harvard.edu/purcell/plink/). To test for allel based association the chi-
square test and the Fischer’s exact test were applied. 
2.3.6 PCR and Sequencing reaction of Candidate Genes 
Direct Sanger sequencing of selected candidate genes was performed on a 3730 sequencer 
with 48 capillaries (Applied Biosystems Foster City, USA). The device uses capillary 
electrophoresis of fluorescent-labelled DNA-fragments. 
Polymerase chain reaction (PCR) and clean up 
Prior to the sequencing reaction PCR products were amplified with specific primers. Primers 
were designed to encompass 400-500bp of the exon sequence of target genes. Primer 
specificity was tested by blasting the primer sequence against the human reference sequence 
with NCBI blast tools (http://www.ncbi.nlm.nih.gov/). Primers were obtained through 
Sigma-Aldrich Chemie GmbH, Germany. PCR reactions were carried out in a total volume 
of 10µl using 5ng DNA, 1µM of each, forward and reverse primer, 1µM dNTPs, 1µl PCR 
buffer 1 and 0.1µl InnuTag polymerase (5U/µl) (Analytikjena, Germany). PCR was 
performed in a Tetrad2 thermocycler (Bio-Rad Laboratories, Inc., Germany). PCR 
parameters consisted of an initial step at 94°C for 1min, followed by 33 cycles each with 
30sec at 94°C, 30sec at the appropriate primer annealing temperature and 1min at 72°C, and 
followed by a final hold at 16°C. 
Subsequent residual nucleotides were removed in a cleanup reaction with Exonuclease I 
(Exo I, 15000U) (Neo Lab) and Shrimps Phosphatase Alkali (SAP, 500U) (Promega). In a 
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final volume of 4µl 0.32µl SAP (1U/µl) and 0.09µl Exo I (20U/µl) were added to the PCR 
product. Reactions were incubated at 37°C for 25 min and then at 72°C for 15 min. 
Gel Electrophoresis 
All PCR products were analysed by electrophoresis using 2% agarose gels. These were made 
by melting 2g agarose in 100ml 1x TAE buffer (89mM Tris HCl, 89mM boric acid, 10mM 
EDTA) by heating in a microwave oven for 2 minutes and then adding 5µl ethidium bromide 
solution. The electrophoresis was performed in gel tanks containing 1x TAE buffer. 1.5µl of 
each PCR was loaded onto the gel and electrophoresis was carried out at 120V for 20-30 
minutes. SmartLadder (Eurogentec, Seraing, Belgium) was co-loaded to specify PCR 
product sizes and estimate product quantity. Agarose gels were analyzed under UV-light and 
photographed. 
Sequencing reaction 
In the sequencing reaction either the forward or the reverse primer is used. In addition to 
unlabelled dNTPs the reaction also contains fluorescence labelled ddNTPs. When 
incorporated into the growing DNA sequence these labelled ddNTPs terminate the 
elongation of the DNA because they don’t have a 3’-hydroxy group. This leads to amplified 
DNA fragments with different sizes that can be separated by capillary electrophoresis and 
detected after excitation by a laser. Sequences were viewed with the program SeqMan which 
is part of the DNASTAR software package (DNASTAR, Inc. Madison, USA). 
Sequencing reactions contained the following in a final volume of 10µl: 2-4µl clean up 
reaction product, 0.25µl ABI Big Dye version1.1 (Applied Biosystems GmbH, Germany), 
1µM primer, and 1.75µl sequencing buffer (Applied Biosystems GmbH, Germany). The 
sequencing reaction was performed in a Tetrad2 thermocycler (Bio-Rad Laboratories, Inc., 
Germany). Parameters consisted of 33 cycles each with 10sec at 96°C, 5sec at 55°C and 
4min at 60°C, followed by a final hold at 16°C. Purification of sequencing reactions 
(CleanSEQ) and the subsequent sequencing run were performed by the CCG sequencing 
facility. 
2.4 RNA Extraction, Quality Control and Quantification 
RNA was extracted from primary tissue samples and from disease tissue derived fibroblasts 
for whole genome and single gene expression analysis. 
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2.4.1 RNA Extraction from primary Tissue 
Tissue samples were taken from Dupuytren Patients undergoing surgery and normal palmar 
fascia was obtained from persons having carpal tunnel release. Patient consent and ethical 
approval was confirmed prior to surgery. Tissue samples were placed in RNAlater and 
shipped at room temperature. Upon arrival samples were stored at -20°C till RNA extraction. 
Per sample approximately 150mg of tissue was removed from RNAlater stabilising reagent 
and cut into very small pieces with a sterile scalpel on a petri dish at room temperature. The 
sample was then placed in a 2ml round bottom eppendorf tube containing one 7mm stainless 
steel ball.1 ml RLT (Qiagen GmbH, Germany) buffer, containing guanidine thiocyanate and 
beta-mecaptoethanol or 1ml trizol (QIAzol, Qiagen GmbH, Germany) was added to the 
sample. In the following samples were kept on ice between steps if not otherwise mentioned. 
The tissue samples were minced in a bead mill (Tissue Lyser 2, Qiagen GmbH, Germany) 
for 2-6 min at 30s
-1
 and room temperature. Homogenised samples were spun in a table 
centrifuge (microcentrifuge) at room temperature at maximum speed (14000 rpm) for 5 
minutes to remove cell debris. The supernatant was transferred to one or distributed equally 
to two fresh 2ml eppendorf tubes. If the sample was homogenised in RLT buffer, an equal 
amount of phenol (Carl Roth GmbH & Co. KG, Germany) was added to the sample. The 
trizol reagent already contains phenol so that no further addition of phenol to samples 
homogenised in trizol is necessary. One-fifth volume of chloroform (Carl Roth GmbH & Co. 
KG, Germany) was then added to the lysate. Samples were vortexed for two to five times 
with one minute incubation one ice between steps. Samples were spun at maximum speed 
(13000rmp) in a refrigerable table microcentrifuge for 30 min at +4°C.  
Phase separation results in an upper aqueous phase containing the RNA, a whitish interphase 
consisting mostly of DNA and a red phenol phase containing proteins. The clear upper phase 
(approximately 500µl) was transferred to a new tube. Again an equal amount of phenol and 
one-fifth volume of chloroform were added and the samples were spun at 13000rmp for 30 
min at +4°C. The aqueous phase was carefully transferred into a new 1.5ml eppendorf tube 
minimizing chloroform carryover. An equal amount of 99% ethanol (Merck) was added, 
samples were vortexed briefly and immediately spun at 14000rpm at room temperature. The 
precipitated RNA formed a tiny whitish pellet at the bottom of the tube. The RNA pellet was 
washed ones in 80% ethanol and then dried briefly on ice. The dry pellet was dissolved in 
RNase free water. According to pellet size 5 to 80 µl of water were added to the RNA pellet. 
The pellet was dissolved by pipetting up and down for a couple of times and then stored at -
20°C or -80°C. 
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2.4.2 RNA Extraction from Primary Fibroblasts 
For total RNA extraction from cultured fibroblasts the Qiagen RNeasy Midi Kit (Qiagen 
GmbH, Germany) was used. The procedure is based on columns with a silica membrane that 
selectively binds RNA molecules. In brief, RNA is bound to the membrane, washed and then 
eluted with water. The silica membrane absorbs RNA molecules that are longer than 200 
bases, which excludes smaller RNAs from this isolation method. The protocol was followed 
as provided in the kit’s handbook (Chapter: Isolation of total RNA from Animal Cells). All 
steps were performed at room temperature. All centrifugations were done at 40000rpm. 
For each sample cells were grown in T225 cell culture flasks till confluence (approximately 
1x10
7
 cells). Media was removed and cells were washed ones with 25ml of PBS. Cells were 
trypsinised with 15ml 0.5% Trypsin-EDTA (Invitrogen GmbH, Germany) during incubation 
for five minutes at 37°C. Digestion was monitored with a light microscope and cells were 
further loosened through gently tapping the flask. Upon debonding of cells the digestion 
process was stopped by adding 15ml of media. The cells were transferred to a 50ml falcon 
tube and centrifuged at 1600rpm and 4°C for 3 minutes. Media was removed and 2ml of 
RLT buffer (Qiagen GmbH, Germany), containing guanidine thiocyanate and beta-
mecaptoethanol (~1%) was added to the cell pellet. Guanidine thiocyanate is highly 
denaturing and inactivates RNases in the lysate while β-mecaptoethanol is used to prevent 
the reformation of the intra-molecular disulphide bridges. The sample was vortexed 
vigorously to lyse cells and then stored at -20°C or -80°C till further processing. 
A minimum of 8 and a maximum of 12 samples were extracted simultaneously. Thawed to 
room temperature each sample was mix with 2ml of 70% ethanol and transferred 
immediately to an RNeasy midi column placed in a 15ml centrifuge tube. The sample was 
centrifuged for 5 minutes till the lysate had passed completely through the column. The 
flow-through was discarded and 2ml of wash buffer was added to the column (the first wash 
step). The sample was again centrifuged for 5 minutes. After that a DNA digestion was 
preformed. Therefore the RNase free DNase Set (Qiagen GmbH, Germany) was used. In 
preparation the lyophilized DNase 1 pellet (1500 Kunitz units) was solved in 550µl of 
RNase-free water. Then 20µl DNase stock was added to 140µl of buffer provided in the set. 
The DNase mix was pipetted onto the membrane and the sample was incubated for 15 
minutes. This was followed by the second wash step. Another volume of 2ml wash buffer 
was added to the sample. To inactivate the DNase, the sample was incubated for 5 minutes 
before centrifugation for 5 minutes. In the third wash step 2.5ml of the second wash buffer 
(RPE) was added to the column and the sample was centrifuged for 3 minutes. This wash 
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step was repeated ones with a 5 minutes centrifugation. The RPE buffer contains ethanol in 
order to dry the silica membrane. The dry column was transferred to a fresh 15ml tube and 
150µl of RNase-free water were pipetted onto the membrane. The sample was centrifuged 
for 3 minutes and a second volume of 150µl RNase-free water was added to the column. The 
sample was again centrifuged for 3 minutes and ~300µl of eluate were transferred to a 1.5ml 
eppendorf tube. The sample was stored at -20°C or -80°C. 
2.4.3 RNA Quantification with NanoDrop Spectrophotometer 
Absorbance at 260nm was measured with a NanoDrop ND-8000 Spectrophotometer 
(Wilmington, USA). 1µl of well mixed RNA sample was loaded onto the ND-1000 
Spectrophotometer. Light absorbance at 230nm, 260nm and 280nm was measured and 
concentration and purity were calculated directly by the provided software. 
Absorption at 230nm is caused by contamination with phenol, thiocyanates, and other 
organic compounds. For a pure RNA sample, the ratio of absorbance at 260 and 230nm 
(A260/230) should be around 2. If the RNA sample is heavily contaminated with proteins, the 
A260/280 will be less than the ideal value of 2. RNA samples were diluted as required for 
downstream applications. 
2.4.4 RNA Quality Control with Bioanalyzer Instrument 
While a spectrophotometer measures the concentration of nucleic acids, it gives no 
information about the integrity of the RNA (or DNA) in the sample. Highly degraded RNA 
can be unsuitable for downstream applications. Therefore the 2100 Bioanalyzer (Agilent 
Technologies GmbH, Germany) was used to access RNA integrity. In addition the 
Bioanalyzer offers a more accurate method to determine purity and quantity of a RNA 
sample. The Bioanalyzer is a microfluidics-based platform for separating RNA with a 
capillary electrophoresis system. The associated software program estimates the integrity of 
the RNA based on the entire electrophoretic trace of the sample (Schroeder et al. 2006). This 
includes the presence or absence of degradation products and is independent of sample 
concentration. The software automatically assigns an integrity number (RIN) to an eukaryote 
total RNA sample. The RIN ranges from 1 to 10, with 10 describing a completely non-
degraded RNA sample. The RIN is dependable on isolation method with which the RNA 
sample was extracted. RNA purification over silica based columns bias towards larger RNAs 
overestimating RNA quality (Schroeder et al. 2006). Figure 13 and 14 give examples for 
electrophoretic traces separated with the Bioanalyzer instrument. 
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Figure 13. Example for an electrophoretic trace of a total RNA sample with RIN 9.8. 
 
Figure 14. Example for an electrophoretic trace of a total RNA sample with RIN 6.7. 
The Agilent RNA 6000 Nano Kit was applied to analyse RNA samples with the bioanalyzer 
instrument. The Agilent RNA 6000 Nano Assay Protocol (Edition April 2007) was followed 
for the procedure. 12 RNA samples can be loaded onto one RNA 6000 Nano chip. In 
preparation 1.5µl of RNA samples was pipetted into 0.2ml PCR tube-stripes. RNA samples 
were denatured at 70°C for 2 minutes in a PCR cycle machine and transferred on ice 
afterwards. The RNA 6000 Nano gel matrix was filtered prior to use. 1µl of dye concentrate 
was added to 65µl of filtered gel. The bioanalyzer instrument comes with a priming station 
for loading the gel dye mix into the chip. 18µl of gel dye mix was loaded onto the chip as 
described in the manual. Then 5µl of RNA 6000 Nano marker were loaded into all 12 
sample wells and an additional marker well on the chip. Finally 1µl of denatured RNA 
sample was loaded in each of the 12 sample wells. The chip was vortexed for 1 minute at 
2400rpm and then run on the bioanalyzer instrument. Data analysis was done automatically 
on the associated desk top computer. 
2.5 Whole Genome Gene Expression Analysis 
The Illumina HumanHT-12 v3 Expression BeadChip was used for whole genome expression 
analysis of DD samples and controls. Each array on the HumanHT-12 v3 Expression 
BeadChip targets more than 25,000 annotated genes with more than 48,000 probes derived 
from the National Center for Biotechnology Information Reference Sequence (NCBI) 
RefSeq (Build 36.2, Rel 22) and the UniGene (Build 199) databases. The BeadChip is 
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designed to support highly efficient genome-wide association studies (GWAS). 12 samples 
can be processed per BeadChip. 12 DD primary tissue samples were compared with 12 
matched controls. Control connective tissue samples were obtained during trigger finger or 
carpal tunnel release. All participating subjects were of European origin. The mean age of 
DD patients was 65±10 years. While the average age of the control subjects was 61±13 
years. Table 2 gives an overview over analysed samples. For the whole genome gene 
expression analysis only RNA samples with RIN≥6.9 were used. 
Table 2. Whole Genome Expression Analysis Samples. 
NR sample sample ID status gender birth yr familial source conc. 260/280  260/230  RIN 
1 7509601 7509601 control f 1930 no TVS III 209 1.98 1.86 7.4 
2 7511401 7511401 control f 1938 no KTS 323 1.93 1.96 7.5 
3 7510801 7510801 control f 1954 no KTS 311 1.92 2.24 7.9 
4 7512601 7512601 control f 1960 no KTS 224 2.06 2.07 7.8 
5 7012201 7012201 patient f 1934 no DD 408 2.08 1.87 7.1 
6 3012101 3012101-2 patient f 1937 no DD 533 2.10 1.96 8.3 
7 7001501 7001501 patient f 1941 no DD 65 2.01 2.08 9.5 
8 3015701 3015701-2 patient f 1952 yes DD 116 1.96 1.89 8.2 
9 7509901 7509901-2 control m 1930 no TVS IV 74 1.93 2.09 7.1 
10 7512101 7512101 control m 1934 no KTS 169 1.89 2.23 7.3 
11 7510401 7510401 control m 1946 no TVS V 186 1.94 1.96 6.9 
12 7513101 7513101 control m 1950 no KTS 196 2.05 2.08 7.0 
13 7512501 7512501 control m 1956 no KTS 118 2.07 2.13 9.1 
14 7510001 7510001 control m 1961 no KTS 125 1.89 2.23 7.6 
15 7511101 7511101 control m 1965 no KTS 150 1.94 1.75 7.3 
16 7509501 7509501 control m 1966 no KTS 169 2.01 2.02 8.5 
17 7301801 7301801-2 patient m 1932 no DD 99 2.03 2.01 9.8 
18 7002601 7002601-2 patient m 1942 yes DD 263 2.00 1.99 8.5 
19 7020901 7020901 patient m 1946 yes DD 440 2.00 2.24 7.8 
Samples used in the Whole-Genome Gene Expression Analysis. NR: sample number in order of appearance on 
the expression chip (samples 1-12: chip 1, samples 13-24: chip 2); gender: f: female, m: male; birth yr: year of 
birth of the proband, familial: yes, if family members of the subject were affected by DD, source: source of the 
analysed tissue: DD: Dupuytren, TVS: trigger finger, KTS: carpal tunnel; conc.: RNA concentration (ng/µl) in the 
original sample as determined with the bioanalyzer instrument, 260/280: absorbance ratio at 260nm and 280nm 
measured with NanoDrop ND-8000 Spectrophotometer, 260/230: absorbance ratio at 260nm and 230nm 
measured with NanoDrop ND-8000 Spectrophotometer, RIN: RNA integrity number. 
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Table 2 continued: 
NR sample sample ID status gender birth yr familial source conc. 260/280  260/230  RIN 
20 7514101 7514101-2 patient m 1948 no DD 526 2.09 2.03 8.6 
21 7000501 7000501-1 patient m 1936 yes DD 491 2.07 2.00 7.3 
22 3012901 3012901-2 patient m 1953 no DD 49 1.97 1.97 9.4 
23 7001901 7001901-1 patient m 1958 no DD 254 1.97 1.76 8.8 
24 7005901 7005901-1 patient m 1964 no DD 69 1.98 1.73 9.0 
Samples used in the Whole-Genome Gene Expression Analysis. NR: sample number in order of appearance on 
the expression chip (samples 1-12: chip 1, samples 13-24: chip 2); gender: f: female, m: male; birth yr: year of 
birth of the proband, familial: yes, if family members of the subject were affected by DD, source: source of the 
analysed tissue: DD: Dupuytren, TVS: trigger finger, KTS: carpal tunnel; conc.: RNA concentration (ng/µl) in the 
original sample as determined with the bioanalyzer instrument, 260/280: absorbance ratio at 260nm and 280nm 
measured with NanoDrop ND-8000 Spectrophotometer, 260/230: absorbance ratio at 260nm and 230nm 
measured with NanoDrop ND-8000 Spectrophotometer, RIN: RNA integrity number. 
2.5.1 RNA Amplification for Array Analysis 
The Illumina TotalPrep RNA Amplification Kit (Ambion Inc., USA) was applied for 
generating biotinylated, amplified RNA for hybridisation with the Illumina HumanHT-12 v3 
Expression BeadChip. The protocol comprises three oligonucleotide synthesis steps and two 
column purification steps. In the first step (Reverse Transcription) the mRNA in the 
sample is used as a template by the reverse transcriptase (ArrayScript) to generate single 
stranded cDNAs. The oligo-dT primer in this reaction binds to the poly-A tails of the 
mRNAs. In addition the primer contains a T7 promoter sequence that gets thus incorporated 
into the cDNA. 
In the second step the single stranded cDNA is converted into double-stranded DNA 
(Second Strand Synthesis). This reaction employs DNA polymerase and RNase H to 
simultaneously synthesize second strand cDNA and degrade the RNA. The cDNA is purified 
in the third step to remove RNAs, primer and enzymes. In the following in vitro 
transcription antisense RNA (cRNA) copies of the original mRNA are generated from the 
double-stranded cDNA template by a T7 RNA polymerase. The cRNAs are biotin-labelled 
through the incorporation of biotin-UTP. This is the amplification step of the procedure. In 
the last step the cRNA is purified over a silica membrane column. 
Eight samples were processed simultaneously. Appropriate master mixes were prepared for 
each reaction. All centrifugations were carried out at 10000rpm and room temperature. Per 
sample 500ng total RNA in 11µl of nuclease-free water was placed in 0.2ml sterile PCR 
tube-stripes. 9µl of reverse transcription master mix was added to the sample. The master 
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mix consisted of 1µl T7 Oligo(dT) primer, 2µl 10x first strand buffer, 4µl dNTP mix, 1µl 
RNase inhibitor and 1µl ArrayScript. Sample and master mix were mixed thoroughly by 
pipetting up and down 2-3 times and flicking the closed tube-stripe 3-4 times. The tube-
stripe was centrifuged briefly to collect the reaction mix at the bottom of the tube and then 
incubated for 2h at 42°C in a thermal cycler with the lid temperature set to 50°C to prevent 
condensation. 
After 2 h the sample was removed from the cycler und immediately transferred on ice. 80µl 
of second strand master mix containing 63µl of nuclease-free water, 10µl 10x second strand 
buffer, 4µl dNTP mix, 2µl DNA polymerase and 1µl RNase H, was added to the sample. 
The sample was then incubated for 2 h at 16°C. After second strand synthesis the sample 
was placed on ice and transferred to a 0.5ml reaction tube. 250µl of cDNA binding buffer 
was mixed with the sample. The sample was then pipetted onto a cDNA filter cartridge 
sitting in a wash tube. The sample was centrifuged for 1min till the mixture had passed 
through the filter. The flow-through was discarded. The cDNA sample bound to the filter 
membrane was washed with 500µl of wash buffer. The wash buffer was passed through the 
filter during 1min centrifugation. The flow-through was discarded and the sample was 
placed back in the empty wash tube for another 1min centrifugation to remove the wash 
buffer completely from the filter before the filter cartridge was placed in an elution tube.  
Nuclease-free water was pre-heated to 55°C. 20µl of the water was pipetted onto the filter. 
The sample was incubated for 2 min and then centrifuged for 1min. Elution resulted in 
~17.5µl purified cDNA. The eluate was transferred in a 0.2ml PCR tube-stripe. The in vitro 
transcription (IVT) mater mix was prepared at room temperature. It consisted of 2.5µl T7 
10x reaction buffer, 2.5µl T7 enzyme mix and 2.5µl biotin-NTP mix. 7.5µl of the IVT 
master mix was mixed with the cDNA sample. The sample was then incubated for 14h at 
37°C in a thermal cycler with the lid temperature set to 100°C. After 14h the product was 
cooled to 4°C and incubated for ~16h. The reaction can be held post-IVT for up to 48h at 
4°C for convenience. The reaction was stopped by adding 75µl of nuclease-free water to the 
sample. The sample was then transferred to a 0.5ml reaction tube. 350µl of cRNA binding 
buffer was mixed with the sample. 250µl of 99% ethanol was added ad the whole mixture 
was immediately transferred to a cRNA filter cartridge sitting in a wash tube. The sample 
was centrifuged for 1min and the flow-through was discarded. The sample was then washed 
with 650µl of wash buffer. After the wash buffer had passed through the filter the flow-
through was removed and the filter was placed back in the wash tube and centrifuged for an 
additional 1min. The filter cartridge was then transferred to a fresh elution tube and 200µl of 
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preheated (55°C) nuclease-free water was pipetted onto the filter. The sample was incubated 
in a heat block at 55°C for 10 min. the sample was then centrifuged for 1.5min. 
Approximately 200µl of cRNA was eluted. CRNA yield was determined with NanoDrop 
8000 Spectrometer. For the whole genome gene expression direct hybridisation assay the 
biotin-labelled cRNA was normalised to 750ng in 5µl. The appropriate amount of sample 
constituting 750ng was vacuum dried in a vacuum centrifuged (speed rac) and then 
resuspended in 5µl of water. 
2.5.2 Whole Genome Gene Expression Direct Hybridisation Assay 
The whole genome gene expression direct hybridisation assay was preformed over two days. 
On the first day the cRNA sample was dispensed to the BeadChip and then hybridised over 
night for 14-20h. On the following day the BeadChip was washed, labelled and analysed 
with the Illumina BeadArray Reader. 
In preparation the cRNA sample was heated at 65°C for 5 minutes, vortexed and pulse 
centrifuged at 250xg. After the sample had cooled again to room temperature it was mixed 
with 10µl of hybridisation mix (HYB) and loaded onto the BeadChip. The 15µl was pipetted 
onto the inlet port for each lane on the BeadChip. The liquid was then transported by 
capillary forces between BeadChip and coverseal. The BeadCip was placed in a humidified 
hybridisation chamber and incubated in a hybridisation oven at 58°C for 19:20h on a slow 
moving rocker. 
After hybridisation the BeadChip was removed from the hybridisation chamber and 
submerged face up in wash buffer (E1BC). Then the coverseal was removed while the chip 
was under the buffer. The BeadChip was placed in a slide-rack submerged in a cuvette 
containing 250ml wash buffer (E1BC). The rack was the transferred to a wash bath 
containing high temperature wash buffer. The chip was incubated static at 55°C for 10 
minutes in this wash bath. After that the chip in the slide-rack was immediately transferred 
back into the cuvette containing fresh wash buffer E1BC. The slide-rack was gently moved 
up and down 5-10 times under the buffer. The cuvette with the slide-rack was then placed on 
an orbital shaker and shaken at room temperature for 5 minutes. The slide-rack was 
transferred to a cuvette containing 250ml 99% ethanol and washed for 10 minutes on the 
orbital shaker. Afterwards the chip was washed again in wash buffer as above, this time with 
two minutes incubation on the rocker. 
In the next step the BeadChip was blocked with block buffer. Therefore the chip was placed 
in a wash tray, covered with block buffer and incubated on the shaker for 10 minutes. 
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After the blocking step the BeadChip was transferred to a fresh wash tray containing 2µg 
Cy3-Streptavidin in 2ml blocking buffer. Streptavidin is a bacterial protein that binds non-
covalently to the biotin in the cRNA. Cy3 is a fluorescent dye of the cyanine dye family. The 
excitation of Cy3 by ~550 nm laser light induces a light emission maximum of ~570 nm. 
The chip was completely covered with the buffer and incubated for 10 minutes on the shaker 
at room temperature. After the incubation the chip was washed again in wash buffer E1BC 
for 5 minutes. Lastly the BeadChip was dried by 4 minutes centrifugation at 1400rpm and 
room temperature. The chip was then scanned with the Illumina BeadArray Reader.  
2.5.3 Expression Data Analysis with Illumina Genome-Studio 
The data generated with the BeadArray Reader was visualized with the Illumina 
GenomeStudio Data Analysis Software. This tool supports the primary analysis of 
microarray-based data and offers different graphical interface to view results. Differential 
mRNA expression results were exported as table in Excel (Microsoft). 
2.5.4 Expression Data Analysis with Ingenuity Pathway Analysis 
With the Ingenuity Pathways Analysis software expression data was further analyzed. The 
software integrates data from a variety of experimental platforms to analyse protein networks 
and pathways. The software enables the search for networks and pathways that are altered in 
expression data sets.  
2.6 Quantitative Real-Time PCR 
Reverse-transcription quantitative real-time PCR (RT-qPCR) was performed using the 
LightCycler®480 platform (Roche Diagnostics GmbH, Germany) and corresponding 
LightCycler® (Roche Diagnostics GmbH, Germany) 480 software release 1.5.0 (version 
LCS480 1.5.0.39, Roche Diagnostics). 
Eleven target genes were selected from the expression chip results for verification with RT-
qPCR (TGFβ3, MAFB, RSPO2, SFRP4, WNT2, ACTA2, APP, CASP3, CAT, MAOA and 
SOD2). Each target gene was compared to four reference genes (EIF3H, EIFC2C, GAPDH 
and PCDH18). Reference genes were also chosen from the chip results for showing similar 
expression levels in disease and control fascia. 
The experiment was carried out for nine DD patients and nine controls. The patient samples 
were different ones from the ones used in the expression chip experiment. The control 
samples were different except two that were used before in the expression chip experiment. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker - 52 - 
Primer pairs for selected target genes were either designed with the Roche probe primer 
design tool provided via the Roche homepage or with the web based NCBI primer blast tool. 
Specificity was tested against the human RNA reference sequence with NCBI and/or 
ensemble blast tools. Primer sequence and product size are given in table 32 (in the 
appendix). 
 
Figure 15. Depicted are two examples for melting and amplification curves generated in RT qPCR. A 
melting and amplification curves for EIF3H as an example for one reference gene, B melting and 
amplification curves for FZD4 as an example for one target gene. 1. Melting curve; 2. Negative derivative 
of the sample fluorescence versus temperature showing one melting peak for all samples. This indicates a 
pure, homogenous amplification of a single PCR product. 3. Amplification curve. 
The SYBR® GreenER™ qPCR reagent system (Invitrogen GmbH, Germany) was applied to 
perform the RT-qPCR. The SYBR Green dye incorporates into double-stranded DNA, and 
emits light upon excitation. Thus, as the double-stranded PCR product accumulates, 
fluorescence increases. The drawback of this relatively simple system is that the dye also 
binds to any other double-stranded DNA present in the reaction, including primer dimers and 
other non-specific reaction products. This may result in false positives if primers are not 
specific. Primer specificity was therefore carefully checked in preparation and confirmed 
with melting curve analysis. Melting curves were done for all reference and target genes to 
assure that the same target was amplified in patient and control samples. Figure 15 gives 
examples for melting and amplification curves for one reference and one target gene. 
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Each RT-qPCR reaction was carried out in a final volume of 20μl, consisting of 2μl diluted 
RNA (approximately 10ng RNA), 10μl EXPRESS SYBR GreenER qPCR SuperMix 
Universal (Invitrogen GmbH, Germany), 0.4μM of forward and reverse primer each (Sigma-
Aldrich Co, Germany), 0.5μl of Express SuperScript Mix for One-Step SYBR GreenER 
(Invitrogen GmbH, Germany), and 6.7μl DNase/RNase-free water (Invitrogen GmbH, 
Germany). Each reaction was done in duplicate. The reactions were carried out in white 96-
well plates (Roche Diagnostics GmbH, Germany). 
The RT-qPCR program consisted of the following steps, 1. Reverse transcription (RT): 
Firstly the template RNA was transcribed into cDNA. Therefore samples were incubated at 
55°C for 5 minutes. 2. Pre-Incubation: The qPCR reactions were then initiated at 95°C for 
2 minutes to activate the Hot Start Taq polymerase. 3. Amplification: Each of the following 
50 amplification cycles consisted of a 10seconds denaturation step at 95°C, a 30 seconds 
annealing step at 60°C and a 6 seconds elongation step at 72°C. The fluorescence intensity 
was recorded at the end of the elongation step in each cycle. 4. Melting curve: After the 50 
cycles of amplification a melting curve was recorded in order to test product specificity. This 
included a 5 seconds step at 95°C, a 1 minute step at 60°C and a final heating of the product 
to 97°C. 5. Cooling: The program was concluded with a cooling step at 40°C for 10 seconds. 
PCR efficiency (E) was set to two for all target and reference genes, implying that the 
amount of respective PCR product was doubled in each cycle. However this is rarely the 
case, because a variety of factors influence PCR efficiency e.g. primer annealing, annealing 
temperature and sample preparation, and not all may be optimal. So that E is likely to be 
lower than two and may also differ slightly between target and reference genes. This was 
borne in mind during data analysis. Target genes that showed low PCR efficiency as evident 
from complanate amplification curves were exclude from the analysis. 
Data analysis 
Difference between the gene expression levels of DD and controls was assessed with the 
quantification cycle (Cq) method (Livak and Schmittgen, 2001) as provided by the Light 
Cycler 480 software (Roche Diagnostics GmbH, Germany). Cq values were obtained from 
the qPCR. ΔCq was calculated by subtracting Cq of the internal controls, which was the 
averaged Cq of the reference genes, from the Cq of the target genes. Levels of target gene 
expression normalized using reference genes or relative gene expression levels were 
represented by 2
-ΔCq
 (Schmittgen et al. 2008). Two-tailed student's t-test on the 2
-ΔCq
 of DD 
and controls for all reference and target genes were carried out in excel. The significance 
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level was set to P = 0.05. If the P-value was below 0.05 the null hypothesis that relative 
expression levels between DD and controls did not differ was rejected. Fold change of the 
relative gene expression levels of DD compared to controls were calculated using the 2
-ΔΔCq
 
method (Livak and Schmittgen, 2001). 
In order to further assess the expression of the eleven target genes in DD, disease and control 
tissues within the same patient were compared. Therefore the relative expression values of 
disease tissue were compared with those of macroscopically normal appearing fascia tissue, 
which was removed from adjacent to the disease tissue. This experiment was carried out for 
four DD patients. Additionally the gene expression of disease tissue was compared to that of 
fat tissue from the same patient. The fat tissue also originated from adjacent to disease tissue. 
This was done for two patients. 
In a next step the expression values of the eleven afore mentioned target genes as well as 
those of additional target genes (THBS4, EPDR1, FZD4, GSK3β; CDH1 and ATP5B) were 
compared for DD and control derived primary fibroblast cell lines. A slightly different set of 
reference genes was used in this experiment (EIF3H, EIFC2C, GAPDH, and RN18S1). The 
analysis was done for eleven patient cell lines and seven control cell lines. Cells were 
harvested in passage two. To assess the influence of TGFβ1 on target gene expression, the 
relative expression values of fibroblasts treated with TGFβ1 were compared to the same cell 
line not treated with TGFβ1. This was done for five DD patients and one control. Data 
analysis in all RT-qPCR experiments was done as described above. 
2.7 Cell Culture of Human Fibroblast Cell Lines 
2.7.1 Isolation of Human Fibroblasts from primary Tissue 
Primary disease tissue was sampled from Dupuytren´s patients undergoing surgery. Control 
tissue of unaffected palmar fascia was taken from control persons requiring carpal tunnel 
release. 
Tissue samples were immediately placed in twenty millilitres of transport media containing: 
10% FCS, 75μg/ml Amphotericin, 100 IU/ml Penicillin, 100µg/ml Streptomycin and 10 
mg/ml Gentamycin in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen GmbH, 
Germany). Samples were sent to the CCG at room temperature. All further processing of 
samples at the CCG was done under sterile conditions under a Biowizard Xtra XF-130 cell 
culture fume hood (Kojair Tech Oy, Finland). Upon arrival tissue samples were removed 
from transport media and washed ones in phosphate-buffered physiological saline solution 
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(PBS: 136.8mM NaCl, 2.5mM KCl, 0.8mM Na2HPO4, 1.47mM KH2PO4, 0.9mM CaCl2, 
0.5mM MgCl2 (6H2O), Invitrogen GmbH, Germany). Most fat was macroscopically 
removed. Samples were then cut into small pieces of approximately 0.3cm
3
 with sterile 
scalpels. Up to ten of those pieces were placed in one round 8cm Petri dish. A small amount 
of culture medium containing the following: 10% FCS (foetal calve serum, Invitrogen 
GmbH, Germany), 100 IU/ml Penicillin, 100µg/ml Streptomycin and 2mM Glutamine was 
carefully added to the Petri dish and samples were incubated in a Heraeus BBD6220 cell 
culture incubator (Thermo Fisher Scientific Inc., Germany) at 37°C in a humidified 
atmosphere of 95% air and 5% CO2 over night. On the following day approximately ten 
millilitres of culture medium was added to the culture dish. Media was change every two to 
four days. Outgrow of fibroblasts from the tissue pieces was checked weekly with an 
Axiovert40CFL light microscope (Carl Zeiss AG, Germany). 
2.7.2 Cultivation of Human Fibroblasts 
Once the tissue pieces were surrounded by a ring of fibroblasts, the tissue pieces were 
removed and media was aspired. Cells were washed once with PBS and 5ml of 0.5% Trypsin 
with 0.53mM EDTA (Invitrogen GmbH, Germany) pre-warmed to 37°C was added to the 
dish. Cells were incubated at 37°C. Digestion of cells was monitored with a light microscope 
(Axiovert40CFL, Carl Zeiss AG, Germany). Upon debonding of cells the digestion process 
was stopped by adding 5ml of culture media. Cells were transferred to a 15ml tube and 
centrifuged at 1600rpm for 3 minutes. Media was aspirated and the cell pellet was dissolved 
in 10ml of fresh media. Cells were transferred to a 225cm
2 
cell culture flask in a final 
volume of 50ml culture medium. Cells were grown till confluence and then harvested by 
trypsinization: medium was removed; cells were washed once with 20ml of PBS; 15ml of 
0.5% Trypsin was added; digestion at 37°C; 15ml of culture medium was added; centrifuged 
at 1600rpm for 3 minutes. Liquid was aspirated and the cell pellet was dissolved in 4.5ml 
FCS supplemented with 10% DMSO. Cell content of one 225cm
2
 flask was split to three 2ml 
cryoconservation tubes. Samples were frozen at -80°C over night followed by long term 
storage in a liquid nitrogen tank. 
2.7.3 Cultivation of Fibroblasts on Coverslips 
Human fibroblasts were grown either on poly-L-Lysine, fibronectin, collagen coated or non-
coated glass coverslips. One coverslip was placed in each well off six-well cell culture 
plates. Approximately 1x10
5
 cells were planted per well. Each well contained 2ml of culture 
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medium. Cells were either untreated or treated with 2ng/ml TGFβ1 and cultivated for 2-5 
days. 
22mm round fibronectin (human) coated glass coverslips were purchased from BD 
Bioscience. Poly-L-lysine coated coverslips were prepared as follows. 22x22mm glass 
coverslips were roughened in 65% nitric acid and 37% hydrochloric acid (2:1) for 2h on a 
slow moving magnet stirrer. Coverslips were washed in dH2O for 15 minutes. Coverslips 
were stored in 99% ethanol. Under a cell culture fume hood the appropriate number of 
coverslips was air dried and one coverslip was transferred to each well of a six well culture 
dish. Coverslips were covered with 0.01% Poly-L-Lysine solution (Sigma Aldrich GmbH, 
Germany) and incubated for 10 minutes. Poly-L-lysin solution was aspirated and coverslips 
were dried ~1h. Coverslips were sterilised with UV-light for 45 minutes. Six well plates 
were stored at 4°C. For collagen coated coverslips, coverslips were roughen as described 
above, dispersed to 6-well plates, sterilised with UV-light and then coated with 3% collagen 
solution (bovine, pH 2) (Advanced BioMatrix). Collagen polymerised at room temperature 
and 6-well plates were stored at 4°C. 
Cells were stained immunohistological as follows. The media was aspirated and cells were 
washed twice with PBS. Cells were fixed with 4% PFA for 15 minutes at 4°C or room 
temperature. Fixation agent was removed and cells were washed four times with PBS. Cells 
were permeabilised with 3% BSA, 1% TritonX in PBS for 10 minutes at room temperature. 
Cells were washed twice and blocked for 1h with 3% BSA in PBS at room temperature. 
Blocking solution was removed and primary antibody solution (in PBS containing 1% BSA, 
0.025% Triton X-100) was added. The αSMA antibody (ab7817, Abcam plc, UK) was 
diluted 1:1000. Samples were incubated at 4°C over night or ≥1h at room temperature. 
Primary antibody solution was aspirated and the cells were washed 3 times in PBS. Cells 
were incubated with secondary antibody for ≥1h at room temperature protected from light.  
As secondary antibody Alexa Fluor 488 goat anti-mouse IgG (Invitrogen GmbH, Germany) 
was used, in a concentration of 5ng/µl. Cells were washed once with dH2O and then 
incubated with Alexa Flour 594 phalloidin (Invitrogen GmbH, Germany) for 15 minutes in 
the dark. Samples were washed ones in dH2O and then stained with DAPI (4´,6-diamidino-2-
phenylindole, dilactate, Biotium Inc, USA) for 2-3 minutes. Samples were washed four times 
in dH2O. Coverslips were removed from the cell culture dish, excess liquid was carefully 
removed with a tissue and coverslips were placed face down on glass slides in a drop of 
mounting media (0.05M Tris, 25% glycerine, 10% polyvinyl alcohol, 0.4% phenol, pH 8). 
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Slides were dried in the dark and then viewed with Leica DM6000 B (Leica Microsystems 
GmbH, Germany). 
2.7.4 Collagen Matrix Contraction Assay 
In order to compare contraction properties of disease derived primary fibroblasts with 
control fibroblast a simple contraction assay was performed. Cells (0.5 x 10
5
 per well) were 
grown in 3-dimensional collagen gels (1.5mg/ml). 
Three parts 3% bovine collagen solution, pH 2 (Advanced BioMatrix) were mixed with one 
part 10x HBSS (Invitrogen GmbH, Germany). A small amount of NaOH was added to adjust 
the pH value to ~7. Cells were dispensed in FCS and two parts of FCS were given to the 
collagen mixture. The ready collagen mixture (3:1:2) was cast into 24 well plates 
(0.5ml/well) and dried at 37°C in a cell culture incubator for 2 hours. Negative controls were 
cast without cells. Once the collagen-gel was stiff 1ml of media was added to each well and 
gels were cultivated for up to 13 days. 
Gel-matrices were photographed daily and the weight of the gel was measured. As the gel 
continues to contract, water is excluded from the matrix and the gel weights less. 
2.7.5 Functional Assays: Oxidative Stress Enzyme Function 
The Amplex® Red Catalase Assay Kit (Invitrogen GmbH, Germany) was used to measure 
catalase enzyme activity in patient and control primary fibroblasts. Fibroblasts in passage 3 
to 6 were used in this experiment. Fibroblasts were cultivated at 37°C and 40.5°C. Cells 
were grown in 225cm
2
 cell culture flasks to confluence, harvested by trypsinization at 37°C 
and resuspended with 10ml 20mM phosphate buffer. Cell concentration was measured for 
each sample with a Z2 Cell Counter instrument (Beckman Coulter GmbH, Germany). Cells 
were then sonicated in 0.1M tris buffer (pH 7.5). The obtained cell homogenate was 
centrifuged at 4°C and 17xg for 20 minutes. The supernatant was aliquoted into two 1.5ml 
eppendorf tubes and shock frosted in liquid nitrogen. Samples were stored at -80°C. 
In the assay, the catalase (CAT) in the sample first reacts with H2O2 to produce water and 
oxygen. Next the Amplex Red reagent reacts with a 1:1 stoichometry with any unreacted 
H2O2 in the presence of horseradish peroxidase (HRP) to produce the fluorescent oxidation 
product, resorufin. As catalase activity increases, the signal from resorufin decreases. The 
results are plotted by subtracting the observed fluorescence from that of a no-catalase 
control. Resorufin has absorption and fluorescence emission maxima of approximately 571 
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nm and 585nm, respectively. Because the absorbance is strong, the assay can be performed 
either fluorometrically or spectrophotometrically. 
Samples were thawed at room temperature and transferred on ice. Samples were then diluted 
to a cell homogenate of approximately 1000 cells/µl. 25µl of each diluted sample was 
transferred to a 96-well plate. A standard curve of CAT activity (range from 0.626 to 1U/ml) 
was simultaneously run for quantification. The analysis was done in triplicate. 25µl of 40µM 
H2O2 solution was added to each well. The reaction was incubated for 30 minutes at room 
temperature. 50µl of 100µM Amplex Red (Resazurin) containing 0.4U/ml HPR was added 
to each well. The reaction was incubated at 37°C for 30 minutes in the dark. Fluoresces was 
measured in a microplate reader using excitation at 558nm and emission detection at 610nm. 
A standard curve was generated from the standard samples and the curve equation was used 
to determine catalase activity in the patient and control samples. Student’s t-test was applied 
to access significance of catalase activity differences between cases and controls. 
2.8 Functional Assays: RNA interference 
Based on the results of GWAS and whole genome expression experiments, three genes were 
selected for RNA interference assays. For each of the following genes: glycogen synthase 
kinase 3 beta (GSK3β), nucleoredoxin (NXN) and NADPH oxidase 4 (NOX4) three Stealth 
RNAi siRNA Duplex Oligoribonucleotides were purchased through Life Technologies 
(Paisley, GB). Per gene, each of the three siRNAs targets a different sequence of the same 
mRNA. 
For RNAi experiments fibroblasts were seeded onto collagen gels in six-well-plates. For the 
collagen gel 0.25ml collagen/well were mixed with 10x HBSS (Invitrogen GmbH, 
Germany). The pH-value was adjusted with NaOH till the color indicator within the HBSS 
turned pink. OptiMEM (Invitrogen GmbH, Germany) was added to bring the mixture to 1ml 
per well. The collagen mixture was added to the six-well-plate and the plate incubated at 
37°C (incubator without CO2-connection) till the collagen-gel polymerized. 
After polymerization plates were seeded with cells and incubated over night (at 37°C in a 
humidified atmosphere of 95% air and 5% CO2). On the next day cells were either treated 
with target or control (Stealth RNAi siRNA negative control Med GC, Life Technologies, 
Germany) siRNA. 1µl of Lipofectamine 2000 (Invitrogen GmbH, Germany) was diluted in 
50µl OptiMEM. The mixture was incubated for 5 min. The Lipofectamine dilution was then 
combined with a dilution of either target or control siRNA in OptiMEM. The combined 
solution was incubated for 20min and then added to the cells. Target or control siRNA were 
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diluted to a final concentration of 50nM when added to the cells. Cells were incubated for 2-
4 hours. Cells were then either left untreated or one of the following stimuli was added: 
50ng/ml Wnt3a (Sigma Aldrich GmbH, Germany), 2.5ng/ml TGFbeta1 (Abcam plc, UK), 
1µM BIO (Sigma Aldrich GmbH, Germany). Cells were incubated for 70 hours. Cells were 
then harvested by dispatching the collagen gel from the well. The collagen gel was 
transferred to a 15ml falcon and pelleted by centrifugation. The media was aspirated and the 
collagen gel stored at -20°C. RNA was extracted with the InviTrap Spin Universal RNA 
Mini Kit (Stratec Molecular GmbH, Germany). Relative expression levels of target genes 
were measured by qPCR on the LightCycler®480 platform (Roche Diagnostics GmbH, 
Germany). The overall knock-down efficiency ranged from 70-80%. 
2.9 Histology of primary Tissue Samples 
Primary disease tissue samples of DD patients and connective tissue samples of control 
individuals were collected in transport media (as described above). Upon arrival at the CCG 
a portion of the sample was transferred to formalin and incubated at 4°C approximately for 
one day. The sample was then embedded in paraffin, sectioned and stained 
immunhistochemical and with Haematoxyilin/Eosin. 
2.9.1 Fixation, Paraffin Embedding and Sectioning 
Tissue samples were cut into small pieces (approx. 3mm
3
). The pieces were then put in a cell 
safe capsule. Each cell safe capsule was placed in a processing cassette and fixation was 
performed with the tissue processor LEICA ASP200S (Leica Microsystems GmbH, 
Germany) with the protocol shown in table 3. 
Table 3. Fixation Protocol. 
Step  Time  Reagent  Step  Time  Reagent  
1  2 hours  Formalin  7  1 hour  100% Ethanol  
2  1,5 hours  Formalin  8  1,5 hours  Xylol  
3  1,5 hours  70% Ethanol  9  1,5 hours  Xylol  
4  1,5 hours  80% Ethanol  10  1,5 hours  Histowax (62°C)  
5  1 hour  100% Ethanol  11  1,5 hours  Histowax (62°C)  
6  1 hour  100% Ethanol  12  1,5 hours  Histowax (62°C)  
Fixation protocol run on the LEICA ASP200S instrument (Leica Microsystems 
GmbH, Germany). 
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After fixation samples were transferred to the paraffin station LEICA EG1150H (Leica 
Microsystems GmbH, Germany) preheated to 65°C. Samples were then halved with a scalpel 
and put in a stainless steel base mould with the cutting edge on the downside. The processing 
cassette was filled with 65°C warm paraffin from the paraffin station. The moulds were left 
to cool on a cold plate until the paraffin block could be easily retrieved. 
5μm thin sections were cut with the fully automated rotary microtome LEICA RM2255 
(Leica Microsystems GmbH, Germany) and put in a water bath with 37°C. From there the 
sections were transferred to poly-L-Lysine coated slides. The slides were left to dry on a 
heating plate at 37°C for one hour and then transferred to an incubator with 37°C overnight. 
2.9.2 Haematoxylin-Eosin (HE) Staining 
HE stain is a widely used stain in histology. It consists of haematoxylin which stains cell 
nuclei blue. This nuclear staining is followed by counterstaining with a solution of eosin. 
Eosin stains protein structures e.g. collagen fibres red. Prior to staining paraffin sections 
must be deparaffinised and re-hydrated. Sections of disease and control tissue were 
incubated in xylol for 20 minutes and then re-hydrated by placing the slides two-times in 
100% ethanol, two times in 80% ethanol, two times in 30% ethanol, and two times in 
deionised water (dH2O) for 10 seconds each. The slides were then transferred to a glass 
cuvette containing 250ml haematoxylin solution and incubated for three to five minutes. 
Slides were washed once with dH2O and the stain was developed under tap water for up to 
10 minutes. Slides were rinse again with dH2O and then incubated in eosin solution for three 
minutes. Samples were dehydrated by placing the slides two times in dH2O, two times in 
30% ethanol, two times in 80% ethanol, two times in 100% ethanol. From there slides were 
transferred back to xylol for 5 minutes. Slides were removed, excess xylol was wiped off 
with a tissue paper and slides were mounted. Dried slides were viewed under a Leica 
DM6000 B microscope (Leica Microsystems GmbH, Germany). 
2.9.3 Immunohistochemical (IHC) Staining 
Sections of disease and control tissue were deparaffinised in xylol for 20 minutes at room 
temperature. Sections were then re-hydrated by placing the slides in each of eight 250ml 
cuvettes containing decreasing ethanol concentrations (two-times of each 100%, 80%, 30% 
and 0% ethanol in dH2O) for ~5sec. while moving the slide-rack gently up and down under 
the liquid. After that antigen retrieval was preformed. This is necessary because of the 
formation of methylene bridges during fixation, which cross-link proteins and therefore 
mask antigenic sites. Either heat-mediated or enzymatic antigen retrieval was performed as 
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recommended for the single antibodies in their data sheets. For heat-mediated antigen 
retrieval 250ml of Sodium citrate buffer (10mM Sodium citrate, 0.05% Tween 20, pH 6.0) 
was boiled in a standard microwave. The slide-rack with the samples was then placed in the 
hot but no longer boiling citrate buffer and incubated for 30 minutes.  
For enzymatic antigen retrieval 100ml of 0.05% Trypsin-EDTA was heated to 37°C in a 
water-bath before adding the slides and incubating them for 7 minutes at 37°C. After antigen 
retrieval slides were transferred to TBST buffer (20mM Tris HCl, 150mM NaCl, 0.04% 
Tween 20, pH 7.4), washed ones in a new volume of TBST and then submerged in 250ml of 
blocking solution (10% FCS, 1%BSA in PBS). Sections were blocked for 30 minutes at 
room temperature. After blocking slides were transferred faces up to a staining chamber. 
(The staining chamber contains a reservoir for H2O in order to prevent drying out of the 
sections during staining.) A volume of 70µl primary antibody dilution (in PBS containing 
1% BSA, 0.025% Triton X-100) was applied to each section. The αSMA antibody (ab7817, 
Abcam plc, UK) was diluted 1:1000, the collagen 4 antibody (ab6586, Abcam plc, UK) was 
also diluted 1:1000. The lid of the staining chamber was closed and samples were incubated 
over night at 4°C.  
On the next day slides were again placed in a slide-rack, washed twice in TBST and 
transferred back to the staining chamber. Fluorescence labelled secondary antibody was then 
applied. As secondary antibody for αSMA either Texas Red goat anti-mouse IgG or Alexa 
Fluor 488 goat anti-mouse IgG (both Invitrogen GmbH, Germany) each in a concentration of 
5ng/µl (~350ng per section) were used. As a secondary antibody for collagen 4 Alexa Fluor 
488 rabbit anti-goat IgG (Invitrogen GmbH, Germany) was used. Samples were protected 
from light with the staining chamber lid and incubated for 1-2h at room temperature. Slides 
were placed back in the slide-rack, washed once in TBST and then stained with DAPI 
(10µg/ml) for 3 minutes. Slides were washed four-times in TBST. Slides were placed on 
tissue paper with sections facing up. Mounting media (0.05M Tris, 25% glycerine, 10% 
polyvinyl alcohol, 0.4% phenol, pH 8) was pipetted onto each section and coverslips were 
mounted. Slides were dried over night in the dark. Fluorescence was visualised with Leica 
DM6000 B (Leica Microsystems GmbH, Germany). 
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2.10 Statistical Tests 
The chi-square test of goodness-of-fit was used to compare observed allele frequencies of a 
single nucleotide polymorphism (SNP) marker with the expected allele frequencies under 
Hardy-Weinberg equilibrium (1 degree of freedom). 
If the frequency of one allele in a population is p and the other allele is q, the null hypothesis 
is that expected frequencies of the three genotypes are p
2
, 2pq, and q
2
. 
The test statistic is calculated by taking the observed number (O), subtracting the expected 
number (E) and squaring the difference. Each difference is divided by the expected number, 
and these standardized differences are summed. The equation is: 
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
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The chi-square test of goodness-of-fit was preformed with the computer software Plink (see 
e.g. chapter 2.3.3). 
The Fisher’s exact test was used to examine the association between two nominal variables 
in a 2 x 2 table (table 2.1). The null hypothesis for this test is that the relative proportions of 
one variable are independent of the second variable. 
 
Table 4 Example for a 2x2 table used in Fisher's exact test 
a b a + b 
c d c + d 
a + c b + d n = a + b + c + d 
 
The probability of getting the observed data given in table 2.1 is calculated with the 
hypogeometric distribution under the null hypothesis that the proportions are the same: 
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The Student's t-test was applied to compare the means of two samples. The statistical null 
hypothesis is that the means are equal for the two categories. The t-test assumes that the 
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observations within each group are normally distributed and the variances are equal in the 
two groups. The test statistic, ts, to test whether the means of two unequal sample sizes are 
different can be calculated using the t-distribution: 
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Where 1X  and 2X  are the means of group 1 and 2 and 
21 XX
s

 is the standard error of the 
difference in the means, which gets smaller as the sample variances decrease or the sample 
sizes increase. Thus ts gets larger as the means get farther apart, the variances get smaller, or 
the sample sizes increase. The probability of getting the observed ts value under the null 
hypothesis depends on the number of degrees of freedom. The degrees of freedom for a t-test 
is the number of observations in each group minus two (n1 + n2 – 2). In the equation above 
s
2
 is the unbiased estimator of the variance of the two samples. All t-tests were performed 
two-tailed. 
The significance level for all tests was set to P = 0.05. If the P-value was below 0.05 the null 
hypothesis was rejected. Statistical tests were performed with excel and were taken from 
http://udel.edu/~mcdonald/ (McDonald 2009). 
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3 Results 
3.1 Epidemiology 
903 samples were collected from summer 2007 to summer 2012. Of those 51 were control 
samples and 852 were DD patient samples. 815 patients completed the questionnaire while 
for 37 patients only name, gender and birth date were recorded by the attending physicians. 
14 patients were relatives of other participants. 801 of the DD samples were of unrelated 
patients who completed the questionnaire (table 5). 143 (17.9%) of these were women, 
resulting in an overall male/female ratio of 4.6:1. Table 5 gives the age distribution of 
collected samples for men and women. 
Table 5. Male-female ratio in DD patients. 
3.1.1 Age at first Surgery 
For each patient the age at sample collection and the age at first surgery were recorded. The 
mean age of patients at the sampling date was 63.5 ± 10.5 years (N = 801). The mean age at 
first surgery was 59.0 ± 12.2 years for all patients that underwent surgery till the collection 
date (N=736). Women were on average 61.1 ± 11.4 years old when they first underwent 
surgery (N = 121, 16.4%) while men were 58.6 ± 12.3 years old (N = 615). Men were 
therefore on average 2.5 years younger than women at the time of first surgery. 65 patients 
contributed a blood sample but did not require surgery till the time of sample collection. 
They were on average 61.2 ± 11.7 years old at collection date. 22 (33.8%) of these were 
women. 
Figure 16 and 17 summarise the age distribution of patients. Shown in figure 16 is the age of 
first surgery for male and female DD patients grouped in decades. The number of patients in 
decade of live all men women ratio familial % 
29-39 15 11 4 2.8:1 8 53.3 
40-49 80 70 10 7.0:1 44 55.0 
50-59 191 158 33 4.8:1 84 44.0 
60-69 278 225 53 4.2:1 102 36.7 
70-79 208 169 39 4.3:1 63 30.3 
80-89 29 25 4 6.3:1 5 17.2 
all 801 658 143 4.6:1 306 38.2 
Given are the numbers of male and female DD patients for each 
decade of live. Considered was the age at collection date. Familial: 
number and percentage of cases with a positive family history. 
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each age group is given on the y-axis. In each of the seven age classes more men than 
women underwent surgery for DD. Figure 17 gives the proportion of operated patients for 
each decade of live separated by sex. 30% of men underwent surgery in their sixth and 28% 
in their seventh decade of live while the largest proportion of women underwent surgery in 
their seventh decade of live (37%). The youngest male patient was 22, the oldest 87 years of 
age when they underwent first surgery. The age of first surgery in women ranged from 27 to 
84 years of age. 
 
Figure 16. Age distribution of DD patients at the time of first surgery. Given are the numbers of female 
(dark colour) and male (light colour) patients that underwent first surgery for each decade from 20 to 89 
yrs of age. 
 
Figure 17. Age distribution of DD patients at first surgery in percent. Given are the percentages of 
female (dark colour) and male (light colour) patients that underwent first surgery for each decade of live 
from 20 to 89 yrs. of age. 
3.1.2 Affected Hands 
In half of the DD patients both hands were affected (see table 6). In 26.9% of cases the right 
hand and in 22.9% the left hand was affected. For both left and right hand the degree after 
Tubiana was recorded for each patient. This degree ranged from 0 to 4. Only one affected 
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finger per hand was taken into account (see introduction). The mean degree for all patients 
was 2.17 ± 1.13 (N = 711). It was 1.90 ± 1.15 in women (N = 123, 17.3%) and 2.23 ± 1.12 in 
men (P-value of student´s t-test: 0.00375). 192 (25.0%) of patients had two or more surgeries 
on the same hand due to recurrence of the disease. Several patients had many surgeries over 
time.  
Table 6. Affected hands in DD patients. 
N % 
hand 767 100 
both hands 385 50.2 
left hand 176 22.9 
right hand 206 26.9 
recurrence 192 25.0 
3.1.3 Family Predisposition 
306 (38.2%) patients reported a family predisposition for DD (see table 7). In 89 (29.1%) 
cases family members from the maternal line were affected. In 70 (78.6%) of those the 
mother was affected while in the remaining 19 cases family members other than the mother 
were affected, e.g. a grandparent or aunt or uncle. 140 patients had affected family members 
in their paternal line. The father was affected in 134 (95.7%) of those. In three of the 
remaining six cases the paternal grandfather was affected while the father was not affected.  
Table 7 Family predisposition for DD. 
familial cases   N % 
total   306 100 
lineage known maternal line 89 29.1 
  paternal line 141 45.8 
  both 10 3.3 
lineage unknown siblings 43 14.1 
  children 4 1.3 
  other 19 6.2 
Ten patients had affected family members in both maternal and paternal line. Nine of those 
had both parents affected. For 66 cases the parental line was unknown (siblings or children 
affected) or not specified (6.2%). 98 (32.0%) patients had more than one affected family 
member. In 18 cases a grandparent but not the parent was affected by DD. For a number of 
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additional patients a family predisposition was suggestive but not confirmed e.g. due to the 
death of relatives (not included in table 7). 
DD patients with family predisposition were on average 55.9 ± 12.2 years old when they first 
underwent surgery for DD (N = 268) compared to patients without family predisposition 
who were 61.1 ± 11.7 years old (N = 458). This age difference was also evident for males 
and females separately. Women with family predisposition for DD (N = 48, 17.9%) were 
58.8 ± 11.7 years old when they underwent fist surgery while women without family 
predisposition (N = 71, 15.5%) were 62.9 ± 11.0 years old (Table 8). Men with family 
predisposition (N = 220) had a mean age of 55.3 ± 12.3 years at first surgery and men 
without family predisposition (N = 387) were 60.8 ± 11.8 years old. 
Table 8. Mean age at first surgery for DD patients with and without familial predisposition. 
                        
    N EDATE SD dif P-value N surgery SD dif P-value 
All Non-familial 495 65.1 10.06     458 61.1 11.7     
 
Familial 296 61.1 10.6 4.0 1.2E-07 268 55.9 12.2 5.2 2.2E-08 
  
Maternal and 
paternal line 10 54.8 10.5 10.3 1.5E-03 10 47.9 12.1 13.2 4.8E-04 
Women Non-familial 82 65.2 9.9     71 62.9 11.0     
 
Familial  59 63.0 10.5 2.2 0.2 48 58.8 11.7 4.1 5.4E-02 
 
Maternal line 23 65.0 10.3 
  
16 61.9 9.4 
    Paternal line 23 58.4 10.2 6.6 3.8E-02 21 54.8 13.2 7.1 8.3E-02 
 
Line unknown 13 67.8 7.8 2.9 0.4 11 61.9 9.0 0.0 1.0 
Men Non-familial 413 65.1 10.1 
  
387 60.8 11.8 
  
 
Familial 237 60.6 10.6 4.5 1.0E-07 220 55.3 12.3 5.5 1.4E-07 
 
Maternal line 66 59.6 10.3 
  
63 54.5 13.3 
  
 
Paternal line 118 60.2 10.7 0.6 0.7 108 55.0 12.2 0.5 0.8 
 
Line unknown 53 62.8 10.4 3.2 0.1 49 56.9 10.8 2.4 0.3 
            Mean ages at sample collection date (EDATE) and first surgery (surgery) for DD patients with and 
without familial predisposition for all patients, and women and men separately. P-values are those of 
student’s t-test. Mean ages at first surgery of familiar cases were compared to those of the non-familiar 
cases within each group (“all”, “women” and “men”) and paternal line and line unknown were compared 
to maternal line. 
Patients who had affected family members both in their maternal and paternal line (N = 10) 
were youngest when they first underwent surgery (table 8). Women had an earlier mean age 
at first surgery when the affected family member was in their paternal line and men had a 
slightly earlier mean age at first surgery when the affected family member was in their 
maternal line. For both these categories the standard derivation was larger than in the control 
group. 101 (34.1%) patients with family predisposition had more than one surgery compared 
to 102 (20.6%) without family predisposition. Patients with family predisposition had both 
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hands affected in 59.5% of cases compared to 44.5% in patients without family 
predisposition (P-value of Fischer’s exact test: 0.02). Patients with a family predisposition 
had a mean stage after Tubiana of 2.2 ± 1.1 compared to 2.2 ± 1.2 in patients without family 
predisposition. 
3.1.4 Ectopic Manifestations and other Diseases 
Sample collection was preformed trough eleven different clinics and hospital departments 
from all over Germany and one in Switzerland. In most centres more than one physician 
collected the samples and completed the questionnaires. Some recorded parameters varied 
between centres. E. g. the percentage of patients with family predisposition for DD varied 
between 24% and 45% (table 9). In contrast the mean ages of sample collection and first 
surgery differed only slightly between clinics (table 9). 
Table 9. Number of samples for the different centers. 
        Center N  Familial % EDATE             SD N Surgery SD 
10 8 3 37.5 61.8 9.5 8 48.5 8.1 
30 119 54 45.4 63.5 10.3 118 58.7 12.6 
40 29 11 37.9 63.0 8.8 27 56.0 9.8 
50 162 54 34.0 65.7 10.9 162 60.4 12.2 
60' 16 8 50.0 62.9 9.8 14 56.9 11.7 
60'' 75 40 53.3 56.8 10.9 52 51.9 13.5 
70 110 37 33.6 62.4 9.1 103 58.7 9.9 
73 25 8 32.0 66.9 9.0 19 63.1 12.2 
75 141 61 43.3 64.8 10.0 119 61.1 12.2 
77 73 18 24.7 64.2 9.6 72 60.4 11.8 
78 43 12 27.9 62.6 11.4 42 58.5 12.6 
all 801 306 38.2 63.5 10.5 736 59.0 12.2 
         Number of samples and mean ages at sample collection date (EDATE) and first surgery 
(Surgery) for DD patients collected at different clinics (centres). Number and percentages of 
familial cases are given for each clinic. 
The observed inter-centre variance was especially true for ectopic manifestations of the 
disease. 102 (12.7%) of all patients had ectopic manifestations. 58 (7.2%) patients showed 
knuckle pads. The percentage of patients with knuckle pads per centre ranged from 0% to 
17.9%. A plantar fibromatosis was present in 41 (5.1%) of all patients. The percentage of 
plantar fibromatosis ranged from 0% to 11.3% between centres. Two patients had both 
plantar fibromatosis and knuckle pads. One patient suffered from frozen shoulder and four 
patients did not specify the location of the ectopic manifestation. 
Patients were asked for the presence of other diseases, namely diabetes, rheumatoid arthritis 
and epilepsy. Most common were hypertension, diabetes, arrhythmia and respiratory 
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diseases (e.g. asthma, bronchitis, COPD (chronic obstructive pulmonary disease)). Not 
uncommon were e.g. cancer, thyroid dysfunction, cataract and elevated uric acid levels (or 
gout). For 135 (16.9%) patients arterial hypertension was recorded while 279 (34.8%) 
patients took antihypertensive drugs. 108 (13.5%) patients had diabetes type 2. 18 (2.2%) 
patients had rheumatoid arthritis while 11 additional patients suffered from arthritis (not 
specified). 3 (0.4%) patients had epilepsy and 6 (0.7%) patients took antiepileptic drugs.  
Again prevalence for diseases varied between clinics. Recorded hypertension cases per clinic 
are given in table 10 as an example for inter-centre variance. 
Table 10. Hypertension and antihypertensive drug intake of DD patients from different centres. 
      Centre N Hypertension % Antihypertensivies % 
10 8 0 0,0 1 12,5 
30 119 23 19,3 60 50,4 
40 29 2 6,9 8 27,6 
50 162 13 8,0 56 34,6 
60' 16 2 12,5 3 18,8 
60'' 75 4 5,3 11 14,7 
70 110 2 1,8 13 11,8 
73 25 1 4,0 6 24,0 
75 141 48 34,0 55 39,0 
77 73 29 39,7 43 58,9 
78 43 11 25,6 23 53,5 
all 801 135 16.9 279 34.8 
      Numbers and percentages of DD patients with hypertension and anti-hypertensive 
drug intake per clinic (centre). N: total number of DD patients sampled at each centre. 
3.1.5 Diabetes Mellitus 
Diabetes patients are thought to suffer from a milder form of DD than non-diabetic patients. 
The age at first surgery was therefore compared between the two groups (table 11). Diabetic 
patients (N = 102, 13.8% female) were on average 3.5 years older (62.1 ± 11.1 yrs) than non-
diabetic patients (58.5 ± 12.3 yrs; N = 634, 18.3% female, P-value student’s t-test: 0.007) 
when they first underwent surgery for DD. The same tendency was true for females and 
males separately (data not shown). The percentage of familiar cases was higher for both 
women and men in the non-diabetic subgroups (female: 26.7% vs. 44.2%, male: 34.4% vs. 
37.8%). The mean degree after Tubiana for diabetic patients was 2.3 ± 1.1 compared to 2.1 ± 
1.1 for non-diabetic patients (P-value student’s t-test: 0.2). 
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Table 11. Diabetes mellitus in DD patients. 
           
 
N EDATE SD dif P (t-test) N Surgery SD dif P-value 
no diabetes 693 63,0 10,6 
  
634 58,5 12,3 
  diabetes 108 66,7 9,1 3,7 5,5E-04 102 62,1 11,1 3,5 6,5E-03 
familial no diabetes 270 60,2 10,6 
  
243 55,0 12,4 
  familial diabetes 36 65,9 9,3 5,7 2,7E-03 35 60,0 10,9 5,0 2,5E-02 
non-familial no diabetes 423 64,8 10,2 
  
391 60,7 11,8 
  non-familial diabetes 72 67,2 9,0 2,4 6,1E-02 67 63,2 11,0 2,4 0,1 
           Mean ages at sample collection date (EDATE) and first surgery (Surgery) for DD patients with and 
without diabetes and familiar predisposition for DD for all patients, and women and men 
separately. P-values are those of student’s t-test. Mean ages at first surgery of familiar cases were 
compared to those of the non-familiar cases within each group (“all”, “familial” and “non-familial”). 
3.1.6 Alcohol and Smoking 
Alcoholism and heavy smoking were suggested as risk factors for DD. DD patients were 
asked about smoking behaviour and alcohol consumption. 361 (45.2%) were current or 
former smokers. Smokers (N = 331, 10.3% women) had a mean age of 58.1 ± 12.3 years at 
the time of first surgery. Non-smokers (N = 405, 21.5% women) were on average 59.7 ± 
12.3 years old (P-value, student’s t-test: 0.077). Heavy smokers (N = 81, 4.9% women) who 
consumed more than twenty cigarettes per day had a mean age of 57.1 ± 11.8 years when 
they underwent first surgery.  
Table 12. Smoking behaviour in DD patients. 
                N EDATE SD dif P-value N Surgery SD dif P-value 
all non-smoker 438 64.0 10.6 
  
405 59.7 12.3 
  
 
smoker 361 63.4 10.3 0.6 0.5 331 58.1 12.3 1.6 7.7E-02 
 
<5 64 63.2 11.0 0.8 0.7 59 58.6 11.3 1.1 0.5 
 
<20 139 62.2 11.6 1.8 0.2 127 57.3 13.0 2.4  5.6E-02 
  >20 87 62.8 9.2 1.2 0.5 81 57.1 11.8 2.7 7.1E-02 
non-
familial 
non-smoker 254 65.9 9.7 
  
236 62.7 10.8 
  smoker 241 64.3 10.3 1.6 7.3E-02 222 59.4 12.4 3.3  2.7E-03 
 
<5 40 64.6 10.6 1.3 0.4 37 58.9 11.4 3.8  5.1E-02 
 
<20 95 63.2 11.8 2.7  3.2E-02 88 58.8 13.1 3.8 8.0E-03 
  >20 58 64.3 9.1 1.6 0.3 54 59.1 11.3 3.5 3.3E-02 
familial non-smoker 184 61.4 11.0 
  
169 55.6 12.7 
  
 
smoker 120 61.1 10.1 0.2 0.7 109 55.6 11.7 0.0 1.0 
 
<5 24 60.9 11.3 0.5 0.9 22 58.2 11.1 -2.6 0.4 
 
<20 44 60.1 10.8 1.3 0.7 39 53.9 12.0 1.8 0.4 
  >20 29 59.9 8.7 1.5 0.7 27 52.9 11.8 2.7 0.3 
            Mean ages at sample collection date (EDATE) and first surgery (Surgery) for DD patients with and 
without family predisposition for DD for smoker and non-smoker. SD – standard derivation, <5: less 
than 5 cigarettes per day, <20: less than 20 cigarettes per day, >20: more than 20 cigarettes per day. 
P-values are those of a two-tailed student’s t-test. 
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When cases were divided into patients with and without familial predisposition (table 12) the 
age difference between smokers and non-smokers was more pronounced in patients without 
familial predisposition and non-existent in patients with familial predisposition.  
When smokers were further subdivided according to the amount of consumed cigarettes per 
day, the age difference increased with the amount of consumed cigarettes for patients with 
family predisposition. Patients with family predisposition who consumed less than 5 
cigarettes per day were 2.6 years older than non-smokers with family predisposition. In 
contrast patients with family predisposition who consumed more than 20 cigarettes per day 
were on average 2.7 years younger than non-smokers and 6.2 years younger than heavy 
smokers without family predisposition. 
Table 13. Alcohol consumption in DD patients. 
N % 
total 801 100 
alcohol consumption 663 82.8 
occasional 487 60.8 
regular 176 22.0 
never 136 17.0 
alcoholic 2 0.2 
   
Given are the total numbers and percentages of all, 
occasional, regular, never and diseased alcohol 
consumers within the sample collective.  
663 (82.8%) of DD patients consumed alcohol (see table 16). They were divided into 
occasional and regular alcohol consumers. The dosage of regular consumers comprised e.g. 
1-3 bottles of beer or 1-3 glasses of wine per day. Alcoholism was recorded for two patients. 
3.1.7 Early Menopause 
Prof. Dr. Sigrid Tinschert noted that some female patients presenting with DD at the clinic in 
Dresden had a noticeable early menopause. Therefore the parameters age at menopause, 
hormone intake and ovarian surgery were included in the questionnaire. 76 women gave 
details about age at menopause, hormone intake and ovarian surgery. The mean age at 
menopause for these women was 48.2 ± 5.9 years. 39 (51.3%) were under 50 years of age, 
19 (25.0%) were between 50 and 51 years and 18 (23.7%) were older than 50 years. 20 
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(26.3%) underwent ovarian surgery. The mean age of menopausal onset for women without 
ovarian surgery (natural menopause, N = 56) was 48.5 ± 4.9 years. 
3.1.8 Trauma and Sudeck-Dystrophy 
18 patients developed DD after hand trauma (surgery). Nine patients suffered from sudeck-
dystrophy after DD operation. All 25 patients (two with both trauma and sudeck-dystrophy) 
had either one or several of the following characteristics: a family predisposition for DD, 
ectopic manifestations of DD, an aggressive course of disease or fast recurrence after 
treatment. 
3.1.9 Occupational Exposure 
Participants were asked about their profession and hobbies in order to classify occupational 
exposure in DD patients. 454 patients stated their profession or hobby in the questionnaire. 
384 could be grouped into professions or groups of profession consisting of more than five 
members. Of these 352 underwent surgery for DD. Office workers were taken as control 
group (table 14).  
Table 14. Profession of DD patients. 
           Profession N EDATE SD dif P-value N Surgery SD dif P-value 
Office worker 128 63.1 11.4 
  
116 60.3 12.0 
  Teacher 17 66.9 8.6 -3.8 0.2 17 62.6 9.8 -2.3 1.0 
Salesclerk 30 63.0 9.2 0.1 1.0 17 61.9 10.3 -1.6 0.8 
Carpenter 8 67.7 11.1 -4.6 0.3 8 65.9 12.1 -5.6 0.4 
Laboratory technician 7 69.6 8.3 -6.5 0.1 6 66.5 6.1 -6.2 0.4 
Electrician 16 65.1 7.4 -2.0 0.5 15 62.7 8.7 -2.4 1.0 
Agriculturist, Gardener 22 68.3 8.4 -5.2 0.0 21 60.1 12.5 0.2 0.4 
Cook, Baker, Butcher 6 66.9 9.6 -3.8 0.4 6 56.0 17.2 4.3 0.2 
Builder 30 62.9 11.0 0.2 0.9 30 58.9 12.8 1.5 0.1 
Engineer
1
, Machinist 29 60.4 10.8 2.7 0.2 28 55.3 14.6 5.1 3.5E-03 
Heavy labour
2
 9 58.2 11.1 4.9 0.2 8 55.5 12.6 4.8 8.5E-02 
Metalworker 59 64.4 9.4 -1.3 0.5 58 59.1 12.0 1.3 4.4E-02 
Driver 23 59.2 8.8 3.8 0.1 22 54.8 11.3 5.5 2.8E-03 
           384 participants who stated their profession in the survey and 352 who also underwent surgery for 
DD. N: number of workers, EDATE: mean age at sample collection, Surgery: mean age at first 
surgery, SD: standard derivation, 
1 
exclusive 7 engineers without work specifications; 
2
 as stated by 
participant/ attending physician (not specified); P-values are those of student’s t-test, the ages of 
first surgery of each category were compared to those of office workers as a control group. 
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Office workers (e.g. secretaries, bankers and computer workers) had a mean age of 60.3 ± 
12.0 years of age when they first underwent surgery for DD. The mean ages at first surgery 
of builders and drivers were significantly lower (table 14). These two groups of profession 
had a mean stage of disease after Tubiana of 2.6 ± 1.3 and 2.7 ± 1.3, respectively, while 
office workers had a mean stage of disease after Tubiana of 2.2 ± 1.0. Carpenters and 
laboratory technicians had a higher mean age of first surgery than office workers. The mean 
stage after Tubiana was highest in carpenters (3.1 ± 0.6). 
Table 15. Profession of DD patients. 
   
 
Non-familial Familial 
Profession N surgery SD dif P-value N surgery SD dif P-value 
Office worker 60 62.6 10.7 
  
56 57.8 12.7 
  Teacher 10 64.7 10.8 -2.1 0.6 7 59.7 7.3 -1.9 0.7 
Salesclerk 9 64.9 11.4 -2.3 0.6 8 58.5 7.6 -0.7 0.9 
Carpenter 8 65.9 12.1 -3.2 0.4 0 
    Laboratory technician 5 66.6 6.7 -4.0 0.4 1 66.0 0 -8.2 
 Electrician 10 66.3 7.1 -3.7 0.3 5 55.6 7.1 2.2 0.7 
Agriculturist, Gardener 12 59.4 14.2 3.2 0.4 9 61.1 9.7 -3.3 0.5 
Cook, Baker, Butcher 4 50.8 18.8 11.9 5.0E-02 2 66.5 4.5 -8.7 0.4 
Builder 25 58.8 11.9 3.9 0.1 5 59.4 16.3 -1.6 0.8 
Engineer
1
, Machinist 16 60.9 12.7 1.8 0.6 12 47.8 13.5 10.1 1.8E-02 
Heavy labour
2
 4 66.3 8.3 -3.6 0.5 4 44.8 4.3 13.1 4.9E-02 
Metalworker 34 60.0 12.7 2.7 0.3 24 57.8 10.9 0.0 1.0 
Driver 17 56.3 11.4 6.3 3.9E-02 5 49.6 9.2 8.2 0.2 
           352 participants who stated their profession in the survey and underwent surgery for DD. Those without 
and with family predisposition considered separately. N: number of workers, EDATE: mean age at 
sample collection, Surgery: mean age at first surgery, SD: standard derivation, dif: difference in years 
between the mean ages of each profession and those of office workers, 
1 
exclusive 7 engineers without 
work specifications; 
2
 as stated by participant/ attending physician (not specified); P-values are those of 
student’s t-test, the ages of first surgery/EDATE of each category were compared to those of office 
workers as a control group. 
Patients were further sub-divided in those with and without familial history (table 15). Only 
professional drivers had a lower mean age at first surgery than office worker for both 
familial and non-familial groups. The proportion of familial cases in the group of office 
workers was about 50% while the percentage of familial cases in the group of builders and 
drivers was much lower (17% and 22%, respectively).  
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3.2 Genome wide Association Study 
Chronological order of experiments is given in the beginning to clarify experimental design. 
First a genome wide association study was conducted to identify susceptibility loci for DD. 
186 unrelated DD DNA samples were compared with 1618 control samples from the 
POPGEN and KORA cohorts in a case-control setting (904,440 SNPs). Eight candidate 
regions on chromosomes 1, 2, 6, 7, 9, 11, 16, and X were identified. Four of these reached 
genome-wide significance with at least one marker with P < 5x10
-8
. The others showed 
suggested association. A summary of results for the different loci is given in table 33 of the 
appendix. 
At the same time the group of Prof. Wijmenga at the Department of Genetics, University 
Medical Center Groningen, the Netherlands conducted a GWAS with 960 Dutch persons 
with DD and 3117 controls. They genotyped the samples with Illumina HumanCytoSNP-12 
arrays, which comprise 301,232 SNPs. These were called with the use of the Illumina 
algorithm (Genome Studio, version 2.10.1). To test for replication of association, they 
selected SNPs that showed an association with a P value of less than 10
−4
.  
In order to replicate both the findings from the Netherlands and the initial findings from the 
small GWAS of the present study a selection of 48 SNPs were genotyped with the 
SNPstream genotyping platform at the CCG (465 DD patients and 282 control samples 
provided through the University of Essen). In addition more samples from the Netherlands 
and samples from the UK were genotyped in the group of Prof Wijmenga for their 
replication SNPs (32 SNPs). The meta-analysis included 2325 DD cases and 11,562 controls 
and identified nine loci associated on a genome wide level (Dolmans et al. 2011). 
The remaining German DD cases that were not genotyped with the Affymetrix 6.0 chip were 
then genotyped on the Affymetrix Axiom platform at the CCG (587,299 SNPs). To date 379 
cases have been genotyped with the Axiom CEU 1 chip. These 379 cases were compared 
with 1219 POPGEN controls that had been genotyped on the same platform at the CCG. The 
Affymetrix 6.0 (186 cases) and Axiom 2.0 (379 cases, 1219 controls) data were then 
imputated with the Beagle v.3.3.2 software using the HapMap Phase3 refernce panel. The 
subsequent association test considered 5,204,451 SNPs. 
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3.2.1 GWAS results: Axiom Genome-Wide CEU 1 Array Data 
57,084 SNP genotypes were excluded because they did not meet quality-control criteria, 
leaving 530,215 SNPs typed in 359 patients with DD and in 1173 controls. The call rate for 
the remaining SNPs was 99.4%. There was moderate evidence for inflation in the test 
statistic (λgc = 1.199) (see figure 18). Adjustment for differential population stratification 
with the use of the first four components on the basis of a multidimensional scaling analysis 
of uncorrelated SNPs reduced the inflation to λgc = 1.00. The inflation was caused by 
genetic heterogeneity between cases. Patients from Switzerland showed the strongest 
difference to the control samples from the north of Germany (see figures 19-20). There were 
no signs of differences in SNP call rates between cases and controls.  
 
Figure 18. Quantile-quantile plot (qq-plot) of expected vs. observed P-values for a chi-square-test of 
association (red) before correction for population stratification. Many markers showed P-values of 10
-3
 
caused by genetic heterogeneity withing cases. 
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Figure 19. Scatter diagram of the first two principal components (covariates). Visible are the differences 
between samples from Switzerland (green dots) and the Popgen controls (light green dots). 
 
 
Figure 20. The first four covariates plotted against all samples. Samples are sorted after their 
geographical origin on the x-axis. Differences are visible between the cases from different geographical 
origins. The greatest differences can be observed between samples from the east of Germany (red and 
green coloured dots) and from the Switzerland’s (salmon coloured dots). No genetic differences are seen 
in the sample collective from the third covariate onwards. Three outliers are present in the control 
sample set. 
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Figure 21. Manhattan plot showing the genomewide P-values (-log10) plotted against their respective 
chromosomal position. The horizontal blue line shows the suggestive genomewide significance threshold 
of 1x10
-5
. The plot includes 359 DD cases and 1173 controls tested for 530,215 SNPs. P-values are those of 
a 2df test of logistic regression, which involves two variables representing an additive effect of allele 
dosage and a dominance deviation. The association test was corrected for the first four covariates of a 
multidimensional scaling analysis conducted with a selection of uncorrelated SNPs. 
Figure 21 shows a manhattan plot for the GWAS data from the Axiom genotyping 
experiment. The genomewide P-values were obtained with the use of a test of association 
with 2 degrees of freedom, which involves two variables representing an additive effect of 
allele dosage and a dominance deviation. This test was used in order to correct for genomic 
inflation. No SNP tested for association reached genomewide significance of 5.0x10
-8
. Some 
SNPs showed suggestive association and reached P-values below 1.0x10
-5
. The noticeable 
structure on chromosome six corresponds to the HLA region. A manhattan plot for 
chromosome 20 is given in figure 23. Regional plots for all loci of interest (containing the 
SNPs with the lowest P-values) were generated with the locusZoom (Pruim et al. 2010) 
software and are given in figure 26-33. Table 16 gives a summary of the individual SNPs 
with the lowest P-values. 14 of the candidate loci identified in this study were also identified 
in the study by Dolmans et al. 2011 (for comparison the p-values from the meta-analysis are 
given for these SNPs in table 16). A number of additional potential candidates for 
association are also listed in table 16. Among them for example rs703558 (figure 31) on 
chromosome 12q23.2 located upstream of the IGF1 gene showing a p-value of 2.0x10
-5
 and 
odds ratio of 1.52 and rs7714289 with a p-value of 9.2x10
-5
 and odds ratio of 0.69 located on 
5q33.1 near the GPX3 gene. Another interesting candidate was rs2281146 on chromosome 
20q11.23 with a p-value of 1.9x10
-4
 and odds ratio of 0.63 located near the CTNNBL1 gene. 
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Figure 22. Manhattan plot showing the genomewide P-values (-log10) of chromosome 20 plotted against 
their respective chromosomal position. The horizontal blue line shows the suggestive genomewide 
significance threshold of 1x10
-5
. The plot includes 359 DD cases and 1173 controls tested for 530,215 
SNPs. P-values are those of a 2df test of logistic regression, which involves two variables representing an 
additive effect of allele dosage and a dominance deviation. The association test was corrected for the first 
four covariates of a multidimensional scaling analysis conducted with a selection of uncorrelated SNPs. 
 
 
Figure 23. Regional plot of the identified candidate risk loci on 2p16.3. The P-values obtained using a 1-
degree-of-freedom basic Chi-square allelic test (y-axis) were plotted against their chromosomal map 
positions (x-axis). The colour of each SNP spot reflects its r
2
 value. Estimated recombination rates were 
plotted in blue. The gene NRXN1 is located near rs964865l. 
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Figure 24. Regional plot of the identified candidate risk loci on 4q21.22. The P-values obtained using a 1-
degree-of-freedom basic Chi-square allelic test (y-axis) were plotted against their chromosomal map 
positions (x-axis). The colour of each SNP spot reflects its r
2
 value. Estimated recombination rates were 
plotted in blue. The SNP rs17005129 is located near the RASGEF1B gene. 
 
 
Figure 25. Regional plot of the identified DD risk loci on 5q33.1. The P-values obtained using a 1-degree-
of-freedom basic Chi-square allelic test (y-axis) were plotted against their chromosomal map positions 
(x-axis). The colour of each SNP spot reflects its r
2
 value. Estimated recombination rates were plotted in 
blue. The gene GPX3 (glutathione peroxidase 3) is located near rs3857422. The gene codes for a 
glutathione peroxidase, which functions in the detoxification of hydrogen peroxide. 
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Figure 26. Regional plot of the identified DD candidate risk loci on 5p13.1. The P-values obtained using a 
1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted 
against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. 
Estimated recombination rates were plotted in blue. SNP rs3843908 is located intronic of the DAB2 gene. 
DAB2 was the only gene in this region expressed in disease and control tissue (Whole genome 
expression). This risk loci was also identified by Dolmans et al. 2011. 
 
 
Figure 27. Regional plot of the identified DD candidate risk loci on 8q23.1. The P-values obtained using a 
1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted 
against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. 
Estimated recombination rates were plotted in blue. SNP rs1457210 is located near the genes EIF3E, 
RSPO2 and TTC35. This risk loci was also identified by Dolmans et al. 2011. 
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Figure 28. Regional plot of the identified DD candidate risk loci on 8p22. The P-values obtained using a 
1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted 
against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. 
Estimated recombination rates were plotted in blue. SNP rs4831518 is located downstream of the SGCZ 
gene. 
 
 
Figure 29. Regional plot of the identified DD candidate risk loci on 9q22.31. The P-values obtained using 
a 1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted 
against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. 
Estimated recombination rates were plotted in blue. SNP rs1319000 is located intronic of the ROR2 gene. 
ROR2 is receptor for Wnt5a and is upreguated 10fold in DD primary tissue. 
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Figure 30. Regional plot of the identified DD candidate risk loci on 10q22.1. The P-values obtained using 
a 1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted 
against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. 
Estimated recombination rates were plotted in blue. SNP rs4935578 is located intronic of the PCDH15 
gene. 
 
 
Figure 31. Regional plot of the identified DD candidate risk loci on 12q23.2. The P-values obtained using 
a 1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted 
against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. 
Estimated recombination rates were plotted in blue. SNP rs703558 is located upstream of the IGF1 gene. 
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Figure 32. Regional plot of the identified DD candidate risk loci on 14q31.1. The P-values obtained using 
a 1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted 
against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. 
Estimated recombination rates were plotted in blue. SNP rs7142926 is located upstream of the SEL1L 
gene. 
 
 
Figure 33. Regional plot of the identified DD candidate risk loci on 18p11.31. The P-values obtained 
using a 1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were 
plotted against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 
value. Estimated recombination rates were plotted in blue. SNP rs7142926 is located downstream of the 
TGIF1 gene. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 84 - 
 
 
Figure 34. Regional plot of the identified DD candidate risk loci on 20q11.23. The P-values obtained 
using a 1-degree-of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were 
plotted against their chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 
value. Estimated recombination rates were plotted in blue. SNP rs2235465 is located intronic of the 
CTNNBL1 gene. 
 
 
 
Figure 35. Clusterplot example for one SNP (rs4935578) with differences in signal strength between cases 
(green or blue) and controls (yellow). Note that all samples were annotated to the correct cluster. 
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Table 16. Axiom Genotyping Results 
  Axiom 2011 (359 cases 1173 controls)         Dolmans et al. 2011 Meta-analysis (2154 cases 9972 controls) 
NR CHR SNP POSITION A1 STAT P-value OR GENE SNP POSITION P-value OR GENE 
1 1 rs7543680 22731269 A 21.09 2.63E-5 1.61 WNT4 rs7524102 22571034 2.80E-09 1.28 WNT4 
2 2 rs964865 51401676 C 28.24 7.38E-7 0.46 NRXN1           
3 3 rs17686109 69692981 C 18.51 9.55E-5 1.81 PDZRN3 rs1123148 73973835 4.80E-04 0.87 PDZRN3 
4 3 rs1550743 133411922 C 19.13 7.01E-5 1.41 CPNE4 rs1356802 133320767 1.60E-04 0.36 CPNE4 
5 4 rs11722019 82083409 G 25.61 2.75E-6 2.58 RASGEF1B           
6 4 rs2639583 145602497 C 17.43 1.64E-4 1.68 HHIP           
7 4 rs17068670 180964374 C 18.56 9.30E-5 2.56 RP11-162G9 rs6824106 179038012 1.40E-04 0.12 RP11-162G9 
8 5 rs2548170 39401620 T 16.31 2.87E-4 0.64 DAP2           
9 5 rs7714289 150321163 T 18.59 9.20E-5 0.69 IRGM, GPX3           
10 6 rs9276412 32710552 G 18.5 9.61E-5   HLA region           
11 6 rs9399674 149237452 C 14.14 8.48E-4   TAB2 rs2179367 149804230 2.50E-07 1.23 TAB2 
12 7 rs17151317 25330508 C 17.4 1.67E-4 1.71 OSBPL3 rs4719773 24528683 0.02 0.89 OSBPL3 
13 7 rs2290221 37987632 A 22.47 1.32E-5 1.73 SFRP4, EPDR1 rs16879765 37955620 5.60E-39 1.98 SFRP4, EPDR1 
14 8 rs4831518 13843667 G 21.64 1.99E-5 1.83 SGCZ           
15 8 rs13266130 84319043 T 18.04 1.21E-4 1.92 RP11-51M18.1           
16 8 rs1457210 109261562 C 18.49 9.66E-5   RSPO2 rs611744 109297184 7.90E-15 0.75 RSPO2 
17 9 rs1319000 94370675 T 18.3 1.06E-4 1.51 ROR2           
18 9 rs966155 118445627 T 20.2 4.11E-5 1.67 DEC1, PAPPA           
19 10 rs10825475 56914474 G 18.83 8.17E-5 0.67 PCDH15           
20 10 rs12572196 123707246 A 20.12 4.28E-5 1.99 NSMCE4A           
21 11 rs2256083 108430624 T 17.48 1.60E-4 1.46 EXPH5           
22 12 rs703558 103012080 C 21.63 2.01E-5 1.52 IGF1           
23 13 rs9529480 69571505 C 19.49 5.86E-5 1.51 RP11-501G6.1           
24 14 rs2031857 82169893 G 14.68 6.50E-4 1.90 SEL1L           
25 15 rs1509408 56286313 C 17.48 1.60E-4 1.51 MYO1E rs2171286 57265777 7.50E-05 0.85 MYO1E 
26 15 rs2469179 87135495 T 16.3 2.89E-4 1.49 ISG20 rs4932194 87046243 8.10E-07 0.82 ISG20 
27 17 rs4591175 77658533 A 16.11 3.17E-4 0.55 RBFOX3           
28 18 rs4798144 3916561 G 14.79 6.13E-4 0.70 DLGAP1 rs1944967 37785137 4.10E-03 1.11 PIK3C3 
29 19 rs17273603 57677373 G 15.71 3.89E-4 1.61 DUXA rs11672517 62370006 6.80E-14 1.34 DUXA 
30 20 rs2281146 36434857 T 17.1 1.93E-4 0.63 CTNNBL1           
31 22 rs16980831 26226840 G 18.1 1.17E-4 1.51 MYO18B rs4820663 24684655 3.50E-03 1.20 MYO18B 
32 22 rs7292297 46458123 G 15.26 4.87E-4   WNT7B rs6519955 44800506 3.20E-33 1.54 WNT7B 
                            
GWA results: Given are the SNPs with the lowest P-value from each of the 32 regions that were associated with DD in the Axiom genotyping experiment. Results are compared with 
the replication SNPs from the meta-analysis by Dolmans et al. Significant P-values (<5.0x10-8) are given in bold. GENE: genes of interest located in the region of association; genes 
involved in Wnt-signalling are given in bold. STAT: P-values of the Axiom Data are those of a logistic regression corrected for the first four principal components (covariates). A1: 
minor allele; OR: odds ratio 
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3.2.2 GWAS Results: Imputed Data 
The data from 186 cases genotyped with the Affymetrix 6.0 platform and 379 cases and 
1219 controls genotyped with the Affymetrix Axiom platform was imputated with the 
Beagle v.3.3.2 software using the HapMap phase III Reference Panel. After quality control 
543 cases and 1174 controls were included in the association testing. Again genomic 
inflation was in evidence because of the different geographic origin of cases and controls 
(figure 36). Based on the inflation factor, the first six components of a MDS analysis were 
included in the adjusted model of association testing. 5,204,451 SNPs reached an imputation 
score (Beagle’s r2) of >0.8 (resulting in a Bonferroni-Level: 9.6E-09). Figure 38 shows the 
Quantile-quantile plots under the adjusted model for different r
2
 thresholds. Only SNPs with 
r
2
>0.95 were considered here. 
 
Figure 36. Scatterplots showing the first two components of a MDS analysis, for cases (red) and controls 
(blue) and for the different geographic origins of cases and controls. Based on this MDS analysis the first 
six components were included in the association testing in order to correct for genomic inflation. 
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Figure 37. Quantile-quantile plot (qq-plot) of expected vs. observed P-values for a chi-square-test of 
association after correction for population stratification (adjusted model) for different imputation score 
thresholds (r
2
).  
 
Figure 38. Manhattan plot showing the genomewide P-values (-log10) plotted against their respective 
chromosomal position. The plot includes 543 DD cases and 1174 controls tested for 5,204,451 SNPs. P-
values are those of a 1df test of logistic regression, which takes into account an additive effect of allele 
dosage. The association test was corrected for the first six covariates of a multidimensional scaling 
(MDS). Gaps in chromosomes are non-imputed regions. 
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Figure 38 shows a Manhattan plot for the imputed data set. 21.1% (125 of 592 chunks, 
5000bp each) of the genome could not be imputed. These are represented by gaps in the 
chromosomes (figure 38). The genomic region giving the strongest signal was the region on 
chromosome 7p14 already identified by Dolmans et al. 2011 (figure 39). 14 regions showed 
suggestive association. From these regions the SNPs showing the lowest p-values are 
summarised in table 17. 
Table 17. Imputation GWAS results. 
Chr SNP Position (bp) A1 FRQ_A1 A2 P_adj OR_adj Beagle r
2 GENE 
2 rs13388985 51393653 C 0.1418 T 9.63E-05 0.5921 0.989 NRXN1 
3 rs13093477 86255678 C 0.2356 T 1.47E-08 0.5404 0.976 CADM2 
3 rs9822103 181542324 T 0.0267 C 2.16E-05 3.1202 0.970 SOX2 
4 rs1374657 30837143 C 0.1444 T 1.41E-05 1.6491 0.964 PCDH7 
4 rs36007254 83875089 T 0.1891 G 7.36E-06 1.6212 0.996 LIN54 
4 rs113075608 100240016 A 0.1625 G 6.91E-06 0.5644 0.950 ADH1B 
7 rs2290221 37987632 G 0.1349 A 2.21E-10 2.1344 1.000 SFRP4 
7 rs17172182 43285598 C 0.2037 G 9.40E-07 1.6663 0.994 HECW1 
8 rs2981200 107850948 G 0.0927 A 2.74E-07 2.0331 0.966 ABRA 
10 rs72785850 20236065 A 0.0659 G 4.58E-06 2.1051 0.991 PLXDC2 
12 rs2946834 102787814 A 0.6802 G 4.51E-05 0.6915 0.997 IGF1 
15 rs4640119 56195191 T 0.4868 C 2.38E-05 1.4436 0.975 MYO1E 
17 rs16960070 64701109 G 0.021 A 7.36E-09 57.9719 0.963 PRKCA 
18 rs56909423 12614456 C 0.0144 G 3.23E-07 49.8087 0.978 SPIRE1 
18 rs8098349 39433420 A 0.4316 G 1.83E-06 1.4976 0.997 PIK3C3 
22 rs2858477 37368878 C 0.26 T 0.0001442 0.675 0.971 TST, MPST 
CHR: Chromosome, SNP: Single nucleotide polymorphism, A1: Allele 1, FRQ: Frequency of A1, from 
dosage data, OR:  Odds ratio for association, P: p-value for association tests (adjusted for the first 
six covariates of a MDS analysis), Gene: genes of interest in this region. 
Two of these SNPs feature p-values below 5x10
-8
. Among these was rs2290221 on 
chromosome 7p14, showing the strongest association signal with a p-value of 2.2x10
-10
, odds 
ratio of 2.13 and r
2
 of 1. The other SNP was rs13093477 on chromosome 3p12.1 with a p-
value of 1.5x10
-8
, odds ratio of 0.54 and r
2
 of 0.97. SNP rs13093477 is located downstream 
of the CADM2 gene. Four genomic regions showing suggestive association were also 
identified by Dolmans et al. 2011 (genomic regions around rs2290223 on chromosome 7p14, 
rs2981200 on 8q23.1, rs4640119 on 15q21.3 and rs8098349 on 18q12.3). SNPs from five 
genomic regions showed p-values comparable to those seen in the axiom data. The other loci 
identified in the axiom data had higher p-values in the imputed data. 
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3.2.3 SNPstream Genotyping 
Selected SNPs were genotyped with the Genome Lap SNPstream 48-plex Genotyping 
System (Beckman Coulter GmbH, Germany) in order to replicate and validate GWAS 
findings. 48 SNPs were typed in 465 DD patients and 282 control samples (provided through 
the University of Essen). Four SNPs (rs2738694, rs1123148, rs1450843 and rs514839) failed 
in the analysis. Results were analysed with PLINK 
(http://pngu.mgh.harvard.edu/purcell/plink/). Association was tested with chi-square test and 
Fischer’s exact test. Only results from the chi-square test are given. SNPs were typed in part 
to validate own GWAS results and in part to replicate GWAS findings from the University 
of Gröningen, the Netherlands (Dolmans et al. 2011) (see table 18). Results are given table 
18. Seven additional SNPs all located on 7p14.1 showed no association (rs4719773, 
rs10261983, rs10250905, rs10276139, rs1802074, rs1802073, and rs1668357). These are not 
listed in table 18. The strongest SNP from the GWASs rs16879765 (P-value: 0.0007, OR: 
1.69) on 7p14.1 also showed a strong association in the SNPstream analysis. rs423940 (P-
value: 4x10
-5
, OR: 0.64) on chromosome 8, rs7863802 (P-value: 2x10
-5
, OR: 1.81) on 
chromosome 9 and rs6519955 (P-value: 0.0005, OR: 1.46) on chromosome 22 also showed 
significant association. 
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Table 18. SNP stream Genotyping Results. Comparing 465 patient samples vs. 282 control samples. 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
1 rs7524102 22698447 C 0.1850 0.1771 T 0.1422 0.7061 1.055 MCG WNT4 
3 rs11672517 73891145 A 0.2837 0.2463 G 2.3910 0.1221 1.212 MCG RP11-20B7.1 
3 rs1356802 131838077 C 0.3079 0.3040 A 0.0248 0.8748 1.019 MCG CPNE4 
4 rs6824106 178801018 C 0.3670 0.3907 T 0.8120 0.3675 0.904 MCG RP11-162G9.1, AGA 
5 rs12372139 36828019 G 0.0011 0 A 0.5973 0.4396 NA MCG SLC1A3 
6 rs7747741 18301503 G 0.4305 0.4278 A 0.0099 0.9205 1.011 MCG DEK, TPMT 
6 rs237018 149743930 T 0.4814 0.5111 C 1.2010 0.2731 0.888 MCG MAP3K7IP2 
7 rs2722372 37890267 T 0.2357 0.2721 C 2.401 0.1213 0.8254 CCG/MCG SFRP4, EPDR1 
7 rs2722333 37892719 C 0.2307 0.2714 T 3.0150 0.0825 0.805 CCG/MCG SFRP4, EPDR1 
7 rs4720265 37944246 A 0.2818 0.2343 G 3.9430 0.0470 1.282 CCG/MCG SFRP4, EPDR1 
7 rs16879765 37989095 A 0.1897 0.1218 G 11.420 0.0007 1.688 CCG/MCG SFRP4, EPDR1 
7 rs6953285 38038637 C 0.4097 0.4430 T 1.5490 0.2134 0.873 CCG/MCG SFRP4, EPDR1 
7 rs6951125 116917118 A 0.4446 0.4357 G 0.1092 0.7411 1.037 MCG WNT2 
8 rs13269711 69979828 A 0.2555 0.2454 G 0.1839 0.6680 1.055 MCG SULF1 
8 rs2912522 69992380 G 0.2052 0.2463 A 3.3510 0.0672 0.790 MCG SULF1 
8 rs423940 109228008 T 0.3896 0.5000 C 16.850 4.051E-005 0.638 MCG RSPO2 
9 rs7863802 1199448 G 0.2578 0.1611 A 18.290 1.899E-005 1.808 MCG DMRT1-3 
9 rs10809650 1202371 G 0.2549 0.3125 A 5.6380 0.0176 0.753 MCG DMRT1-3 
9 rs10759289 111280824 C 0.3626 0.3309 T 1.5000 0.2207 1.151 CCG ACTL7A, ACTL7B 
Given are the SNPstream results for 465 patient samples and 282 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical position (base pair), A1: Minor allele name 
(based on whole sample), F_A: Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: Basic allelic test chi-square (1df), P: 
Asymptotic p-value, OR: Estimated odds ratio (for A1, i.e. A2 is reference), Group: Group that identified this SNP in initial GWAS: CCG: Cologne Centre for Genomics, MCG: 
Department of Genetics, University Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to these regions, underlined 
genes are involved in the Wnt signalling pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-value below 0.01. 
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Table 15 continued. 
            
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
10 rs11188849 98364544 T 0.1396 0.1562 C 0.7614 0.3829 0.876 MCG PIK3AP1 
11 rs11216534 117628968 A 0.0691 0.0778 G 0.3826 0.5362 0.880 CCG IL10RA-201 
11 rs11216674 117879639 T 0.0615 0.0701 C 0.4123 0.5208 0.870 CCG IL10RA-201 
12 rs2073950 111894072 A 0.1872 0.2022 G 0.4905 0.4837 0.909 MCG ATXN2 
15 rs17302219 59478485 A 0.2077 0.2333 G 1.3100 0.2523 0.861 MCG MYO1E 
15 rs7168492 89238255 T 0.3180 0.3160 C 0.0062 0.9371 1.009 MCG ISG20 
16 rs1833203 5339095 C 0.0143 0.0126 G 0.0763 0.7823 1.139 CCG Sweden 
16 rs8052047 79812854 A 0.0394 0.0378 T 0.0243 0.8762 1.045 CCG c-MAF 
17 rs4789939 76881703 A 0.1689 0.1741 G 0.0651 0.7986 0.964 MCG TIMP2 
18 rs625896 39531139 C 0.3275 0.3764 T 3.5930 0.0580 0.807 MCG PIK3C3 
18 rs474605 39662517 G 0.4783 0.5268 A 3.2750 0.0703 0.8236 MCG PIK3C3 
19 rs11743146 57678194 A 0.1223 0.1237 C 0.0060 0.9383 0.987 MCG several ZNFs 
20 rs6093338 39028436 G 0.0824 0.0772 A 0.1250 0.7237 1.074 MCG MAFB 
20 rs742745 39313690 A 0.1258 0.1339 C 0.2044 0.6512 0.9307 MCG MAFB 
22 rs4820663 26354655 C 0.0826 0.0824 A 0.0001 0.9907 1.002 MCG MYO18B 
22 rs6519955 46440273 A 0.4903 0.3971 C 12.120 0.0005 1.460 MCG WNT7B 
            
Given are the SNPstream results for 465 patient samples and 282 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical position (base pair), A1: Minor allele name 
(based on whole sample), F_A: Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: Basic allelic test chi-square (1df), P: 
Asymptotic p-value, OR: Estimated odds ratio (for A1, i.e. A2 is reference), Group: Group that identified this SNP in initial GWAS: CCG: Cologne Centre for Genomics, MCG: 
Department of Genetics, University Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to these regions, underlined 
genes are involved in the Wnt signalling pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-value below 0.01. 
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The association of SNPs was tested for different patient subgroups. It was tested for patients 
with family predisposition and patients without or unknown family predisposition, and for 
patients affected early in life (Surgery before the age of 50 years.) and late and mild affected 
patients (Surgery after 50 years of age, or no surgery till collection date). Table 19 provides 
an overview for conducted data analyses. 
Table 19. Summary of conducted analyses with SNPstream data. 
     
N of 
patients patient subgroup description 
N 
controls control subgroup description Table 
     
465 all typed with SNPstream 282 all typed with SNPstream 18 
184 with positive fam. history 282 all typed with SNPstream 20 
281 with negative or unknown fam. history 282 all typed with SNPstream 21 
96 with age at first surgery <50yrs 282 all typed with SNPstream text 
369 with age at first surgery >50yrs 282 all typed with SNPstream text 
465 all typed with SNPstream 1972 all SNPstream + affy (1235 POPGEN; 455 KORA) 22 
184 with positive fam. history 1972 all SNPstream + affy (1235 POPGEN; 455 KORA) text 
281 with negative or unknown fam. history 1972 all SNPstream + affy (1235 POPGEN; 455 KORA) text 
96 with age at first surgery <50yrs 1972 all SNPstream + affy (1235 POPGEN; 455 KORA) text 
369 with age at first surgery >50yrs 1972 all SNPstream + affy (1235 POPGEN; 455 KORA) text 
     
Given is an overview of compared patient and control datasets and the table in which their results are presented. N: 
number. 
The 184 patients with family history for DD mostly contributed to the association of 
rs16879765 (P-value: 4.7x10
-5
, OR: 2.08) (Table 20). For these 184 samples rs16879765 hat 
a minor allele frequency of 0.22 compared to 0.12 in controls and 0.17 in patients without or 
with unknown family predisposition (Table 21). rs423940 (P-value: 8.1x10
-6
, OR: 0.54) on 
chromosome 8 also showed a stronger association for the subgroup of patients with family 
predisposition. More SNPs, rs11672517 (P-value: 0.09. OR: 1.29) on chromosome 3, 
rs237018 (P-value: 0.06. OR: 0.77) on chromosome 6, rs11216674 (P-value: 0.07. OR: 0.58) 
on chromosome 11, rs17302219 (P-value: 0.04. OR: 0.71) on chromosome 15, rs625896 (P-
value: 0.01. OR: 0.70) and rs474605 (P-value: 0.05. OR: 1.30) on chromosome 18 tended 
towards an association, for the 184 DD samples with positive family history, compared to all 
465 patient samples (table 16) and patients without family history (table 21). In contrast SNP 
rs7863802 (P-value: 1.5x10
-5
. OR: 1.92) on chromosome 9 showed a stronger association in 
the subgroup of patients without a family history for DD (table 21) compared to those with 
family predisposition (P-value: 0.003. OR: 1.66). 
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Table 20. SNP stream Genotyping Results. Comparing 184 patient samples with fam. predisposition vs. 282 control samples. 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
1 rs7524102 22698447 C 0.1639 0.1771 T 0.2662 0.6059 0.9106 MCG WNT4 
3 rs11672517 73891145 A 0.2972 0.2463 G 2.8590 0.0909 1.2940 MCG RP11-20B7.1 
3 rs2323206 73951152 T 0.3785 0.3781 G 9.372e-005 0.9923 1.0010 MCG RP11-20B7.1 
3 rs1356802 131838077 C 0.3122 0.3040 A 0.0692 0.7925 1.0390 MCG CPNE4 
4 rs6824106 178801018 C 0.3667 0.3907 T 0.5307 0.4663 0.9027 MCG RP11-162G9.1, AGA 
5 rs12372139 36828019 0 0 0 A NA NA NA MCG SLC1A3 
6 rs7747741 18301503 G 0.4330 0.4278 A 0.0236 0.8779 1.0210 MCG DEK, TPMT 
6 rs237018 149743930 T 0.4472 0.5111 C 3.5300 0.0603 0.7739 MCG MAP3K7IP2 
7 rs2722372 37890267 T 0.232 0.2721 C 1.8270 0.1765 0.8085 CCG/MCG SFRP4, EPDR1 
7 rs2722333 37892719 C 0.225 0.2714 T 2.4560 0.1171 0.7795 CCG/MCG SFRP4, EPDR1 
7 rs4720265 37944246 A 0.2778 0.2343 G 2.1700 0.1408 1.2570 CCG/MCG SFRP4, EPDR1 
7 rs16879765 37989095 A 0.2238 0.1218 G 16.580 4.668e-005 2.079 CCG/MCG SFRP4, EPDR1 
7 rs6953285 38038637 C 0.4139 0.4430 T 0.7492 0.3867 0.8878 CCG/MCG SFRP4, EPDR1 
7 rs6951125 116917118 A 0.4438 0.4357 G 0.0582 0.8094 1.0340 MCG WNT2 
8 rs13269711 69979828 A 0.2806 0.2454 G 1.3930 0.2380 1.1990 MCG SULF1 
8 rs2912522 69992380 G 0.2099 0.2463 A 1.6150 0.2037 0.8131 MCG SULF1 
8 rs423940 109228008 T 0.3492 0.5000 C 19.910 8.127e-006 0.5365 MCG RSPO2 
9 rs7863802 1199448 G 0.2417 0.1611 A 8.9880 0.0027 1.6590 MCG DMRT1-3 
Given are the SNPstream results for 184 patient samples with family history for DD and 282 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical position (base pair), 
A1: Minor allele name (based on whole sample), F_A: Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: Basic allelic test chi-
square (1df), P: Asymptotic p-value, OR: Estimated odds ratio (for A1, i.e. A2 is reference), Group: Group that identified this SNP in initial GWAS: CCG: Cologne Centre for 
Genomics, MCG: Department of Genetics, University Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to these 
regions, underlined genes are involved in the Wnt signalling pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-value 
below 0.01. 
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Table 20 continued: 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
9 rs10809650 1202371 G 0.2472 0.3125 A 4.5160 0.0336 0.7225 MCG DMRT1-3 
9 rs10759289 111280824 C 0.3481 0.3309 T 0.2866 0.5924 1.0800 CCG ACTL7A, ACTL7B 
11 rs11216674 117879639 T 0.0417 0.0701 C 3.1650 0.0752 0.5767 CCG IL10RA-201 
12 rs2073950 111894072 A 0.1750 0.2022 G 1.0360 0.3087 0.8369 MCG ATXN2 
15 rs17302219 59478485 A 0.1778 0.2333 G 4.0030 0.0454 0.7104 MCG MYO1E 
15 rs7168492 89238255 T 0.3028 0.3160 C 0.1757 0.6751 0.9401 MCG ISG20 
15 rs4932194 89245239 C 0.3118 0.3183 A 0.0431 0.8356 0.9701 MCG ISG20 
16 rs1833203 5339095 C 0.01944 0.01259 G 0.6822 0.4088 1.555 CCG Sweden 
16 rs8052047 79812854 A 0.05307 0.03777 T 1.219 0.2696 1.428 CCG c-MAF 
17 rs4789939 76881703 A 0.1722 0.1741 G 0.00517 0.9427 0.9871 MCG TIMP2 
18 rs625896 39531139 C 0.2972 0.3764 T 6.001 0.0143 0.7007 MCG PIK3C3 
18 rs474605 39662517 A 0.5385 0.4732 G 3.757 0.0526 1.299 MCG PIK3C3 
19 rs11743146 57678194 A 0.1093 0.1237 C 0.4384 0.5079 0.8696 MCG several ZNFs 
20 rs6093338 39028436 G 0.07263 0.07721 A 0.06498 0.7988 0.936 MCG MAFB 
20 rs742745 39313690 A 0.1346 0.1339 C 0.0008956 0.9761 1.006 MCG MAFB 
22 rs4820663 26354655 C 0.0663 0.08244 A 0.8135 0.3671 0.7903 MCG MYO18B 
22 rs6519955 46440273 A 0.4890 0.3971 C 7.554 0.005987 1.453 MCG WNT7B 
            
Given are the SNPstream results for 184 patient samples with family history for DD and 282 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical position (base pair), 
A1: Minor allele name (based on whole sample), F_A: Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: Basic allelic test chi-
square (1df), P: Asymptotic p-value, OR: Estimated odds ratio (for A1, i.e. A2 is reference), Group: Group that identified this SNP in initial GWAS: CCG: Cologne Centre for 
Genomics, MCG: Department of Genetics, University Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to these 
regions, underlined genes are involved in the Wnt signalling pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-value 
below 0.01. 
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Table 21. SNP stream Genotyping Results. Comparing 281 patient samples without fam. predisposition vs. 282 control samples. 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
1 rs7524102 22698447 C 0.1996 0.1771 T 0.9014 0.3424 1.1590 MCG WNT4 
3 rs11672517 73891145 A 0.2757 0.2463 G 1.2150 0.2703 1.1650 MCG RP11-20B7.1 
3 rs2323206 73951152 T 0.3809 0.3781 G 0.0088 0.9253 1.0120 MCG RP11-20B7.1 
3 rs1356802 131838077 C 0.3043 0.3040 A 0.0002 0.9887 1.0020 MCG CPNE4 
4 rs6824106 178801018 C 0.3650 0.3907 T 0.7689 0.3806 0.8961 MCG RP11-162G9.1, AGA 
5 rs12372139 36828019 G 0.0018 0 A 0.9900 0.3198 NA MCG SLC1A3 
6 rs7747741 18301503 G 0.4286 0.4278 A 0.0007 0.9789 1.0030 MCG DEK, TPMT 
6 rs237018 149743930 C 0.4982 0.4889 T 0.0941 0.7590 1.0380 MCG MAP3K7IP2 
7 rs2722372 37890267 T 0.2372 0.2721 C 1.7450 0.1865 0.8321 CCG/MCG SFRP4, EPDR1 
7 rs2722333 37892719 C 0.2335 0.2714 T 2.0620 0.1510 0.8177 CCG/MCG SFRP4, EPDR1 
7 rs4720265 37944246 A 0.2855 0.2343 G 3.7100 0.0541 1.3050 CCG/MCG SFRP4, EPDR1 
7 rs16879765 37989095 A 0.1679 0.1218 G 4.6750 0.0306 1.4550 CCG/MCG SFRP4, EPDR1 
7 rs6953285 38038637 C 0.4066 0.4430 T 1.4790 0.2239 0.8615 CCG/MCG SFRP4, EPDR1 
7 rs6951125 116917118 A 0.4467 0.4357 G 0.1342 0.7141 1.0460 MCG WNT2 
8 rs13269711 69979828 A 0.2400 0.2454 G 0.0431 0.8355 0.9711 MCG SULF1 
8 rs2912522 69992380 G 0.2029 0.2463 A 2.9680 0.0849 0.7788 MCG SULF1 
8 rs423940 109228008 T 0.4158 0.5000 C 7.7780 0.0053 0.7116 MCG RSPO2 
9 rs7863802 1199448 G 0.2695 0.1611 A 18.750 1.489e-005 1.9210 MCG DMRT1-3 
9 rs10809650 1202371 G 0.2591 0.3125 A 3.8110 0.0509 0.7695 MCG DMRT1-3 
9 rs10759289 111280824 C 0.3736 0.3309 T 2.1720 0.1405 1.2060 CCG ACTL7A, ACTL7B 
Given are the SNPstream results for 281 patient samples without or with unknown family history for DD and 282 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical 
position (base pair), A1: Minor allele name (based on whole sample), F_A: Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: 
Basic allelic test chi-square (1df), P: Asymptotic p-value, OR: Estimated odds ratio (for A1, i.e. A2 is reference, Group: Group that identified this SNP in initial GWAS: CCG: Cologne 
Centre for Genomics, MCG: Department of Genetics, University Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to 
these regions, underlined genes are involved in the Wnt signalling pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-
value below 0.01. 
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Table 21 continued. 
            
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
10 rs11188849 98364544 T 0.1374 0.1562 C 0.7762 0.3783 0.8599 MCG PIK3AP1 
11 rs11216534 117628968 A 0.0709 0.0778 G 0.1869 0.6655 0.9049 CCG IL10RA-201 
11 rs11216674 117879639 T 0.0748 0.0701 C 0.0898 0.7644 1.0730 CCG IL10RA-201 
12 rs2073950 111894072 A 0.1960 0.2022 G 0.0664 0.7966 0.9616 MCG ATXN2 
15 rs17302219 59478485 A 0.2263 0.2333 G 0.07651 0.7821 0.9609 MCG MYO1E 
15 rs7168492 89238255 T 0.3291 0.316 C 0.2138 0.6438 1.062 MCG ISG20 
15 rs4932194 89245239 C 0.3297 0.3183 A 0.1613 0.6879 1.053 MCG ISG20 
16 rs1833203 5339095 C 0.01099 0.01259 G 0.06056 0.8056 0.8714 CCG Sweden 
16 rs8052047 79812854 A 0.03069 0.03777 T 0.4212 0.5163 0.8065 CCG c-MAF 
17 rs4789939 76881703 A 0.1673 0.1741 G 0.08906 0.7654 0.9531 MCG TIMP2 
18 rs625896 39531139 C 0.3485 0.3764 T 0.9143 0.339 0.8864 MCG PIK3C3 
18 rs474605 39662517 A 0.509 0.4732 G 1.429 0.2319 1.154 MCG PIK3C3 
19 rs11743146 57678194 A 0.1313 0.1237 C 0.1461 0.7023 1.071 MCG several ZNFs 
20 rs6093338 39028436 G 0.08909 0.07721 A 0.5066 0.4766 1.169 MCG MAFB 
20 rs742745 39313690 A 0.1205 0.1339 C 0.4528 0.501 0.886 MCG MAFB 
22 rs4820663 26354655 C 0.09353 0.08244 A 0.4267 0.5136 1.148 MCG MYO18B 
22 rs6519955 46440273 A 0.491 0.3971 C 9.934 0.001623 1.465 MCG WNT7B 
Given are the SNPstream results for 281 patient samples without or with unknown family history for DD and 282 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical 
position (base pair), A1: Minor allele name (based on whole sample), F_A: Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: 
Basic allelic test chi-square (1df), P: Asymptotic p-value, OR: Estimated odds ratio (for A1, i.e. A2 is reference, Group: Group that identified this SNP in initial GWAS: CCG: Cologne 
Centre for Genomics, MCG: Department of Genetics, University Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to 
these regions, underlined genes are involved in the Wnt signalling pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-
value below 0.01. 
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One SNP rs6519955 (P-value: 4.1x10
-5
, OR: 1.99, minor allele frequency: 0.57) on 
chromosome 22 showed strongest association in the “young” DD patients (patients with age 
at first surgery < 50 years, see table 19) compared to the “old” patients (no surgery or first 
surgery after the age of 50 years) (P-value: 0.009, OR: 1.35, minor allele frequency: 0.47, 
(minor allele frequency in controls: 0.40)). This SNP was unfortunately not included in the 
POPGEN and KORA control data set, so that the comparison between young and old 
patients could not be repeated with the larger control set for this SNP. Analysing age at first 
surgery as a quantitative trait did not result in an association of rs6519955 (data not shown). 
The SNP with the best result in this analysis was rs6824106 on chromosome 4 with and 
regression coefficient of 3.7, r
2
 of 0.02, and a P-value of 0.002. 
The 465 patients typed with SNPstream where compared to all available control genotype 
data (table 22). Note that this could be done only for those SNPs that were included in the 
POPGEN and KORA data set, and therefore that not all SNPs from the SNPstream analysis 
were included in this comparison. Results are given in table 22. The SNP rs16879765 on 
chromosome 7 showed the strongest association (P-value: 5.8x10
-10
, OR: 1.84). Two 
additional SNPs, from the initial GWAS with 186 DD patients, showed a suggestive 
association in this analysis: rs10759289 on chromosome 9 (P-value: 0.003, OR: 1.26), and 
rs8052047 on chromosome 16 (P-value: 0.04, OR: 1.48).  
Again rs16879765 (Chr. 7) showed a stronger association in the subgroup of patients with a 
family predisposition for DD (P-value: 9.4x10
-10
, OR: 2.26) compared to the patients without 
or unknown family history (P-value: 0.0003, OR: 1.57). The same tendency was true for 
SNP rs423940 on chromosome 8, which had a P-value of 1.3x10
-6
 and an odds ratio of 0.57 
in patients with family history and a P-value of 0.003 and an odds ratio of 0.76 in patients 
without family predisposition. This tendency was also noted for SNP rs8052047 (Chr. 16) 
with a P-value of 0.005 (OR: 2.03) in patients with a family predisposition while no 
association was seen in patients without family history (P-value: 0.62, OR: 1.14). SNP 
rs11216674 showed a slight hint of association only in the cases with family history (P-
value: 0.08, OR: 0.63). For two SNPs located to different regions on chromosome nine the 
opposite trend was observed: rs7863802 (P-value: 0.0002, OR: 1.48) and rs10759289 (P-
value: 0.004, OR: 1.31) showed a stronger association in the subset of patients without a 
family history for DD than patients with family history (rs7863802: P-value: 0.05, OR: 1.28) 
and rs10759289 (P-value: 0.14, OR: 1.18). 
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Table 22. SNP stream Genotyping Results. Comparing 465 patient samples vs. 1972 control samples. 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
1 rs7524102 22698447 C 0.185 0.158 T 3.907 0.04808 1.21 MCG WNT4 
3 rs2323206 73951152 T 0.3791 0.3723 G 0.1443 0.704 1.029 MCG RP11-20B7.1 
3 rs1356802 131838077 C 0.3079 0.3358 A 2.602 0.1067 0.8798 MCG CPNE4 
4 rs6824106 178801018 C 0.367 0.3794 T 0.476 0.4903 0.9486 MCG RP11-162G9.1, AGA 
5 rs11743146 36844388 A 0.1223 0.125 C 0.04989 0.8233 0.9753 MCG SLC1A3 
6 rs237018 149743930 T 0.4814 0.5 C 1.021 0.3123 0.9281 MCG MAP3K7IP2 
7 rs10261983 37885121 T 0.3377 0.3358 C 0.01206 0.9125 1.009 CCG/MCG SFRP4, EPDR1 
7 rs2722372 37890267 T 0.2357 0.2536 C 1.246 0.2644 0.908 CCG/MCG SFRP4, EPDR1 
7 rs10250905 37907304 T 0.2522 0.2542 C 0.01621 0.8987 0.9892 CCG/MCG SFRP4, EPDR1 
7 rs16879765 37989095 A 0.1897 0.1131 G 38.39 5.802e-010 1.836 CCG/MCG SFRP4, EPDR1 
7 rs1668357 38004406 G 0.05531 0.05192 T 0.1715 0.6788 1.069 CCG/MCG SFRP4, EPDR1 
7 rs6951125 116917118 A 0.4446 0.4592 G 0.6278 0.4282 0.9427 MCG WNT2 
8 rs13269711 69979828 A 0.2555 0.2316 G 2.328 0.127 1.139 MCG SULF1 
8 rs423940 109228008 T 0.3896 0.4828 C 25.5 4.422e-007 0.6838 MCG RSPO2 
9 rs7863802 1199448 G 0.2578 0.1987 A 15.27 9.326e-005 1.4 MCG DMRT1-3 
9 rs10809650 1202371 G 0.2549 0.2937 A 5.379 0.02038 0.8231 MCG DMRT1-3 
9 rs10759289 111280824 C 0.3626 0.3108 T 9.037 0.002645 1.262 CCG ACTL7A, ACTL7B 
10 rs11188849 98364544 T 0.1396 0.16 C 2.335 0.1265 0.8513 MCG PIK3AP1 
11 rs11216534 117628968 A 0.06908 0.07067 G 0.02827 0.8665 0.9759 CCG IL10RA-201 
11 rs11216674 117879639 T 0.06154 0.06493 C 0.14 0.7083 0.9444 CCG IL10RA-201 
SNPstream results for 465 and 1972 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical position (base pair), A1: Minor allele name (based on whole sample), F_A: 
Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: Basic allelic test chi-square (1df), P: Asymptotic p-value, OR: Estimated 
odds ratio (for A1, i.e. A2 is reference, Group: Group that identified this SNP in initial GWAS: CCG: Cologne Centre for Genomics, MCG: Department of Genetics, University 
Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to these regions, underlined genes are involved in the Wnt signalling 
pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-value below 0.01. 
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Table 22 continued: 
 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR Group Genes of interest 
12 rs2073950 111894072 A 0.1872 0.1979 G 0.5282 0.4674 0.9337 MCG ATXN2 
15 rs17302219 59478485 A 0.2077 0.2192 G 0.5761 0.4479 0.9335 MCG MYO1E 
15 rs7168492 89238255 T 0.318 0.3536 C 4.109 0.04266 0.8524 MCG ISG20 
16 rs8052047 79812854 A 0.03939 0.02688 T 4.028 0.04475 1.484 CCG c-MAF 
18 rs625896 39531139 C 0.3275 0.3553 T 2.486 0.1148 0.8837 MCG PIK3C3 
18 rs474605 39662517 G 0.4783 0.4979 A 1.134 0.2869 0.9247 MCG PIK3C3 
20 rs6093338 39028436 G 0.08242 0.0757 A 0.4654 0.4951 1.097 MCG MAFB 
20 rs742745 39313690 A 0.1258 0.1365 C 0.7228 0.3952 0.9108 MCG MAFB 
            
SNPstream results for 465 and 1972 controls. CHR: Chromosome, SNP: SNP identifier, BP: Physical position (base pair), A1: Minor allele name (based on whole sample), F_A: 
Minor allele frequency in cases, F_U: Minor allele frequency in controls, A2: Major allele name, CHISQ: Basic allelic test chi-square (1df), P: Asymptotic p-value, OR: Estimated 
odds ratio (for A1, i.e. A2 is reference, Group: Group that identified this SNP in initial GWAS: CCG: Cologne Centre for Genomics, MCG: Department of Genetics, University 
Medical Centre Gröningen and University of Gröningen, the Netherlands, Genes of interest: Genes that locate to these regions, underlined genes are involved in the Wnt signalling 
pathway, grey colour indicates SNPs with P-values below 0.1 and chi-square values above 3, SNPs in bold with P-value below 0.01. 
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SNPs from four loci of the initial GWAS with 186 DD patients were included for validation 
in the SNPstream genotyping analysis. One SNP, rs16879765 on chromosome 7 was 
validated to be associated with DD. Two other SNPs, rs10759289 on chromosome 9 and 
rs8052047 on chromosome 16 showed suggestive association. Four SNPs (in addition to 
rs16879765) rs423940 on chromosome 8, rs7863802 and rs10809650 on chromosome 9, and 
rs6519955 on chromosome 22, typed in replication to the GWAS findings from the 
University of Gröningen (see Dolmans et al. 2011) were associated in the present sample set 
of 465 DD patients. 
3.2.4 Sequencing of selected Candidate Genes 
The SNP rs16879765 on 7p14.1 showed a strong association with DD in the GWA studies. 
The chromosomal region that showed association is relatively small with high recombination 
rates on both sides (see figure 39).  
 
Figure 39. Regional plot of the identified DD risk loci on 7p14. The P-values, obtained using a 1-degree-
of-freedom basic Chi-square allelic test corrected for genomic inflation (y-axis) were plotted against their 
chromosomal map positions (x-axis). The colour of each SNP spot reflects its r
2
 value. Estimated 
recombination rates were plotted in blue. Region on chromosome 7, EPDR1 and SFRP4 are located near 
rs16879765. From Dolmans et al. 2011. 
Three genes are located in this region: SFRP4, EPDR1 and TXNDC3. The SNP rs16879765 
lies in the intron between exon 5 and 6 of the EPDR1 gene. TXNDC3 showed no signal in 
the expression analysis (see below) while SFRP4 and EPDR1 both were expressed in cases 
and controls. The exons of SFRP4 and EPDR1 were sequenced for mutations in the 26 
patients that were homozygous for the minor allele of rs16879765. A few patients and 
controls with the other two genotypes were sequenced additionally. One patient (3011701) 
heterozygous for the SNP rs16879765, had a heterozygous mutation in exon 5 of the EPDR1 
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gene (7:37988478 T->C) changing the codon GTG to GCG which results in an amino acid 
change from valine to arginine at amino acid position 221 of the first transcript 
(ENST00000199448). Both EPDR1 and SFRP4 were expressed in fibroblasts of this patient. 
No other mutations were identified. 
All patients homozygous for the minor allele of rs16879765 (A) were homozygous for the 
minor allele of two flanking SNPs rs2044831 (7:37988589) in exon 5 of the EPDR1 gene 
and rs1450851 (7:37989775) in exon 6 while patients heterozygous for rs16879765 (AG) 
were also heterozygous for these flanking SNPs in the exon sequence of EPDR1. 
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3.3 Expression analysis 
3.3.1 Whole Genome Gene Expression Analysis 
The Illumina HumanHT-12 v3 Expression BeadChip was used for whole genome expression 
analysis of 12 DD samples (primary disease tissue) and 12 matched controls (normal palmar 
fascia from control persons). The data was viewed with the Illumina genome studio 
software. Figure 40 shows the cluster diagram for analysed samples. Patients and controls 
cluster into two distinct groups with one female patient sample being different to both 
groups. No further sub-clustering of patient samples according to the sample characteristics 
noted in table 2 was observed. Interestingly female samples of neither patients nor controls 
clustered together. 
 
Figure 40. Cluster diagram for whole genome expression chip analysis. The dendrogram clearly 
demonstrates the differential agglomerative hierarchical profiling of disease versus control. Disease and 
control samples separate into two distinct clusters while one patient sample clusters somewhat different 
from the others. Numbers correspond to the sample numbers in table 2. 
50 genes were significantly upregulated with a fold change of 5 to 52. All genes upregulated 
in this range are given in table 23. Among these were many genes coding for cell-adhesion 
molecules (e.g. THBS2, THBS4, TNC and CADM1), extra-cellular matrix components (e.g. 
COL14A1, COL1A1, COL7A1 and FNDC1) and cell signalling proteins (e.g. CDH11, 
SFRP2, FAP). Other genes, namely MAFB and SULF1 were implemented in a GWA study 
(see above). They locate to chromosomal regions associated with DD. 
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Table 23. Genes upregulated in DD patients. 
       
SYMBOL Signal cases SD cases Signal controls SD controls DiffScore Fold Change 
THBS4 11587.0 4139.5 222.5 217.1 51.0 52.07 
TNC 3496.3 2638.4 113.8 105.8 23.0 30.72 
RASL11B 892.0 501.9 50.0 59.7 32.0 17.83 
LOC653499 596.3 1610.4 42.7 63.9 2.2 13.96 
LGALS7 372.7 932.6 34.3 53.8 2.4 10.88 
CADM1 1315.8 571.0 131.7 39.1 41.0 9.99 
LOC728910 572.2 1401.5 57.9 80.3 2.4 9.89 
NPTX2 447.4 402.5 48.4 22.2 14.7 9.25 
ADAMTSL2 480.8 317.5 52.8 22.7 23.8 9.11 
HLA-DRB5 477.6 593.1 54.9 194.7 7.3 8.70 
CDH11 978.8 360.5 114.8 44.7 46.8 8.52 
TMEM158 717.1 593.5 86.3 118.6 16.1 8.31 
ANGPTL7 2464.2 2710.7 298.9 259.0 9.9 8.24 
SCRG1 314.2 296.7 40.0 31.1 12.9 7.85 
C5orf13 2752.8 1127.0 351.9 162.2 41.9 7.82 
PGM2L1 351.8 274.6 47.6 27.3 17.6 7.38 
SLCO2A1 647.6 288.8 88.2 45.2 37.8 7.34 
THBS2 3741.2 1728.0 522.5 229.8 36.3 7.16 
COL14A1 1047.7 461.6 147.6 114.9 37.3 7.10 
FAM43B 278.1 191.5 39.6 52.7 20.2 7.03 
MYO1D 924.3 381.7 133.3 46.8 40.7 6.93 
TMEM45A 425.2 363.0 61.8 22.1 17.4 6.88 
CYR61 1261.6 1009.7 193.0 108.1 16.3 6.54 
FAM38B 456.3 222.6 71.6 121.4 28.3 6.37 
CHSY3 305.3 186.3 48.0 18.8 24.6 6.36 
NOV 1614.0 1343.7 255.1 147.1 15.1 6.33 
COL7A1 583.7 613.3 93.1 109.3 9.8 6.27 
FNDC1 3204.3 1215.4 533.6 593.9 38.8 6.01 
MXRA5 6665.9 2527.2 1132.6 1021.4 40.1 5.89 
FAP 1172.5 759.1 201.2 329.2 19.5 5.83 
GJA1 1005.3 595.5 173.6 80.7 24.9 5.79 
SFRP2 1486.9 763.0 257.5 180.4 29.6 5.78 
COL1A1 15831.0 7355.9 2752.4 3207.5 31.1 5.75 
SMOC2 367.7 74.3 64.8 36.9 64.2 5.67 
LOX 431.1 170.3 76.9 33.6 40.3 5.60 
AEBP1 3316.7 1026.0 592.1 212.1 49.7 5.60 
COMP 10428.7 3964.3 1883.4 1509.8 39.8 5.54 
SC65 349.3 194.7 63.2 43.9 26.1 5.53 
COL5A2 5647.4 3542.2 1026.6 778.2 22.1 5.50 
NT5DC2 1050.8 813.8 191.2 63.3 16.3 5.50 
CRISPLD2 1789.2 648.4 328.7 157.4 43.4 5.44 
RAI14 1481.2 532.2 276.5 97.7 44.1 5.36 
CLEC11A 384.8 211.5 72.0 32.1 26.9 5.34 
SLC16A3 413.0 227.1 78.2 110.3 23.4 5.28 
SPON2 520.6 361.0 99.2 42.2 19.1 5.25 
CHPF 661.7 337.4 126.3 29.7 29.9 5.24 
GUCY1A3 653.3 279.6 124.8 52.9 36.7 5.23 
SULF1 713.8 212.4 138.1 84.2 48.5 5.17 
MAFB 3595.0 2645.9 699.6 292.2 17.3 5.14 
LEPREL2 259.7 130.9 51.7 20.5 29.6 5.02 
       
Given are the 50 most up regulated genes in DD patient samples sorted by fold change. The 
signal detection P-values for all genes and both cases and controls were 0. Diffscore: probability 
for cases and controls to differ in their expression (larger Diffscore = higher probability). Genes 
highlighted in grey have also been identified in other whole genome expression analyses. 
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Several novel genes were identified to be upregulated in DD primary disease tissue that were 
not identified in previous whole genome expression analysis, among them were e.g. 
thrombospondin 4 (THBS4), galectin 7 (LGALS7), cell adhesion molecule 1 (CADM1), 
neuronal pentraxin II (NPTX2), major histocompatibility complex, class II, DR beta 5 
(HLA-DRB5), ADAMTS-like 2 (ADAMTSL2), scrapie responsive protein 1 (SCRG1), 
chromosome 5 open reading frame 13 (C5orf13), phosphoglucomutase 2-like 1 (PGM2L1), 
solute carrier organic anion transporter family, member 2A1 (SLCO2A1), family with 
sequence similarity 43, member B (FAM43B), myosin ID (MYO1D), transmembrane 
protein 45A (TMEM45A), cysteine-rich, angiogenic inducer, 61 (CYR61) and family with 
sequence similarity 38, member B (FAM38B). 
Additionally 797 genes were upregulated with fold changes of 1.5 to 4.9 (Detection signal P-
value = 0). Some additional genes were expressed in patient samples but reached no 
significant detection signal in control samples. Among these was e.g. POSTN which has 
been noted to be differentially expressed in DD in other expression studies (Shih et al. 
2009). 
Table 24 summarises the 46 genes down regulated with fold changes of -16 to -5. The table 
contains e.g. many genes that are involved in adipocyte metabolism e.g. LEP, LIPE, RBP4 
and THRSP; some genes encoding for heat shock proteins e.g. HSPB7 and HSPB6 and pro-
apoptotic genes like G0S2 and BOK. 
Another 655 genes (detection signal P-value = 0) were down regulated with fold changes of  
-4.9 to -1.5. Of 226 nuclear encoded mitochondrial proteins 177 (78.3%) had fold changes 
below 1 compared to non-mitochondrial genes (46.2% with fold changes below 1, N = 5657, 
P-value of student’s t-test = 1.74E-18). 
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Table 24. Most down regulated genes in DD patients. 
        
SYMBOL Signal cases SD cases Signal controls SD controls DiffScore Ratio  Fold Change 
G0S2 152.5 155.6 2391.8 1146.3 -38.2 0.064 -15.68 
PPP1R1A 174.0 231.3 2514.3 953.7 -46.8 0.069 -14.45 
LEP 108.8 132.9 1531.6 663.5 -40.7 0.071 -14.07 
LIPE 103.2 106.5 1451.6 720.1 -36.4 0.071 -14.07 
RBP4 50.8 41.5 705.7 238.3 -50.9 0.072 -13.89 
THRSP 156.4 218.7 1986.3 837.3 -42.0 0.079 -12.70 
TM7SF2 89.6 72.1 1130.4 434.0 -46.6 0.079 -12.62 
TMEM37 64.9 41.3 797.0 650.9 -18.2 0.081 -12.27 
TF 92.3 100.4 1010.2 928.2 -14.6 0.091 -10.94 
PLIN 342.7 493.9 3723.3 1185.4 -50.2 0.092 -10.86 
KIAA1881 1047.9 1058.8 11342.6 2624.9 -64.2 0.092 -10.82 
HSPB7 113.7 57.7 1193.6 672.4 -30.3 0.095 -10.50 
RDH5 177.6 214.5 1756.6 625.8 -46.8 0.101 -9.89 
PNPLA2 195.1 112.0 1841.8 673.3 -46.8 0.106 -9.44 
HSPB6 267.0 174.9 2511.3 2020.1 -17.7 0.106 -9.41 
TIMP4 137.4 103.8 1158.4 508.2 -38.9 0.119 -8.43 
CEBPA 418.3 295.0 3482.4 1535.0 -38.7 0.120 -8.33 
LPL 157.4 192.4 1310.2 535.4 -40.1 0.120 -8.32 
GPAM 340.4 573.5 2770.6 1298.9 -33.4 0.123 -8.14 
MOSC1 141.1 248.7 1126.1 371.8 -43.7 0.125 -7.98 
FAH 89.8 65.6 696.8 334.1 -34.8 0.129 -7.76 
AGPAT2 131.0 43.1 998.5 522.5 -26.4 0.131 -7.62 
RASD1 182.6 140.1 1372.0 574.5 -39.8 0.133 -7.51 
SELENBP1 133.9 116.4 931.7 284.1 -49.7 0.144 -6.96 
MAOA 605.9 682.4 3998.7 1043.5 -50.9 0.152 -6.60 
ALDH2 516.5 340.9 3396.7 1150.3 -46.8 0.152 -6.58 
C6 127.2 110.6 836.4 591.6 -19.6 0.152 -6.57 
RARRES2 440.3 309.7 2732.5 1183.1 -37.0 0.161 -6.21 
ADH1B 147.0 195.7 897.7 419.9 -30.9 0.164 -6.11 
BOK 93.5 27.7 555.7 327.3 -25.5 0.168 -5.94 
HOOK2 103.1 121.1 597.1 198.8 -42.2 0.173 -5.79 
GPT2 177.3 141.5 1021.0 321.0 -46.8 0.174 -5.76 
ADH1A 935.2 1180.9 5332.1 1628.7 -43.4 0.175 -5.70 
ECHDC3 109.4 129.9 609.4 237.8 -36.3 0.180 -5.57 
SCGB2A1 61.1 73.5 337.0 923.9 -1.7 0.181 -5.51 
APOE 552.0 281.0 3009.6 1828.5 -23.4 0.183 -5.45 
SLC19A3 153.9 326.2 822.7 373.4 -24.0 0.187 -5.35 
ACSL1 101.8 60.9 542.1 155.4 -50.2 0.188 -5.32 
FASN 803.9 277.2 4261.4 4017.4 -11.4 0.189 -5.30 
IRX6 60.6 33.1 320.6 266.6 -14.2 0.189 -5.29 
MMD 381.7 480.1 1990.9 782.1 -34.1 0.192 -5.22 
HRASLS3 1033.8 1065.0 5298.4 1490.4 -45.9 0.195 -5.13 
PECR 107.6 80.0 547.8 216.0 -37.8 0.196 -5.09 
SNCG 63.3 37.3 321.0 146.5 -33.0 0.197 -5.07 
SLC1A3 64.7 60.4 327.0 134.9 -34.6 0.198 -5.06 
        
Given are the 46 most down regulated genes in DD patient samples sorted by fold change. The signal 
detection P-values for all genes and both cases and controls are 0. Diffscore – probability for cases 
and controls to differ in their expression (larger Diffscore – higher probability). Ratio 
In order to access protein networks and signalling pathways of differentially expressed genes 
in DD, the IPA software tool was employed. Table 25 shows the molecules involved in the 
highest ranking networks and the molecules’ primary functions related to these networks. 
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In Network 1 the majority of genes (P-value = 1.73E-03, N = 23) are involved in genetic 
disorders e.g. diabetes mellitus (P-value = 4.91E-02, N = 9), glucose metabolism disorder (P-
value = 2.98E-02, N = 10), metabolic disorder (P-value = 4.07E-02, N = 11) and for example 
neuronal diseases (e.g. Huntington’s disease, N = 5). Some molecules from network 1 are 
implemented in cell morphology (P-value = 2.88E-03, N = 10) like cell shape change, 
elongation, spreading, morphology and morphogenesis. The other tabulated networks are 
mainly associated with cell death and cell signalling. The functions of network 2 comprise 
among others: apoptosis (P-value = 6.49E-06, N = 21), quantity of cellular junctions (P-
value = 6.65E-06, N = 8; and adherent junctions). Other functions in network 2 were e.g. cell 
cycle cell growth and migration and cellular assembly (aggregation of filaments). 
Table 25. Top networks identified with the IPA software. 
 
ID Molecules in Network Score Focus Molecules Top Functions 
1 ACTG2 (includes EG:72), ACTN1, ADCY7, AKAP12, ALPL, 
ARHGAP1, ATP2A2, CAP2, CDC42EP4, CDK14, DHCR7, 
DHRS3, FLNC, FSH, GEM, HK2, ITGB5, KIDINS220, Lh, 
MAPK6, MAPRE2, NOL3, P4HA2, PDLIM3, PDXK, PHKA2, 
PLIN3, PPAP2A, RAB31, RAB5A, RGS5, TLN1, TRIB1, 
TUBA1A, TYRO3 
 26  33 Small Molecule 
Biochemistry, 
Drug Metabolism, 
Carbohydrate 
Metabolism 
2 APP, BACE2, CDC42EP2, CDH1, CEBPB, CRABP2, CRYAB, 
DEGS1, DNM1, DSP, EZR, F Actin, GSN, IgG, KRT10, 
KRT16, LGALS7, LPAR1, PALLD, PIM1, PLS3, PPL, PTPRF, 
RAB11FIP5, RAPGEF3, SLC2A3, SNAI2, SPTBN1, STXBP1, 
TNFAIP2, TNFSF13B, TRIM21, TRIM29, UCHL1, ZMPSTE24 
 26  33 Cell Death, Cell-
To-Cell Signalling 
and Interaction, 
Cellular Assembly 
and Organization 
3  ACTL6A, Alpha tubulin, BMI1, CHRNA5, DR1, ETS2, FHL1, 
GADD45A, HERC5, HIF1A, Histone h4, Hsp70, HSPH1, 
HUWE1, LAMP2, LEP, MYC, MYCBP2, MYH11, MYO1B, 
NOX4, PERP, PI3K (complex), SMARCC1, SPAG9, STAT5B, 
TCF7L2, TFDP1, TRIP10, TUBB2C, TYMS, WAS, WIPF1, 
XBP1, ZNF217 
 22  31 Cell Death, Cell-
mediated Immune 
Response, 
Cellular 
Development 
4 A4GALT, ABCB1, ACSL3, BCAR1, BHLHE40, CD9, CD36, 
CD37, CD44, CD53, CD82, CD151, Collagen(s), CYR61, 
DYRK1B, ERK1/2, FCER1A, FCER1G, FGR, Focal adhesion 
kinase, FYN, GJA1, Integrin alpha 3 beta 1, ITGAV, JAK2, 
LYN, P38 MAPK, PDGFRB, PLAUR, RBP4, SERPINB5, 
SPP1, TGFB1I1, TP63, YES1 
 21  30 Cellular 
Movement, Cell 
Signalling, Post-
Translational 
Modification 
5 26s Proteasome, ACO1, AHR, B4GALT5, BCAP31, CD46, 
CD59, CSF1R, CTGF, CYP1B1, Eotaxin, ETS1, F10, F8A1, 
Fibrinogen, FOS, FOSB, FOXP1, FTH1, GAS1, IL12 
(complex), IL7R, ITGA5, ITGAM, ITGB2, JUNB, LMNA, MMP2, 
Pkc(s), RAC2, SCD, TEK, TGFB3, THY1, TNC 
 21  30 Cell-To-Cell 
Signalling and 
Interaction, 
Inflammatory 
Response, 
Cellular Growth 
and Proliferation 
6 BAZ1A, BCL2L13, CAV1, CAV2, CBX5, CDK2, COL1A2, 
CSF2RA (includes EG:1438), DEFB1, DNM2, E2f, EGR1, 
FLOT2, Hsp90, IGF1, IGFBP4, Interferon alpha, IRAK1, IRS1, 
IRS2, ISG20, Jnk, MAP3K11, p85 (pik3r), PCNA, PRKD1, 
PTGES, RFC4, SFN, SMARCA5, STAT5A, TICAM1, TLR5, 
TRIB2, ZNF160 
 21  30 Cellular Growth 
and Proliferation, 
Cell Death, 
Organismal 
Development 
     
Given are the six highest ranking molecule interaction networks allocated by the IPA. © 2000-
2011 Ingenuity Systems, Inc. All rights reserved. 
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Figure 41 exemplary depicts a graphical view of network 1 from table 25. In the centre stand 
two hormones, luteinizing hormone and follicle stimulating hormone that both are 
glycoprotein hormones secreted by the pituitary gland. In conjunction they induce egg and 
sperm production. Grouped around these are the other members in this network. 
 
Figure 41. Graphical view of network one (from table 25). Upregulated genes are depicted in red, 
downregulated genes in green. The intensity of the colour corresponds to the fold change.  
 
Figure 42. Graphical view of network one (from table 25). Upregulated genes are depicted in red, 
downregulated genes in green. The intensity of the colour corresponds to the fold change. 
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Figure 42 depicts network 2 of the IPA analysis (table 25). In its centre stands the 
immunoglobulin G (IgG), which is an antibody produced by b-cells in response to (bacterial) 
antigens. Next to it the 11fold upregulated galactoside-binding lectin 7 (LGALS7) catches 
the eye because of its red colour. The product of this gene is implicated in modulating cell-
cell and cell-matrix interactions. It was originally cloned from epidermis (Magnaldo et al. 
1995). The authors found by in situ hybridisation that it is expressed in keratinocytes and 
found mainly in stratified squamous epithelium. It expression is altered in cancer and 
LGALS7 was proposed as a biomarker in breast cancer (Demers et al. 2010) and esophageal 
squamous cell carcinoma (Zhu et al. 2010). It was found to induce the expression of matrix 
metalloproteinase 9 (MMP9) in HeLa cells (Park et al. 2010). In this study MMP9 was 
downregulated (-23fold, detection P-value in patients: 0.003, in controls: 0). LGALS7 is 
located on chromosome 19 with a gene duplicate adjacent to it on the other strand which was 
also upregulated (LOC728910 and LOC653499 in table 23). Keratin 10 and keratin 16 are 
found upregulated in this network while e.g. the small heat shock protein CRYAB is 
downregulated (fold change: -4.81). 
Table 26. Top canonical pathways. 
   
Name P-value Ratio 
Mitochondrial Dysfunction 4,28E-14 83/127 (0.654) 
Oxidative Phosphorylation 4,52E-12 84/140 (0.600) 
Estrogen Receptor Signalling 4,55E-08 78/135 (0.578) 
Valine, Leucine and Isoleucine Degradation 7,56E-08 45/63 (0.714) 
Protein Ubiquitination Pathway 1,12E-07 138/270 (0.511) 
   
Given are the five top canonical pathways as attributed by the IPA software. Ratio: 
number of deregulated genes/ number of genes in the network. 
Table 26 summarises the highest ranking canonical pathways identified in the IPA analysis 
also graphical depicted in figure 43. Top ranks mitochondrial dysfunction followed by 
oxidative phosphorylation. 
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Figure 43. Graphical illustration of top canonical pathways with IPA. Given are P-values for each 
pathway (blue bars) and the ratio of the genes differentially expressed in this analysis divided by all 
genes in this pathway according to IPA used databases (yellow line). Note that network 5 (Fatty acid 
elongation in mitochondria) contains few (N = 5) genes compared to most other networks. 
Figure 44 shows molecules involved in mitochondrial function and dysfunction and their 
localisation in the cell. Orbital spheres in the inner mitochondrial membrane represent the 
complexes I, III, and IV of the respiratory electron transporters chain. The majority of genes 
in this sketch appear to be downregulated (green colour). The main function of mitochondria 
is ATP production, which occurs during mitochondrial oxidative phosphorylation (see top 
canonical pathways, table 26). Reactive oxygen species (ROS) form as by-product of 
oxidative phosphorylation. ROS play an important role in cell signalling and create oxidative 
stress. Among the downregulated genes are those involved in the generation of, and response 
to ROS e.g. monoamine oxidase A (MAOA), catalase (CAT) and uncoupling protein 2 
(UCP2). 
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Figure 44. Mitochondrial dysfunction. Downregulated genes are highlighted in green, upregulated genes 
in red. Intensity in colour corresponds to fold change (source IPA). 
Table 27 gives the top networks identified by IPA when only upregulated genes were 
considered in the analysis. Again genetic disease dominates the top functions allocated to the 
top networks. Together network 1 and 2 contained 38 molecules with functions and/or 
diseases allocated by IPA. 18 molecules are linked with cancer (P-value: 6.89E-05), 16 have 
been associated with genetic disorders (P-value: 6.89E-05) e.g. knuckle pads, non-insulin 
dependent diabetes mellitus, coronary artery disease and non-alcoholic fatty liver disease. 
Among allocated functions were e.g. cellular growth and proliferation (N = 15, P-value: 
1.20E-03), cellular movement (N = 11, P-value: 9.38E-03 and cell death (N = 15, P-value: 
3.33E-03). Network 1 and 2 are depicted in figure 45. 
Table 27. Top networks upregulated genes only. 
     
ID Molecules in Network Score Focus Molecules Top Functions 
1 ARHGAP22, ATL1, CLEC11A, Cpla2, DPY19L1, FABP5, FJX1, 
GALNT4, GJB2, GJB6, Glutathione peroxidase, GMPPA, GMPPB, 
GPX2, GPX7, hCG, Ikb, IKK (complex), KDM5B, KLHL4, MAGED2, 
MPZL2, MTHFD1L, MUC1, MYO1B, RECQL, REEP1, SLC25A22, 
SPAG9, TMEM158, TNFRSF12A, TRO, TSC22D1, UCK2, ZNF217 
 37  30 Auditory 
Disease, 
Genetic 
Disorder, 
Neurological 
Disease 
2 ABCC4, AMACR, CASP3, CKAP4, CLCA2 (includes EG:9635), CNN3, 
CRY1, DLG4, DUSP5, EIF4E2, EZH2, FMO1, FOXQ1, FRMD6, GEM, 
Insulin, KIF13B, LYN, MYCN, NUCB2, NUDT1, OMD, p85 (pik3r), 
PCGF2, PDGF BB, PHC3, PLEKHA1, PTEN, RYBP, STK38, TMED9, 
UBE2Q2, Ubiquitin, UNC5B, ZSWIM4 
 37  31 Cancer, 
Neurological 
Disease, Cellular 
Development 
3 ADSS, BACH2 (includes EG:60468), CAMK2N1, Cbp, CCDC136, 
CDCA4, CXADR, DEGS1, DLK1, DSP, ERK, Fc gamma receptor, Fc 
receptor, FCER1A, FCGR1B, HES1, HEY2, HSD17B14, ID3, IgG, 
IgG1, KLF6, MAFB, MVP, PAQR3, PRSS23, SERPINH1, SMARCC1, 
SNAI2, SRGAP3, TCF12, TNFAIP1, ZFHX3, ZMPSTE24, ZNF408 
 35  29 Gene 
Expression, Cell 
Cycle, Cellular 
Development 
4 ACPL2, BOP1, CDR2, CHPF, CHPF2 (includes EG:54480), CHSY1, 
CHSY3, CNOT6, FAM129A, FAM57A, GAR1, glucuronyl-N-
acetylgalactosaminylproteoglycan beta-1,4-N-
acetylgalactosaminyltransferase, GSR, IMPACT, LRRN1, MIR1, 
MIR101, MYC, N-acetylgalactosaminyl-proteoglycan 3-beta-
glucuronosyltransferase, NOLC1, OAT, PAM, PERP, PGM2, Rfc, 
RFC4, RRM2B, SH3PXD2B, SLC16A9, SLC44A1, SNIP1, TAGLN2, 
TSPAN7, UST, Vla-4 
 35  29 Gene 
Expression, 
Infection 
Mechanism, 
Cellular 
Assembly and 
Organization 
5 26s Proteasome, Angiotensin II receptor type 1, Arf, ARF4, C1QTNF5, 
Calcineurin A, COG6, FKBP2, FKBP7, FKBP9, FKBP10, FKBP11, 
Gsk3, KDELR2, KDELR3, LAMP2, LEPRE1, MGAT2, MYOZ3, 
NFATC1, peptidylprolyl isomerase, PPAP2A, PPAP2C, PPIC, 
PPP3CA, PRUNE2, RCN3, SDF2L1, SEC63, SEC24D, SRPRB, 
SURF4, TRAM1, XBP1, YIF1A 
 34  29 Genetic 
Disorder, 
Metabolic 
Disease, 
Cardiovascular 
Disease 
     
Given are the five highest ranking molecule interaction networks allocated by the IPA software 
when only upregulated genes were considered in the analysis. © 2000-2011 Ingenuity Systems, 
Inc. All rights reserved. 
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Figure 45. Network 1 and 2 upregulated genes only. Only upregulated genes were considered in the IPA 
analysis. The two top ranking networks, both with a score of 37 are depicted. 
When only up regulated genes were considered in the IPA analysis (table 28, figure 46), 
Wnt/β-catenin signalling ranked top under the canonical pathways (P-value = 6.05E-07, 
ratio: 33/175 (0.189)), followed by p53 signalling (P-value = 4.04E-05, ratio: 22/99), axonal 
guidance signalling (P-value = 4.27E-04, ratio: 47/410) and Cdc signalling (P-value = 4.48E-
04, ratio: 21/180). 
Table 28. Top Signalling pathways upregulated genes only. 
Pathway P-value Ratio 
Wnt/β-catenin Signalling  6.05E-07 33/175 (0.189) 
p53 Signalling 4.04E-05 20/99 (0.202) 
Axonal Guidance Signalling 4.27E-04 47/410 (0.115) 
Cdc42 Signalling 4.48E-04 21/180 (0.117) 
Factors Promoting Cardiogenesis in Vertebrates 9.97E-04 16/95 (0.168) 
      
Given are the five top canonical pathways as attributed by the IPA software. Ratio: number 
of upregulated genes/ number of genes in the network. 
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Figure 46. Graphical illustration of top canonical pathways with IPA for upregulated genes only. Given 
are P-values for each pathway (blue bars) and the ratio of the genes differentially expressed in this 
analysis divided by all genes in this pathway according to IPA used databases (yellow line). Note that 
network 5 (Fatty acid elongation in mitochondria) contains few (N = 5) genes compared to most other 
networks. 
Table 34 of the appendix gives the genes involved in Wnt/β-catenin signalling (source IPA) 
that were expressed in the whole genome expression analysis. 40.9% (N = 110) of the genes 
were upregulated with fold changes above 1.5 and 11.8% genes were downregulated with 
fold change below -1.5). WNT11 was downregulated in patients with a fold change of -3.54. 
All other Wnt genes were poorly detected in the whole genome expression analysis or 
showed heterogeneous expression levels in patients and controls. 
3.3.2 Quantitative Real-Time PCR 
Quantitative real-time PCR (qPCR) was preformed for selected target genes in order to 
verify and refine whole genome expression analysis findings. Comparison was done for (1) 
patient and control tissue samples; (2) disease and control samples from the same patient; (3) 
patient and control fibroblasts and (4) patient fibroblasts treated with or without TGFβ1. 
Results are summarised in table 29. 
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Table 29. qPCR Results. 
    Tissue (P/C)     Tissue (P/P)     Cells (P/C)     Cells (+/- TGFβ1)   
Nr.   Gene 
Fold Change 
Chip 
P-value 
(sTTEST) 
Fold 
Change SD 
P-value 
(pTTEST) 
Fold 
Change SD 
P-value 
(sTTEST) 
Fold 
Change SD 
P-value 
(pTTEST) 
Fold 
Change SD 
1 Ref. ACTB 1.228 n.d.     n.d.     2.02E-06     0.006     
2 Ref. EIF3H -1.008 0.605     0.057     0.847     0.918     
3 Ref. EIFC2C 1.004 0.834     0.150     0.363     0.289     
4 Ref. GAPDH 1.011 0.333     0.106     0.057     1.48E-04     
5 Ref. PCDH18 1.001 0.589     0.530     0.798     0.009     
6 Ref. RN18S1 n.d. n.d.     n.d.     0.860     0.025     
7 Ref. RPS18 1.081 0.707     n.d.     0.877     0.251     
8 Ref. TBP -1.146 n.d.     n.d.     0.466     0.147     
1 Myo. ACTA2 1.221 0.203 1.738 0.468 0.024 3.795 2.421 0.444 1.170 0.255 0.001 17.696 10.922 
2 Oxi. APP 2.314 0.040 2.345 0.510 0.025 2.904 1.672 0.703 1.022 0.156 2.26E-04 1.801 0.196 
3 Oxi. ATP5B -1.195 n.d.     n.d.     0.616 -1.039 0.184 0.144 1.370 0.184 
4 Oxi. CASP3 2.679 0.098 2.060 0.410 0.053 2.166 1.453 0.769 1.057 0.387 0.031 1.576 0.415 
5 Oxi. CAT -3.372 3.04E-05 -2.968 0.173 0.164 -2.465 0.221 0.844 1.083 0.366 0.796 1.174 0.177 
6 Exp. CDH1 1.888 n.d.     n.d.     6.95E-05 2.113 0.456 0.048 9.239 9.316 
7 Oxi. COX8A -1.357 n.d.     n.d.     0.227 1.072 0.192 0.022 1.576 0.415 
8 GWA EPDR1 -1.152 n.d.     n.d.     9.15E-04 -1.641 0.225 9.31E-05 2.014 0.289 
9 beta FZD4 -3.583 n.d.     n.d.     0.0098 -1.348 0.233 0.185 -1.149 0.412 
10 beta GSK3β 1.550 n.d.     n.d.     0.592 -1.073 0.207 0.516 1.386 0.364 
11 GWA MAFB 5.139 0.004 5.801 3.823 0.034 7.586 7.115 0.584 -1.408 0.359 0.001 -6.314 0.127 
12 Oxi. MAOA -6.599 4.51E-07 -11.300 0.052 0.001 -7.059 0.107 0.212 -1.125 0.453 0.858 1.134 0.385 
13 GWA RSPO2 1.682 1.26E-04 26.587 16.035 0.005 20.423 23.737 8.47E-05 -7.122 0.100 0.657 1.620 1.135 
14 GWA SFRP4 2.678 0.003 5.224 1.633 0.004 7.272 5.942 0.190 -1.382 0.720 0.073 1.840 0.668 
15 Oxi. SOD2 n.d. 0.634 -1.040 0.517 0.753 -1.753 0.481 0.026 -1.698 0.245 0.019 -2.536 0.159 
16 Exp. TGFß3 4.964 9.95E-05 8.465 2.026 0.006 6.311 4.734 0.130 1.200 0.393 0.102 -1.054 0.130 
17 Exp. THBS4 52.070 n.d.     n.d.     0.010 -1.348 0.233 4.95E-04 9.867 3.328 
18 GWA WNT2 -1.288 0.563 1.3049 0.6320 0.033 1.730 2.450 0.420 1.702 0.970 0.068 2.377 1.174 
19 GWA WNT4 1.973 n.d.     n.d.     0.008 1.988 0.844 0.059 12.398 13.444 
20 GWA WNT7B 4.193 n.d.     n.d.     0.003 1.425 0.239 4.26E-04 4.634 1.764 
Given are the expression changes in 20 target genes detected with qPCR in total RNA samples derived from patient (P) and control (C) tissue and patient and control primary fibroblasts. 
P-values are those of paired t-test (pTTEST) and student’s t-test (sTTEST). Type: Ref.: reference gene, beta: genes involved in the Wnt/β-catenin pathway, Exp.: genes of interest from 
the whole genome expression analysis, GWA: genes localised to regions found associated with DD in the GWAS, Oxi.: genes involved in oxidative stress and mitochondrial function; Fold 
change Chip: fold changes found in the whole genome expression analysis; SD: standard derivation. Significant P-values are given in bold (< 0.05). Fold changes with significant p-values 
are highlighted in colour. N.d.: not determined. 
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Reference gene expression was not significantly different between patient and control samples 
(table 29). Those reference genes for which the expression was significantly different between 
compared groups (e.g. ACTB) were excluded from the analysis. 
Expression in Patient and Control Tissue Samples 
The gene expression of 11 genes was compared in nine DD patients and nine controls. The 
patient samples were different ones from the ones used in the expression chip experiment. The 
control samples were different except two that were used before in the expression chip 
experiment. Results from the whole genome expression analysis could be verified in the qPCR 
experiment. For the genes: MAFB, APP, CASP3 and CAT fold changes were in the same range 
as determined in the whole genome expression analysis. For the genes TGFβ3, SFRP4 and 
MAOA fold changes were slightly higher than in the whole genome expression analysis. For 
RSPO2 signal detection failed in the whole genome expression analysis but a significant 
upregulation of this gene was observed in the qPCR experiment. 
In addition the relative expression values of disease tissue were compared with those of 
macroscopically normal appearing tissue from the same patient. The control tissue was removed 
from adjacent to the disease tissue. This experiment was carried out for six DD patients. Most 
genes analysed (TGFβ3, MAFB, RSPO2, SFRP4, WNT2, ACTA2 (αSMA) and APP) showed a 
significant upregulation in disease tissue compared to control tissue from the same patient, while 
MAOA was significantly downregulated in the disease tissue. For CASP3, CAT and SOD2 no 
significant differences could be observed in control and disease tissue from the same patient. 
Expression in Patient and Control Fibroblasts 
DD and control derived primary fibroblast cell lines were harvested in passage three and the 
expression of target genes was compared for eleven patient cell lines and seven control cell 
lines. FZD4, CDH1, THBS4, EPDR1, RSPO2, and SOD2 showed significant expression 
differences in patient and control fibroblast RNA samples. For most of these genes the direction 
of deregulation was consisted with the expression patterns observed in tissue. But for RSPO2 a 
significant downregulation (fold change:-7.1) was observed in patient cells compared to control 
fibroblasts. 
To assess the influence of TGFβ1 on target gene expression, the relative expression values of 
fibroblasts treated with TGFβ1 were compared to the same cell line not treated with TGFβ1. 
This was done for five DD patients and one control. When the expression of patient fibroblasts 
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stimulated with TGFβ1 was compared to the same patient cell line without TGFβ1 treatment, 
FZD4, THBS4, EPDR1, ACTA2, CASP3 and APP showed a significant upregulation and 
MAFB was downregulated in contrast to the expression of this gene in tissue samples. 
Expression of WNT Genes 
WNT2 was expressed in patient and control samples. The observed expression was 
heterogeneous in patient and control samples and no clear tendency for patient samples could be 
seen by comparing patient and control samples. But samples could be grouped into three groups 
according to the relative expression of WNT2. Three patient and three control samples showed a 
medium expression level, while five patient and three control samples showed a lower 
expression level and seven patient samples expressed a higher level of WNT2 than the other 
samples. The mean fold change for these last samples was 1.98±0.49 (P-value: 1.68x10
-5
) 
compared to the first group and 5.25±1.29 (P-value: 4.12x10
-8
) compared to the second group. 
WNT4 and WNT7B were significantly upregulated in patient fibroblasts and WNT7B was 
upregulated in fibroblasts treated with TGFβ1 (fold change: 4.63 ± 1.76, P-value: 4.26x10-4). 
Expression of EPDR1 and SFRP4 
Patients that were homozygous for the major allele (GG) of SNP rs16879765 showed a 
significant downregulation (P-value: 0.0006) of the EPDR1 mRNA in fibroblasts compared to 
controls (mean fold change: -1.78 ± 0.11). The group of patients that carried the minor allele (A) 
for this marker showed a heterogeneous expression of EPDR1 in fibroblasts. Out of nine patient 
samples analysed two showed an upregulation (mean fold change: 1.73 ± 0.008), three a 
downregulation (mean fold change: -2.16 ± 0.12) while four samples showed no difference in 
their expression of EPDR1 compared to controls. 
The same expression pattern was observed for the SFRP4 gene. As before patient samples with 
the GG genotype for rs16879765 showed a downregulation of SFRP4 mRNA compared to 
controls (P-value: 0.005, fold change: -1.5, N = 6 patient samples and 6 controls) and out of the 
nine patients with the minor allele the same two showed an upregulation and the same three 
samples a downregulation of the SFRP4 mRNA, while four samples showed no difference in 
their expression of SFRP4 compared to controls. For the samples carrying the minor allele down 
or upregulation could not be attributed to either homo- or heterozygous genotype. In total 11 
samples with the minor allele for rs16879765 were analysed for SFRP4 expression. Two showed 
an upregulation, four a downregulation larger than the GG samples and five samples showed no 
change compared with controls. Control samples were not genotyped for rs16879765. 
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3.4 Cell culture and Immunohistological Staining 
3.4.1 Functional Assays: Collagen Matrix Contraction Assay 
Collagen contraction assays were carried out using DD and control primary cell cultures taken 
from diseased and normal fascia. Primary cultures (passages 3–6) were grown as three-
dimensional fibroblast populated collagen lattices. Collagen lattices were cast in 24-well tissue 
culture trays with each well containing 500μl collagen. Patient cultures detached themselves 
from the bottom and wall of the culture dish within the first days and progressively contracted 
the collagen gel over 13 days (figure 47 and 48).  
 
Figure 47. Contraction of fibroblast populated 3-dimensional collagen gels monitored over 10 days. Gel 
contraction for one patient cell line and one control (normal human fibroblasts) is shown. Patient cells 
rapidly contract the collagen gel visibly already at day two. The former attached gel detaches itself from the 
well wall within 24 hours. Control gels detach only after several days, while gels without cells (neg. control) 
do not contract. 
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Figure 48. When the collagen gel contracts, water is excluded from the gel, making it lighter. The reduction 
in weight correlates to the amount of contraction. The weight of patient and control fibroblast populated gels 
was recorded over time and compared to the weight of empty gels. 
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3.4.2 Functional Assays: Oxidative Stress Enzyme Function 
Whole genome expression analysis and qPCR revealed differences in catalase mRNA 
expression in disease and control tissue samples while no significant change in catalase mRNA 
levels was seen in cultured patient and control fibroblasts. To access enzyme activity in cultured 
fibroblast a catalase activity assay was preformed. Patient and control tissue derived fibroblasts 
were cultivated under described cell culture conditions at 37°C and 40.5°C. Cell homogenates of 
approximately 25,000 cells per sample were analysed in this assay. Within each run a standard 
curve was generated from known catalase concentrations (figure 49). 
0
50
100
150
200
250
0 200 400 600 800 1000 1200
CAT activity (mU/ml)
C
h
a
n
g
e
 i
n
 f
lo
u
re
s
c
e
n
c
e
 
Figure 49. Catalase activity standard curve. Change in fluorescence is reported as observed fluorescence 
intensity subtracted from that of a non-catalase control. r
2
 = 0.96.  
The samples analysed for catalase activity separated into three distinct groups: Samples in group 
1 showed the lowest catalase activity at 37°C (group 1 in figure 50). For these samples catalase 
activity remained also low at 40.5°C (group 1 in figure 51). Group 2 contained samples with 
medium catalase activity at 37°C (figure 50, group 2) and high catalase activity at 40.5°C (figure 
51, group 2). Group 3 consisted of samples with high catalase activity both at 37°C and 40.5°C 
(group 3 (patients) and 4 (controls) in figure 50 and 51). Group 1 consisted of patients only. 
Group 2 consisted of three patients and two controls. 
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Figure 50. Catalase activity in patient and control fibroblasts cultivated at 37°C. Patient samples are depicted 
as blue diamonds, controls as green circles. P-value of two-tailed student’s t-test: * 0.0003, ** 1.6E-08, 
*** 9.4E-14. 
 
Figure 51. Catalase activity in patient and control fibroblasts cultivated at 40.5°C for 3 days. Patient samples 
are depicted as blue diamonds, controls as green circles. * P-value of two-tailed student’s t-test: 2.6E-11. 
Catalase activity was inversely correlated to the measured cell concentrations in the original 
samples before normalisation (figure 28, r
2
 = 0.76) and positively correlated to the time interval 
between planting of cells and harvesting (r
2
 = 0.77).  
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Figure 52. Catalase activity negatively correlated to cell numbers counted in the samples before 
normalisation. 
3.4.3 Functional Assays: RNA interference 
GWAS and whole genome expression experiments identified the Wnt/β-catenin signalling 
pathway to be potentially involved in DD pathology. One question was therefore whether Wnt 
could promote myofibroblast differentiation. The expression of αSMA as a marker for 
myofibroblast differentiation was measured in cells treated with Wnt. Patient cells were seeded 
onto collagen gels at day one in reduced serum medium (OptiMEM) and treated on day two with 
either Wnt3a (50ng/ml) or BIO (1µM). On day five cells were harvested, the RNA extracted and 
submitted to qPCR. Cells treated with Wnt3a showed a 2.5 fold upregulation of αSMA mRNA 
as determined by qPCR (figure 53) that was evident after 48 hours. Contrary cells treated with 
BIO, a GSK3β inhibitor, showed a 2.7 fold downregulation of αSMA expression after 48 hours.  
 
Figure 53. Expression of αSMA in patient cells either treated with 50ng/ml Wnt3a or 1µM BIO (GSK3β 
inhibitor). Expression was determined by relative quantification (qPCR), 0.5, 24, 48 and 72 hours after 
treatment. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 121 - 
 
 
 
Figure 54. Relative αSMA expression in patient cells. 3 hours after addition of either control or target siRNA 
(GSK3β, NXN or NOX4) cells were treated with 2ng/ml TGFβ1 or 50ng/ml Wnt3a. 
Similarly downregulation of GSK3β by RNAi resulted in downregulation of αSMA in cells 
treated with either TGFβ1 (2ng/ml) or Wnt3a (50ng/ml) (figure 55). RNAi mediated 
downregulation of nucleoredoxin, an inhibitor of Wnt/β-catenin signalling that interacts with 
dishevelled, likewise attenuated the upregulation of αSMA in cells treated with TGFβ1 or Wnt3a 
(figure 54). RNAi mediated downregulation of a third gene, NADPH oxidase 4 (NOX4) also 
prevented the upregulation of αSMA upon TGFβ1 or Wnt3a treatment (figure 54). NOX4 gene 
product is involved in mediating oxidative stress. RNAi experiments were done for two patients 
each. Further experiments with more patient and control cells are necessary to confirm these 
initial findings. Figure 55 shows the expression of GSK3β, NXN and NOX4 in tissue and cells. 
 
Figure 55. Relative expression of GSK3β, NXN and NOX4 in primary patient tissue compared to control 
tissue (whole genome expression) and in patient cells either treated with 2ng/ml TGFβ1 or 50ng/ml Wnt3a. 
Fold changes observed in treated cells are similar to those observed in the whole genome expression analysis. 
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3.4.4 Immunohistological Staining of Primary Tissue and Fibroblasts 
Disease and control primary tissue was fixed in formalin, paraffin embedded, sectioned and HE 
stained. Disease tissue was rich in collagen fibres as evident from the red staining (figure 56). 
Disease tissue is characterised by cell rich (figure 56A) and cell poor (figure 56B) areas that 
alternate (figure 56C). Cell rich areas resemble nodules that contain high amounts of 
proliferating fibroblasts and fewer amounts of collagen fibres than the cell poor cord structures. 
The DD tissue is interspersed with blood vessels (figure 56, arrow). In comparison control fascia 
tissue is nearly devoid of cells and collagen fibres (figure 57). 
   
Figure 56. HE staining of DD tissue. The collagen (red staining) rich tissue consists of cell rich (A and C (blue 
stained nucleus)), and cell poor (B and C) areas. The arrow indicates a blood vessel longitudinally sectioned. 
10 x magnification. 
  
Figure 57. HE stainings of two control fascia samples from the palm. The tissue contains only few cells 
(nucleus stained in blue), few collagen fibres (red), and few small blood vessels (left picture, arrow). 10 x 
magnification. 
Immunohistological staining of disease and control tissue for collagen IV revealed that control 
tissue predominantly consists of fat cells (figure 58B). Fat cells are also found around disease 
tissue (figure 58A). The cell and collagen rich areas that characterise disease tissue stained 
positive for collagen IV (figure 58A and B). 
A       B          C 
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Figure 58. Depicted are disease (A and B) and control (C) tissue samples immunohistochemically stained for 
collagen 4 (green staining) and DAPI (blue staining of the nuclei). Highlighted are the basallamina in blood 
vessels (strong green staining, arrows), the outlining of fat cells (A (upper righthand corner) and C) and the 
collagen rich disease tissue (A and B only). A: 10x, B: 40x, C: 20x magnification. 
Disease and control tissue samples were immunohistochemically stained for the presence of 
alpha smooth muscle actin (αSMA), a marker for myofibroblasts and also for vascular smooth 
muscle cells (VSMCs) that reside in the walls of blood vessels. Figure 59 shows the αSMA 
staining of control tissue. Only small blood vessels (figure 32C) within the tissue stain positive 
for αSMA. Figure 60 shows αSMA staining in primary disease tissue. αSMA is extensively 
present in the cell rich areas of the disease tissue. 
   
Figure 59. Immunohistochemical staining of control fascia tissue. A, B and C: αSMA staining (green) and 
DAPI (blue): vascular smooth muscle cells in small blood vessels are stained positive for αSMA. A and B: 20x 
magnification. C: ~40x magnification of a small blood vessel. 
A        B             C 
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Figure 60. Immunohistochemical staining of disease tissue for αSMA (green) and DAPI (blue). Stained in 
green are myofibroblasts that constitute the disease tissue. Arrows in C indicate blood vessels that also stain 
positive for αSMA. A: 20x, B and C: 40x magnification. 
Alpha Smooth Muscle Actin Staining in Fibroblasts 
Patient and control fibroblasts were grown on different substrates (glass, poly-L-lysis, 
fibronectin and collagen) in the presence of TGFβ1 (2ng/ml) for three days. Cells were then 
immunohitochemically stained for αSMA. Both patient and control cells formed stress fibres 
upon TGFβ1 treatment. These are parallel sheets of actin fibres within the cytoskeleton of the 
cell (stained in red in figure 61, 62 and 63). Some cells additionally expressed αSMA (green 
staining). Both control and disease fibroblasts showed positive αSMA staining. The amount of 
αSMA varied within patient and control samples. While some patient cell lines exhibited 
relatively many αSMA positive cells (figure 62A) others had few αSMA positive cells (figure 
61C). 
   
   
Figure 61. Immunohistochemical staining of primary fibroblast grown on fibronectin in the presents of 
TGFβ1 (2ng/ml) for three days. A-C: fibroblast derived from DD tissue (3 different patients), D-F: 
fibroblasts derived from healthy fascia of three controls. The nucleus is stained in blue (DAPI), the actin 
cytoskeleton is stained in red (Phalloidin) and αSMA is stained in green. A-D 10x, E and F 20x magnification. 
A        B             C 
A          B                C 
 
 
 
 
D          E                F 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 125 - 
 
   
   
Figure 62. Immunohistochemical staining of primary fibroblast grown on collagen in the presents of TGFβ1 
(2ng/ml) for three days. A-C: fibroblast derived from DD tissue (3 different patients), D-F: fibroblasts 
derived from healthy fascia of three controls. The nucleus is stained in blue (DAPI), the actin cytoskeleton is 
stained in red (Phalloidin) and αSMA is stained in green. A, D-F 10x, B and C 20x magnification. 
Controls generally had few αSMA positive cells regardless of used substrates. Patient cells 
grown on collagen showed a trend towards more stress fibres and αSMA positive cells. 
  
Figure 63. Immunohistochemical staining of primary disease fibroblasts grown on fibronectin. A: overlay 
DAPI (blue) and αSMA staining (green); B: overlay DAPI (blue), αSMA staining (green) and phallodin (red) 
staining. 40x magnification. 
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4 Discussion 
4.1 Epidemiology 
A questionnaire based survey of known risk factors and other parameters was conducted in 
order to characterise DD patients epidemiologically. This characterisation is desirable for the 
planning and interpretation of genetic and expression profile analyses. The survey itself can 
also give insights into the mechanisms that lead to DD. The questionnaire was completed by 
the attending physicians to ensure medical accuracy. 
4.1.1 Heredity 
Approximately 38.2% of patients reported a positive family history for DD, with one or 
more affected family members. In comparable studies observed family predisposition rates 
were conspicuously lower. These studies determined a family predisposition in 28% 
(Hakstian 1966), 27% (Coert et al 2006), 26% (Mäkelä et al. 1991), 14.8% (in men) (Early 
1962), and 12.5% (Brenner et al 2001) of cases. In the present study patients were not 
selected for a family predisposition. However it is possible that patients with positive family 
history more readily agree to participate in a study investigating the genetic causes of this 
disease. Regional differences may also explain differences in family predisposition rates (see 
below). 
It is possible that the overall rate of family predisposition noted in this study slightly 
underestimates the actual rate in German DD patients. Especially older patients may not 
have been able to indicate whether their parents or grandparents were affected by DD 
because those may not have presented at a clinic themselves. Within all investigated risk 
factors a family predisposition for DD had the largest impact on the mean age at first 
surgery. Patients were around five years younger, when they had affected family members. 
Coert et al. (2006) investigated the same parameter and found no difference in mean age in 
which patients were operated between those with and without family predisposition. This is 
maybe due to the smaller effective size (N = 261) in their study. 
Additionally 3.3% of DD patients had affected family members in both of their parental 
lines. These patients were about 13 years younger than patients without positive family 
history when they underwent first surgery. This significant age differences could hint on 
additive genetic effects that lead to a stronger disease phenotype in these patients. 
The rate of a family predisposition was highest in the younger patients and declined with 
age. This supports the observation that patients with a family predisposition are affected 
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earlier by the disease. On the other hand older patients are less likely to be able to indicate 
possibly affected family members due to the death of older relatives (e.g. parents). 
The male-female ratio was highest in 40-49 year old patients, underlining that men are 
affected earlier. It was often reported that the observed male-female ratio is due to the later 
age of onset in female DD patients and that the ratio equals one for very old patients 
(Brenner et al. 2001). In this study more men than women underwent surgery for DD in all 
sampled age classes (decades of live). This was still true for 80-89 years old patients. The 
same tendency was noted by Loss et al. (2007). 
4.1.2 Diabetes Mellitus 
The mean age at the time of first surgery for Diabetes patients was significantly different in 
all patients and those with a familial predisposition for DD. Diabetes patients were three to 
four years older than non-diabetic patients when they first underwent surgery for DD. This 
tendency was also true for women and men separately. Diabetes mellitus itself is an ageing 
associated disease. It is therefore impossible to say whether the observed age differences are 
due to a described “milder phenotype” in diabetic DD patients or if the observed correlation 
with age is independent in both diseases. One could test for this e.g. by comparing the 
frequency of diabetes in DD patients to that of a collective of age matched controls. 
4.1.3 Other Risk Factors (Smoking, Alcoholism, Epilepsy) 
Smokers were on average slightly younger at the time of first surgery than non-smokers. 
This age difference was just not significant for all patients and patients without a familial 
predisposition for DD. In patients without familial predisposition the amount of consumed 
cigarettes per day did not correlate with the mean age at first surgery, while in men with 
familial predisposition there was an ~7 year difference in the mean age at first surgery for 
heavy smoker, who consumed more than twenty cigarettes per day and smokers who 
consumed less than five cigarettes per day (difference not significant). Heavy smoking may 
be a risk factor in DD. A larger sample collective would be desirable in order to test for this 
hypothesis. Loos et al. (2007) found no statistical correlation between heavy smoking (>20 
cigarettes per day) and mean stage of disease after Iselin's classification. Brenner et al. 
(2001) noted a higher percentage of bilateral affected patients among heavy smokers 
compared to patients who consumed less than twenty cigarettes per day. In cohort or 
epidemiological case control studies a significant correlation between heavy smoking and 
the occurrence of DD was seen in the majority of studies e.g. An et al. (1988), Burge et al. 
(1997), Gudmundsson et al. (2000), Godtfredsen et al. (2004), and Burke et al. (2007) but 
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not seen in e.g. Zerajic and Finsen (2004). It could be advisable to subdivide patients into 
those with and without familiar predisposition when accessing the prevalence of heavy 
smoking or other suggestive risk factors in DD patients and correct for familial cases in 
cohort studies, respectively because family predisposition may be a strong risk factor for 
DD. 
No correlation was seen between alcoholism and DD in this study. Only 0.9% of patients 
took antiepileptic drugs. Loos et al. (2007) and Brenner et al. (2001) both found 1.3% 
epilepsy patients in their respective patient collectives (2919 and 566 patients, respectively) 
and Coert et al. (2006) noted 1.9% epilepsy patients in a collective of 261 operated patients. 
4.1.4 Occupational Exposure 
Notable the prevalence of a family predisposition for DD was ≥50% in office workers, 
teachers and salesclerks. The family predisposition rate in manual workers was overall lower 
but for some profession groups it was still in the range or above the overall prevalence rate 
of 38.2%. It is possible that participants (and their physicians) who stated profession and 
hobby were in general more thoroughly when completing the questionnaire. This would 
explain the higher rate of family predisposition in all “workers”, 40.5% (N = 454) compared 
to 35.1% (N = 348) in “non-workers” (participants with unknown profession). Still the 
higher frequency of familiar cases in office workers could hint indirectly that manual work 
or certain types of manual work are a risk factor for DD, so that the inherited form of DD is 
more prevalent in non-manual workers. Overall manual workers had a slightly lower mean 
age at first surgery than office clerks, teachers and salesclerks. Interestingly drivers had the 
lowest mean age at first surgery and the highest mean degree after Tubiana. Professional 
driving is not readily associated with heavy manual work but it is associated with e.g. hand-
arm vibration syndrome (Åström et al. 2006). The eleven participants in this category were 
six truck drivers, two dredge drivers, one garbage truck driver, one crane driver and one 
driving instructor. Effective size was small in this category and results could be due to 
chance but they fit in with a recent publication by Descatha et al. (2011). The authors 
conducted a literature based meta-analysis on occupational exposure and DD and found that 
profession title alone was a poor parameter to access the association of manual work and 
DD. They found that studies investigating the duration and intensity of exposure to manual 
work and vibrations found positive associations between manual work and DD. Based on 
these findings the authors concluded that there is an association between DD and heavy 
manual labour and/or vibrations. Repetitive hand trauma and vibrations lead to nerve 
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disorders and fractures in the hands of race drivers (Masmejean et al. 1999, Mansfield and 
Marshall 2001). It is therefore important to inquire duration of manual work and exposure to 
vibrations including hobby and e.g. driving to place of work, when accessing occupational 
exposure in DD. 
Age at first surgery is dependent on individual patients’ needs and disease progression. 
Patients who’s profession involves regular contact to customers e.g. salesclerks, will 
potentially present earlier for surgery than employees without customer contact e.g. 
laboratory technicians or pensioners. This could explain why carpenters had the highest 
mean age at first surgery compared to all other manual and non-manual workers. Disease 
progression can vary considerably from slow, surgery is not considered till late in life or not 
at all - to aggressively fast, surgery is required soon after first evidence of nodules. It 
therefore would be more adequate to compare the age of occurrence of the disease between 
different patient subgroups to access differences for professions and life styles. On the other 
hand stating the year of occurrence may be difficult for some DD patients because they may 
present at a clinic long time after first occurrence. 
4.1.5 Inter-Centre Variance 
The rate of family predisposition for DD varied between centres as did other parameters e.g. 
the prevalence of hypertension. The highest rate of a family predisposition between centres 
(and the lowest mean age of first surgery) had the group of patients that were recruited via 
the Dupuytren e.V. support community. These patients more actively participated in the 
study. They contacted the CCG via e-mail or telephone, got the material for blood collection 
and the questionnaire per post and went to their attending doctor, who took the blood 
sample. The sample was then sent back to the CCG by post. One can assume that patients 
who are not only affected themselves but are additionally confronted with DD in their family 
are more interested in this disease and its cause and are therefore more likely member of a 
support community and more willing to participate in studies investigating the genetic cause 
of DD. This centre, with only 71.7% patients with surgery for DD, has therefore to be treated 
somewhat separately when evaluating inter-centre variance. Sample collection in the other 
centres was not biased towards familiar cases. Nevertheless percentage of family 
predisposition ranged from 23.5% to 45.4% between different clinics. These differences 
could either be a function of regional differences e.g. one could hypothesise that there are 
more manual workers in rural vs. urban regions. Heavy manual work is a risk factor for DD 
and may account for a higher percentage of DD cases without family predisposition in rural 
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regions. Supporting this hypothesis there were 17.6% office worker among the patients from 
two centres from the north-east compared to 38.6% office workers in one centre in the south-
west and e.g. 9.3% and 4.5% builders, respectively. Another possible explanation for the 
observed bias is the variability in persons who completed the questionnaire with the patients. 
Often more than one physician took the samples in each clinic. Dependent on work load they 
can be assumed to be more or less thoroughly in questioning the participant. A hint that 
observed differences may be at least partly due to regional differences is the prevalence of 
hypertension in DD patients from different centres. Interestingly the highest rates of 
hypertension (≥ 50%) were found in the three clinics located in the east of Germany. 
Supporting that Meisinger et al. (2006) reported a 20% difference in the frequency of 
hypertension in a population in located in the north-east compared to one in the south-west 
of Germany. 
4.1.6 Age at Menopause in Women 
The mean age of natural menopause in women is generally given in the literature as 50 years 
of age (e.g. Shuster et al. 2010). Menopause between the ages 40-45 years is termed “early 
menopause” and “premature menopause” describes menopausal onset before the age of 40 
years (Shuster et al. 2010). The mean age of menopause in this study was 48.2 years, 
marginally below the general mean. Jacobsen et al. (2002) analysed the relationship of 
menopausal onset and mortality rate in 19,731 Norwegian women and found a mean age at 
natural menopause of 48.4 years in women born in cohorts 1886 to 1926. The mean age of 
menopause in this study can therefore be considered to be normal. In the Norwegian survey 
2.8% of women had natural menopause before the age of 40, and 1.6% stated natural 
menopause after the age of 55 years. Interestingly in this study 5.4% of women experienced 
natural menopausal onset before the age of 40, and 7.1% reported natural menopause after 
the age of 55 years while 21.4% were 50 years of age at menopausal onset. This may suggest 
a non normal distribution of menopausal age in women with DD. It would be of interest to 
investigate in a larger effective size whether these results are due to chance or not. A 
connection between menopausal onset and DD may point to the importance of aging 
associated factors in the pathogenesis of DD. 
4.2 Genetic Association 
Of all analysed risk factors, a genetic predisposition had the largest negative impact on the 
age of first surgery in DD patients. Genetic factors can be considered one of the major risk 
factors for DD. Accordingly the GWAS revealed several loci associated with DD. A study 
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combining the data sets from Germany, the Netherlands and UK identified nine loci for 
which association was significant on a genome wide level (Dolmans et al. 2011). They 
analysed the data from 2325 DD patients and 11,562 controls and found the following SNPs 
to be associated with DD with P-values (P) below 5.0x10
-8
: rs16879765 (P = 5.6x10
−39
; OR: 
1.98) on 7p14.1, rs6519955 (P = 3.2x10
−33
; OR: 1.54) and rs8140558 (P = 1.2x10
−22
; OR: 
1.39) on 22q13, and rs11672517 (P = 6.8x10
−14
; rs2912522 (P = 2.0x10
−13
; OR: 0.72) on 
8q13 and rs8124695 ((P = 7.6x10
−10
; OR: 1.48) on 20q11.2–q13.1, rs611744 (P = 7.9x10−15; 
OR: 0.75) on 8q23.1, rs10809650 (P = 6.2x10
−9
; OR: 0.80) and rs10809642 (P = 1.2x10
−8
; 
OR: 1.35) on 9p24.3, and rs7524102 (P = 2.8x10
−9
; OR: 1.28) on 1p36.23–p35.1. 
Six of these nine loci contain genes involved in the Wnt/β-catenin signalling pathway: 
WNT4 (rs7524102) (P = 2.8x10
−9
; OR: 1.28), SFRP4 (rs16879765) (P = 5.6x10
−39
; OR: 
1.98), WNT2 (rs4730775) (P = 3.0x10
−8
; OR: 0.83), RSPO2 (rs611744) (P = 7.9x10
−15
; OR: 
0.75), SULF1 (rs2912522) (P = 2.0x10
−13
; OR: 0.72), and WNT7B (rs6519955) (P = 
3.2x10
−33
; OR: 1.54). Together with the findings from the whole expression analysis (see 
below) this indicates that the Wnt/β-catenin pathway plays an important role in both the 
aetiology and the pathogenesis of DD. As described in the introduction the Wnt/β-catenin 
pathway is susceptible for aging associated changes (Marchand et al. 2011, Brack et al. 
2007, Liu et al. 2007). 
All six genes encode for proteins that function extracellulary by being either Wnt ligands 
(WNT2, WNT4 and WNT7B) or proteins that inhibit (SFRP4) or stimulate (RSPO2 and 
SULF1) Wnt signalling by interacting with Wnts, their receptors or other Wnt-signalling 
components in the ECM and the plasma membrane. Another locus associated with DD, 
although not on a genome wide level, rs237018 on 6q25.1 (P = 1.7×10
−5
, OR: 0.86) contains 
the gene TAB2 (MAP3K7IP2) which is an activator of MAP3K7 and also involved in Wnt 
signalling (Dolmans et al. 2011). 
Although the initial GWAS in the present study was quiet small, comparing only 186 DD 
samples with 1618 controls, it identified the strongest associated SNP rs16879765 on 7p14.1 
that was replicated in the joint analysis (Dolman et al. 2011). Three other SNPs (out of four) 
showed a suggestive association in the verification analysis with SNPstream and 465 DD 
samples: rs10759289 on chromosome 9q31.2 (P-value: 0.003, OR: 1.26), and rs8052047 on 
chromosome 16q23.2 (P-value: 0.04, OR: 1.48, gene of interest: MAF) and rs11216674 on 
11q23.3 (in cases with genetic predisposition only: P-value: 0.08, OR: 0.63).  
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379 cases and 1.219 controls were then genotyped with the Affymetrix Axiom platform. 
This data set was imputed together with the 186 cases genotyped with Affymetrix 6.0. The 
imputed data set considered 565 patients and 1219 controls analysed for 5 million SNPs. 
Again the strongest association signal was seen for the locus on chromosome 7p14.1 (SNP 
rs2290221, p-value of 2.2x10
-10
, odds ratio 2.13). This analysis also identified additional hits 
that need to be verified in subsequent experiments because some of the SNPs showing 
suggestive association were imputed. These need to be genotyped in cases and controls to 
confirm the association signal seen in the data.  
No disease causing mutations have been identified so far and further efforts are required to 
unravel the genetic changes that underlie the genetic cause of DD. Several genes involved in 
Wnt signalling locate to different chromosomal regions associated with DD. Wnt signalling 
plays an important role during development and is also involved in many processes in the 
adult organism (see introduction). The genetic changes leading to DD apparently have no 
negative effects on early life. They are therefore rather not expected to abolish gene function 
completely, but may affect gene function in the context of aging associated changes in e.g. 
oxidative stress, tissue composition and immune response. 
Differences in the gene expression patterns between carriers of the minor and major allele of 
rs16879765 on chromosome 7p14.1 were seen. While patients homozygous for the major 
allele showed downregulation of SFRP4 (and EPDR1) in disease derived fibroblasts, patients 
with the minor allele were heterogeneous in their expression of these genes. 11 samples with 
the minor allele for rs16879765 were analysed for SFRP4 expression. Two showed an 
upregulation, four a downregulation and five samples showed no change in SFRP4 
expression compared to controls. SFRP4 has an inhibitory effect on Wnt/β-catenin 
signalling. Its expression is expected to be tightly regulated. Both over and under expression 
of SFRP4 may favour DD. In order to replicate observed differences, this expression 
analysis should be repeated in a larger sample set. In contrast to the downregulation of 
SFRP4 in fibroblasts from carriers of the major allele for rs16879765, SFRP4 was 
upregulated in primary tissue. Further analyses are required to investigate the relationship of 
genetic association and gene expression for this and other loci both in primary tissue samples 
and disease derived cells. 
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4.3 Expression and Function 
A whole genome expression analysis was preformed comparing the expression profiles of 12 
disease tissue samples with 12 matched controls. Most genes already identified in earlier 
whole genome expression analyses (Pan et al. 2002, Rehman et al. 2008, Satish et al. 2008, 
Zang et al. 2008), were also identified in this study, either the same gene other members of 
the same gene family were found to be deregulated in DD. A large number of additional 
genes not previously described were also identified. Given the large number of deregulated 
genes only some shall be discussed in the following. This discussion is divided into four 
paragraphs, (1) extra-cellular matrix components; (2) Wnt/β-catenin signalling pathway 
components; (3) genes involved in oxidative stress and mitochondrial dysfunction and (4) 
other deregulated genes (e.g. immune response). Genes involved in more than one of these 
processes are discussed only in one section, if appropriate. 
4.3.1 Extra-Cellular Matrix Proteins overexpressed in DD 
A number of extracellular matrix components were found to be highly upregulated in DD 
reflecting the high amount of extracellular matrix (ECM) found in the disease tissue. They 
function for example in matrix scaffolding, cell-matrix interaction, cell-cell signalling, cell 
migration and cell adhesion. Similar to processes involved in wound healing, fibroblasts in 
DD tissue heavily remodel the ECM including the deposition of collagens and other matrix 
proteins. The ECM not only provides a structural network but also facilitates migration of 
cells and cell signalling. ECM components therefore play important roles in the pathology of 
DD but it is not known whether they have any causative effect on its aetiology. Some 
examples for markedly upregulated ECM components are given in the following. 
THBS4 was upregulated with a fold change of 52.07 and THBS2 was upregulated with a 
fold change of 7.16. Thrombospondins (THBS 1-5 gene products) are tri- or tetra-meric 
extracellular matrix glycoproteins (Adams et al. 2003). Each monomer contains at the 
cystin-rich c-terminus epidermal growth factor (EGF) - like modules, calcium-binding 
repeats, and a lectin-like C-terminal globe. THBS2 and 4 proteins (TSP2 and 4) differ in 
their module structure, calcium binding properties and inter-modular interactions 
(Misenheimer et al. 2005). THBSP4 is expressed by muscle interstitial cells and neurons, 
promotes neurite outgrowth, and accumulates at the neuromuscular junction (Arber and 
Caroni 1995). High levels of THBS4 mRNA have been detected in heart and skeletal 
muscles (Lawler et al. 1993), and human endothelial cells and vascular smooth muscle cells 
from brain blood vessels and coronary arteries have been shown to express THBS4 mRNA 
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(Stenina et al. 2003). The c-terminal domain of TSP4 binds to collagens I, II, III, and V as 
well as laminin-1, fibronectin, and matrilin-2 (Narouz-Ott et al. 2000). THBS4 is 
overexpressed in muscular dystrophies (Chen et al. 2000) and an A387P single nucleotide 
polymorphism of THBS4 was linked to susceptibility to myocardial infarction (Topol et al. 
2001, Wessel et al. 2004) especially in older women (Cui et al. 2004), which could not be 
confirmed in a large case-control study (Koch et al. 2008). A polymorphism in the 3' 
untranslated region of THBS2 (rs8089) was likewise not confirmed to be associated with 
myocardial infarction in the meta-analysis of this study. 
THBS2 protein (TSP2) binds LRP1 (low density lipoprotein receptor-related protein-1) 
which interacts with Notch3 and Jagged1 and also functions in Wnt signalling. TSP2 and 
LRP1 stimulate Notch activity by driving trans-endocytosis of the Notch ectodomain into the 
signal-sending cell (Meng et al. 2010). LRP1 was found to be downregulated (fold change:  
-1.54) in the present study. 
TSP1 and -2 are similar in their structure (Misenheimer et al. 2005). They inhibit cell 
proliferation in endothelial cells (Jiménez et al. 2000, Nör et al. 2000). However, while 
TSP1 induces cell growth arrest through caspase activation and subsequent apoptosis, TSP2 
proliferation inhibition does not involve induction of apoptosis (Armstrong et al. 2002). 
They also differ in their transcriptional regulation. The production of reactive oxygen species 
(ROS) specifically increases TSP2 mRNA levels, while TSP1 mRNA levels are not affected 
by ROS production (Lopes et al. 2003). The authors found that expression of Rac 1 leads to 
increased ROS production and subsequent TSP2 expression in human aortic endothelial cells 
and in vascular smooth muscle cells. THBS1 (fold change: +2.0) and THBS3 (fold change: 
+2.3) were also found to be upregulated in DD. 
TSP1 and 2, tenascin-C (TCN) (fold change: +30.72), and SPARC (fold change: +1.57) 
induce the process of cellular de-adhesion. They induce the transition to an intermediate state 
of adhesiveness characterized by loss of actin-containing stress fibres and restructuring of 
the focal adhesion complexes with no effects on cell shape (Murphy-Ullrich 2001). This 
intermediate state is thought to be important during tissue remodelling processes like 
embryogenesis, wound healing, and inflammation where it facilitates cell migration and 
ECM remodelling. 
TCN (fold change: +30.72) is a modular extracellular matrix glycoprotein composed of a 
series of epidermal growth factor-like repeats, fibronectin type 3-like repeats and a C-
terminal fibrinogen-like globular domain (Jones and Jones 2000). Tenascin-C is highly 
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expressed in organogenesis and at sites of epithelial-mesenchymal transition (Ekblom and 
Aufderheide 1989). It is induced during wound healing, tumorigenesis, vascular 
hypertension and myocardial infarction (Chiquet-Ehrismann et al. 1995, Imanaka-Yoshida et 
al. 2001). TCN was not found to be differentially expressed in disease tissue and tissues 
adjacent to disease tissue (skin and fat) in DD patients (Shih et al. 2009). 
Scrapie responsive protein 1 (SCRG1) is expressed in the developing brain (Dron et al. 
1998) but is also expressed in cartilage where it locates to the extra-cellular matrix and is 
involved in chondrogenesis (Ochi et al. 2006). 
The gene SULF1 locates to 8q13, a chromosomal region that was found to be significantly 
associated with DD (Dolmans et al. 2011). The heparan sulfate 6-O-endosulfatases (SULF1 
(fold change: +5.17) and SULF2 (fold change: +3.6)) remove glucosamine-6S groups from 
specific regions of heparan sulfate (HS) chains at the cell surface (Dhoot et al. 2001, 
Morimoto-Tomita et al. 2002). HSs are complex glycans, found ubiquitously on the surface 
of nearly all animal cells (Esko and Lindahl 2001) where their sulfate groups form specific 
patterns, interacting with HS binding growth factors and their receptors (Lamanna et al. 
2007). The activity of SULF1 promotes e.g. Wnt signalling: The removal of 6-O sulphate 
groups from HS chains favours the formation of low affinity HS–Wnt complexes that can 
functionally interact with Frizzled receptors to initiate Wnt signal transduction (Ai et al. 
2003). Sulf activity also has an activating effect on BMP signalling (Viviano et al. 2004) and 
disrupts fibroblast growth factor 2 (FGF2) (Wang et al. 2004) and VEGF (Uchimura et al. 
2006) receptor binding. Expression of SULF1 is induced by TGFβ1 (Yue et al. 2008). 
4.3.2 Genes involved in Wnt/β-catenin Signalling 
GWAS and whole genome expression analysis findings point to the Wnt/β-catenin signalling 
pathway as an important factor in the pathology of DD. Figure 64 depicts selected 
components of the Wnt/β-catenin signalling pathway that are deregulated in DD. In the 
absence of Wnt signal cytoplasmic β-catenin is either localised to cadherin-junctions at the 
intracellular side of the plasma membrane or bound in a complex with APC and Axin. The 
later is phosphorylated by casein kinase 1 (Ck1) and then glycogen synthase kinase 3 
(Gsk3β). This leads to the ubiquitylation and proteasomal degradation of β-catenin. In the 
nucleus, prospective target genes of the pathway are kept in a repressed state by interacting 
with T-cell factor (TCF) and lymphoid enhancer-binding protein (LEF) transcription factors, 
with associated co-repressors. If Wnt signalling is active, β-catenin is translocated into the 
nucleus. Secreted frizzled-related proteins (SFRP) antagonize the Wnt pathway by binding to 
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either Wnts or Frizzled and thereby affecting receptor occupancy. Dickkopf (DKK) and 
KREMEN also inhibit Wnt signalling by binding to its receptors. Rspondin positively 
regulates β-catenin signalling by interacting with the Frizzled receptor and LDL-receptor-
related protein (LRP5/6) and by competing with DKK (Moon et al. 2004, Kim et al. 2006). 
SULF also promotes Wnt signalling (Ai et al. 2003). The binding of Wnt to Frizzled leads to 
activation of the phosphoprotein Dishevelled (Dvl). The activation and membrane 
recruitment of Dvl probably recruits Axin and the destruction complex to the plasma 
membrane, where Axin directly binds to the cytoplasmic tail of LRP5/6. Axin is then 
degraded, which decreases β-catenin degradation (Tolwinski and Wieschaus 2004). The 
activation of Dvl also leads to the inhibition of GSK3β, which further reduces the 
phosphorylation and degradation of β-catenin, so that the post-translational stability of β-
catenin, through WNT-dependent degradation of Axin and inhibition of GSK3β is increased. 
As β-catenin levels rise, it accumulates in the nucleus, where it interacts with DNA-bound 
TCF and LEF family members to activate the transcription of target genes. 
The expression of WNT genes was heterogeneous in DD patients and controls. In the whole 
genome expression experiment the signal detection for most Wnt genes was poor, either 
because these Wnt genes were not expressed in analysed samples or because the assay failed 
for these genes. WNT11 was significantly downregulated (fold change: -3.5). O'Gorman et 
al. (2006) found WNT11 to be downregulated in DD tissue and patient derived fibroblasts 
compared to controls (fold change: ~ -5). They also found some Wnts (e.g. WNT10B) to be 
heterogeneous in their expression levels and concluded that Wnts are not particularly 
deregulated in DD. WNT11 is thought not to signal through the Wnt/β-catenin pathway but 
through other Wnt pathways (Pandur et al. 2002). WNT11 expression is induced through the 
interaction of β-catenin and estrogen-related receptor alpha (ESRRA) (fold change: -1.65). 
Transcriptional upregulation of WNT11 through β-catenin and ESRRA influences the 
migratory capacity of cancer cells and expression of ESRRA has been associated with a 
negative outcome in cancer (Dwyer et al. 2010). The observed high heterogeneity in the 
expression of Wnt ligands makes it difficult to evaluate their expression in patients and 
controls. In addition it was relative difficult to design specific qPCR primer for some Wnt 
genes, either because of the high sequence similarity within the Wnt gene family or because 
these genes were poorly expressed in analyzed samples. For the WNT2 gene the division of 
samples into expression groups revealed differences between patients and controls, while the 
comparison of all patients with all controls was less fruitful. Seven out of 15 analysed patient 
samples showed an upregulation of WNT2 (in fibroblasts) that was not seen in controls. 
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Especially for Wnt genes and other genes with heterogeneous expression levels the analysis 
of a large sample set is desirable to assess differences in patients and controls. 
 
Figure 64. Wnt/β-catenin signalling pathway. Depicted are selected components of the Wnt/beta-catenin 
canonical pathway that are deregulated in DD. Red colour symbolises upregulated, green colour 
downregulated gene products. Each symbol stands for one molecule or a molecule group. The gene 
names are given next to the symbols and are tagged with the corresponding fold changes from the whole 
genome expression experiment (in green and red). Values in italics represent fold changes detected with 
qPCR. 
The left hand side of figure 65 depicts the interaction partners of β-catenin in the nucleus. On 
the right hand side a selection of target genes that are upregulated by Wnt/β-catenin 
signalling are depicted. Prominent among these is WISP1 (not expressed in controls) a 
member of the WNT1 inducible signalling pathway (WISP) protein subfamily, which 
belongs to the connective tissue growth factor family (Pennica et al. 1998). Other members 
of this family are cysteine rich 61 (CYR61, fold change: +6.54), connective tissue growth 
factor (CTGF, fold change: +2.86), and nephroblastoma overexpressed (NOV, fold change: 
+6.33) which were also found to be significantly upregulated. WISP1 is a β-catenin 
responsive gene (Marchand et al. 2011). It is induced by Wnt1 and Wnt3a but not by Wnt4 
(Königshoff et al. 2009) and it is also induced by TGFβ1 (Parisi et al. 2006). WISP protein 
is expressed at a high level in fibroblast cells and binds to decorin and biglycan, two 
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members of a family of small leucine-rich proteoglycans present in the extracellular matrix 
of connective tissue (Desnoyers et al. 2003) of which biglycan (BGN) was found to be 
upregulated in this study. The BGN protein contains two attached glycosaminoglycan 
chains. It plays a role in assembly of collagen fibrils and muscle regeneration. It interacts 
with several proteins among them collagen VI, and enhances vascular smooth muscle cell 
proliferation (Shimizu-Hirota et al. 2004). TGFβ induces the expression of biglycan (BGN).  
 
Figure 65. DNA bound β-catenin containing complex and selected target genes. Depicted are selected 
components of the Wnt/beta-catenin canonical pathway and its target genes that are deregulated in DD. 
Red colour symbolises upregulated gene products. Each symbol stands for one molecule or a molecule 
group. The gene names are given next to the symbols and are tagged with the corresponding fold change 
from the whole genome expression experiment. 
Like WISP1 BGN was shown to be induced by TGFβ (Groth et al. 2005). The authors found 
that the TGFβ effect on BGN was dependent on cell adhesion and activated Rac1, which was 
presumed to acts through NADPH oxidases (NOXs). Deficiency of biglycan causes cardiac 
fibroblasts to differentiate into a myofibroblast phenotype (Melchior-Becker et al. 2011). 
GJA1 is a member of the connexin gene family (Cx). Cxs are the major component of gap 
junctions (Loewenstein 1981). Gap junctions are specialized intercellular channels that 
permit functional coupling of cells electrically and biochemically, allowing the selective 
diffusion of ions and metabolites between the cytoplasms of two adjacent cells (Kumar and 
Gilula 1996, Mroue et al. 2011). Additionally Cxs have diverse functions and interaction 
partners which are apparently channel-independent (e.g. Giepmans et al. 2001a, Giepmans et 
al. 2001b, Singh et al. 2005). Most interestingly Cx43 interacts with β-catenin, N-cadherin 
and NOV (member of the CTGF family, see above). Wnt1 induced Cx43 levels through β-
catenin signalling. In response to Wnt signalling, the accumulating Cx43 colocalised with β-
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catenin in the cell membrane of rat cardiomyocytes, thereby sequestering β-catenin to the 
cell membrane which in turn reduces β-catenin transcriptional activity (Ai et al. 2000). Cx43 
also colocalises with N-cadherin in migrating neural crest cells (Xu et al. 2001). Analyses by 
immunohistochemistry, and coimmunoprecipitation and Western immunoblotting indicated 
that Cx43 and N-cadherin, and with them gap junctions and adhesion junctions, are 
coassembled in a large multiprotein complex. Consistent with this, siRNA-mediated 
knockdown of either Cx43 or N-cadherin resulted in the apparent loss of both proteins from 
the cell surface of neural cells (Wei et al. 2005). Likewise N-cadherin knockout 
cardiomyocytes are Cx43 gap junction-deficient (Luo and Radice 2003). 
The cytoplasmic tail of Cx43 associates with NOV. NOV protein is down-regulated in the 
absence of Cx43 (but Cx43 protein levels are not affected by NOV absence). Overexpression 
of NOV increases the activity of the small GTPase Rac1, thereby revealing a pathway that 
links Cx43 directly to actin reorganization (Sin et al. 2009). Pannexins show similarities in 
their structure and topology with connexins and are thought to form channels as well (Dahl 
and Locovei 2006). Pannexin 1 (PANX1) was upregulated 2.51 fold. 
CD44 is induced by Wnt/β-catenin signalling (Wielenga et al. 1999). CD44 is a cell-surface 
adhesion molecule and the major cell-surface receptor for the nonsulfated 
glycosaminoglycan hyaluronan (HA) (Aruffo et al. 1990). HA is a high-molecular-mass 
polysaccharide found in the extracellular matrix, especially of soft connective tissues 
(Laurent and Fraser 1992). CD44 plays a role in removal of extracellular matrix breakdown 
products after tissue injury response (Teder et al. 2002). Mast cells adhesion to bronchial 
smooth muscle cells in asthmatic patients involved collagen1, CD44, and integrin, alpha V 
(Girodet et al. 2010). Integrin, alpha V (ITGAV) was also found to be upregulated in this 
study (fold change: +3.25). CD44 therefore seems to be important for cell adhesion and 
motility in connective tissue. 
V-myc myelocytomatosis viral oncogene homolog (avian) (MYC) expression is induced by 
the Wnt/β-catenin signalling pathway (He et al. 1998). The MYC protein is a 
multifunctional, nuclear phosphoprotein that functions as a transcription factor with over 
2000 identified target genes. The c-Myc target gene database 
(http://www.myccancergene.org) and the literature were browsed to identify Myc target 
genes that were deregulated in DD. 
Among the genes that are upregulated in response to Myc treatment were e.g. genes involved 
in cell adhesion: THBS4 (+ 52.07) (Mao et al. 2003), and apoptosis: APP (+2.31) 
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(Fernandez et al. 2003), CASP3 (+2.68) (Louro et al. 2002). One myc response gene 
downregulated in DD was the small heat shock protein, CRYAB (-4.81) (O'Connell et al. 
2003, Guo et al. 2000). Direct Myc target genes identified by chromatin 
immunoprecipitation (ChIP) and promoter microarrays in human primary fibroblasts (Kim et 
al. 2008) are for example the actin binding proteins TAGLN (+1.50) (also called SM22α) 
and TAGLN2 (+2.09), homo sapiens superoxide dismutase 1 (SOD1, -1.40), SOX4 (+3.52), 
solute carrier family: SLC5A6 (sodium-dependent vitamin transporter, member 6: -3.29), 
SLC35B1 (+1.48), and DEAD (Asp-Glu-Ala-Asp) box polypeptide (DDX) 56 (-1.26). 
TAGLN has an expression pattern very similar to αSMA (Morgan and Gangopadhyay 2001). 
Myc activates nuclear-encoded mitochondrial gene expression, and many direct targets of 
Myc are involved in mitochondrial function such as oxidative phosphorylation, metabolism, 
apoptosis, and glutamate metabolism. (Coller et al. 2000, Kim et al. 2008). The induction of 
proliferation and cell cycle progression by Myc may be in part due to its activation of 
mitochondrial biogenesis and oxidative phosphorylation (Li et al. 2005, Morrish et al. 2003). 
Myc null rat fibroblasts have diminished mitochondrial mass and decreased number of 
normal mitochondria. Reconstitution of Myc expression in Myc null fibroblasts partially 
restored mitochondrial mass and function and normal-appearing mitochondria (Li et al. 
2005). Nuclear-encoded mitochondrial target genes of Myc deregulated in DD are e.g. 
cytochrome c oxidase subunit Vb, COX5B (-1.50) and polymerase gamma, PLOG (-1.35). 
CTCF-binding is required for protection from DNA methylation at the human MYC locus 
(Gombert and Krumm 2009). 
Other target genes of β-catenin upregulated in DD include matrix metallopeptidase 7 
(MMP7, fold change: +1.44) (Crawford et al. 1999, Brabletz et al. 1999) and matrix 
metallopeptidase 14 (MMP14, fold change: +10.08) (Takahashi et al. 2002). Proteins of the 
matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular 
matrix. Most MMPs are secreted as inactive proproteins which are activated when cleaved 
by extracellular proteinases. The MMP7 enzyme degrades proteoglycans, fibronectin, elastin 
and casein and is involved in wound healing. MMP7 mediates cleavage of N-cadherin and 
promotes vascular smooth muscle cell apoptosis (Williams et al. 2010). While MMP9 (fold 
change: -23.22) promoted shedding of the extracellular portion of N-cadherin resulting in 
increased vascular smooth muscle cell proliferation via elevation of β-catenin signalling and 
cyclin D1 expression (Dwivedi et al. 2009). MMP2 was upregulated with a fold change of 
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+4.26. The MMP2 protein degrades collagen IV, and plays a role in endometrial menstrual 
breakdown, regulation of vascularisation and the inflammatory response. 
Fibronectin, another extracellular matrix protein is upregulated by β-catenin signalling 
(Gradl et al. 1999) was upregulated with a fold change of +20.00 in DD. Collagen 1 is also a 
target of β-catenin signalling (Cheng et al. 2008). Although being a β-catenin target gene, 
the expression of cyclin D1 (CCND1) was not altered in DD compared to controls. 
Β-catenin signalling regulates the expression of its own effectors, e.g. Dickkopf 1 (DKK1) 
(Glinka et al., 1998) is itself a direct transcriptional target of β-catenin (Chamorro et al., 
2005; Niida et al., 2004). Expression of Lef-1 (Hovanes et al. 2001) and TCF4 (Kolligs et al. 
2002) is also promoted by β-catenin signalling. The expressions of SFRP2 (Lescher et al. 
1998), FZD7 (Willert et al. 2002), axin2 (Yan et al. 2001), periostin (downregulated by 
Wnt) (Haertel-Wiesmann et al. 2000), are also affected by Wnt/β-catenin signalling. 
The abundance of Wnt/β-catenin target genes underlines the importance of this pathway. In 
the future it will be crucial to determine the components and targets of this pathway that play 
a role in the pathology of DD. One first approach could be the comparison of DD derived 
fibroblasts with cells from young and old controls under different conditions e.g. stress or 
non-stress, and treatment with Wnts or knockdown of Wnt signalling components. In a 
recent study Wnt3A induced αSMA expression and stress fibre formation in mouse 
fibroblasts. This induction was dependant on β-catenin and TGFβ (Carthy et al. 2011). 
Many genes involved in the Wnt/β-catenin canonical pathway were upregulated. Both 
promoting (RSPO, SULF) and repressing factors (SFRP, DKK) were upregulated. This may 
indicate that complex interactions with partly contradictory effects take place nevertheless 
resulting in the upregulation of the Wnt/β-catenin pathway. After renal epithelial injury 
Surendran et al. (2005) found an increase in Wnt/β-catenin signalling and at the same time 
increased expression of SFRP4 (Wnt inhibitor), while SFRP4 protein levels were not 
increased. Therefore expression levels must not necessarily correspond to protein levels. It 
could be desirable to test protein levels of selected in genes in DD samples and controls to 
further assess Wnt signalling in DD. 
4.3.3 Mitochondrial Dysfunction and Oxidative Stress 
The Illumina whole genome expression chip does not contain mitochondrial encoded genes. 
Transcripts of mitochondrial proteins encoded in the nucleus had an overall tendency to be 
downregulated in the whole genome expression analysis. Consequently IPA analysis 
highlighted mitochondrial dysfunction and oxidative stress as pathways significantly 
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affected and involved in the pathology of DD. Mitochondrial dysfunction and oxidative 
stress (ROS production) were associated with aging and aging associated diseases (e.g. Patti 
et al. 2003, Petersen et al. 2004, Lowell and Shulman 2005, Bowling and Beal 1995, 
Swerdlow and Khan 2004, Langston et al. 1983, Schapira et al. 1989, Bindoff et al. 1989, 
Kuwert et al. 1990, Kim et al. 2010). Among the most deregulated genes in these pathways 
were those involved in the generation of, and response to ROS e.g. monoamine oxidase A 
(MAOA) (fold change: -6.60), catalase (CAT) (fold change: -3.37), uncoupling protein 2 
(UCP2) (fold change: -4.16), and glutathione peroxidase 4 (GPX4) (fold change: -2.44) were 
downregulated, while others were upregulated namely, glutathione peroxidase 7 (GPX7) 
(fold change: +3.34) and NADPH oxidase 4 (NOX4) (fold change: +2.17). 
Catalase converts H2O2 to water and oxygen and thereby mitigates the toxic effects of H2O2. 
Mice overexpressing catalase had a ~45% decrease in H2O2 production in muscle. Compared 
to wild type controls, these mice showed no increase in mtDNA mutations or decrease of 
mitochondrial function (e.g. ATP production) with age (16 month) (Lee et al. 2010). Insulin 
resistance in muscle is associated with age and high fat diet. In another study reduction of 
H2O2 (antioxidant treatment or catalase overexpression) in mitochondria of muscle in mice, 
preserved insulin sensitivity despite a high fat diet (Anderson et al. 2009). Oxidative enzyme 
activity and protein levels of mitochondrial respiratory chain subunits were significantly 
elevated in mice fed on high fat diet for 5 or 20 weeks (Turner et al. 2007). This accelerated 
metabolism leads to mitochondria “exhaustion” in old animals. In mice insulin resistance 
proceeds oxidative damage and mitochondrial dysfunction (Bonnard et al. 2008). 
TGFβ induced the expression of NOX4 and at the same time inhibited the expression of 
SOD2 and catalase in airway smooth muscle cells (Michaeloudes et al. 2011). TGFβ1 
treatment reduced SOD2 expression in patient and control cells (fold change: -2.54). 
Changes of CAT expression were not seen upon TGFβ1 treatment in the present study. 
Moreover TGFβ induces αSMA expression via NOX4 in smooth muscle cells (Martin-
Garrido et al. 2011). Transfection of human aortic smooth muscle cells with siRNA against 
NOX4 abolished TGFβ induced αSMA expression and stress fibre formation. Mitogen-
activated protein kinase 1 MAPK1, serum response factor (SRF) and megakaryoblastic 
leukemia (translocation) 1 (MKL1) were also involved in this pathway (Martin-Garrido et al. 
2011). Krause et al. (2011) found elevated MAPK1 phosphorylation upon TGFβ1 treatment 
in DD derived fibroblasts. 
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UCP2 is expressed in several tissues and shows highest expression in skeletal muscle. UCPs 
facilitate the transfer of anions (OH
-
) from the mitochondria to the space between inner and 
outer mitochondrial membrane and the return transfer of protons (H
+
). Thereby they reduce 
the mitochondrial membrane potential, separating oxidative phosphorylation from ATP 
synthesis. This process is also referred to as the mitochondrial proton leak (Rigoulet et al. 
2011). UCP2 (and UCP3) are activated by ROS and do not catalyse proton leak in the 
absence of ROS (Esteves and Brand 2005). 
Catalase Enzyme Activity Assay 
A catalase activity assay was preformed to test for oxidative stress enzyme function in 
patient and control fibroblasts. Of 16 analyses patient samples 7 showed reduced catalase 
activity. Five patient samples had reduced catalase activity at 37°C and 40.5°C. 
After planting fibroblasts in 225cm
2
 cell culture flasks, populations reached confluence in 
six to twelve days. Most control cell lines showed slow growth while some patient cell lines 
grew extremely fast. Different growth behaviour was reflected in catalase activity. Fast 
growing patient cell lines had low enzyme activity compared with slow growing patient and 
control cell lines. Catalase overexpression is known to reduce cell population doubling times 
by prolonging the G0/G1 phase in the cell cycle (Onumah et al. 2009). 
It is likely that observed growth rate differences due to catalase activity differences reflect 
the situation in vivo. At least for one patient included in the group of fast growing cell lines 
showing low catalase activity a very fast reoccurrence of the disease after surgery was 
observed. 
Connections between Wnt/β-catenin and ROS 
The Wnt/β-catenin signalling pathway was linked to ROS (Shin et al. 2004, Funato et al. 
2006, Korswagen 2006). H2O2 induces a rapid increase in Wnt signalling that peaks around 
20 min after stimulation (Funato et al. 2006), but signalling is reduced several hours after 
H2O2 treatment (Shin et al. 2004, Korswagen 2006). Influence of ROS on Wnt/β-catenin 
signalling is likely mediated via Disheveled (Dvl). Dvl interacts with nucleoredoxin (NXN) 
(Funato et al. 2006). NXN (+2.46) belongs to the family of thioredoxins. Thioredoxin (TXN) 
is a thiol oxidoreductase that is essential for DNA synthesis and for various redox signalling 
pathways (Holmgren 2000). TXN can scavenge ROS mainly by reducing various target 
proteins, including the H2O2-quenching enzyme peroxiredoxin (PRDX1-6) (Rhee et al. 
2005). PRDX2 (-1.93), PRDX 3 (-1.28), PRDX 5 (-1.12) and PRDX 6 (-1.59) were by trend 
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downregulated, PRDX1 was not differentially expressed (fold change: 1.07), and PRDX4 
was upregulated (fold change: 2.10). TRX also regulates stress signalling pathways (Fujino 
et al. 2006). TXN and related proteins compose a large heterogeneous family. Another gene 
similar to NXN is NXNL1 (Funato and Miki 2007) which was downregulated in DD (-7.08). 
NXN selectively affects Dvl function on β-catenin. NXN does not inhibit JNK activation by 
Dvl (Funato et al. 2006). 
Β-catenin interacts with E-cadherin, and the transcription factors Tcf/Lef, FOXO (FOXO1: -
1.49), HIF1 (HIF1A: +2.11). These transcription factors are all regulated by ROS and the 
interaction with β-catenin enhances their activity, like was shown for the β-catenin/FOXO 
interaction (Esser et al. 2005). Under normal cellular conditions β-catenin, through Wnt 
signalling, is involved in cell proliferation and differentiation but under changed ROS 
conditions its function can shift to regulate transcription factors that support cell survival 
through increased stress resistance and ROS clearance. These findings may be taken to 
suggest that β-catenin is a pivot in reprogramming transcriptional activity following changes 
in ROS (Hoogeboom and Burgering 2011). SFRP4 treatment induced lower catalase activity 
and consequently higher H2O2 levels in cultured endothelial cells (Muley et al. 2010).  
Oxidative stress and decline in mitochondrial function play an important role in aging and 
aging associated diseases. In how far they are a force that drives the aging process, as 
predicted by the free radical theory of aging, or are consequence of the aging process is not 
know. Nevertheless their association with DD emphasizes the importance of aging factors in 
the pathology of DD. Therefore DD can only be considered in the contest of aging. 
Further experiments that investigate the role of oxidative stress in the pathology of DD are 
required. Disease tissue derived fibroblasts could be cultured under different stress 
conditions and analysed in terms of their contraction behaviour in collagen gels or their 
expression off target genes. Especially the relationship between oxidative stress and the 
Wnt/β-catenin signalling pathway should be considered in these experiments in order to 
determine whether this relationship plays a decisive role in DD. 
Signalling Cascade that leads to Myofibroblast Differentiation 
Wnt3A induced the expression of αSMA in (mouse) fibroblasts (Carthy et al. 2011). This 
induction was dependant on β-catenin, suggesting that the signal is transmitted through the 
Wnt/β-catenin signalling pathway. The induction of αSMA through Wnt3A was also 
dependant on TGFβ, suggesting that signal transmission requires TGFβ/SMAD signalling 
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(Carthy et al. 2011). As shown by e.g. Cucoranu et al. (2005), TGFβ induces the 
differentiation of fibroblasts into myofibroblasts. NOX4 is also required for αSMA induction 
through TGFβ (Martin-Garrido et al. 2011). NOX4 generates ROS (Babior 1999). 
Additionally TGFβ upregulation reduces the expression of CAT and SOD, which also leads 
to elevated ROS levels (Michaeloudes et al. 2011). Having established that this signalling 
cascade is present in DD fibroblasts the next step could be to determine whether αSMA 
expression is induced directly through smad DNA binding, as was shown for TAGLN 
(SM22α) (Shafer and Towler 2009) or if TGFβ/smad signalling leads to the upregulation of 
NOX4, which in turn induces αSMA expression through ROS signalling and the MAPK 
pathway, as shown by Martin-Garrido et al. (2011) for human aortic smooth muscle cells 
and by Bondi et al. (2010) for kidney fibroblasts (figure 66). In the 
later scenario the expression of αSMA would be sensitive to ROS. 
In this case it would be conceivable that elevated ROS levels may 
trigger myofibroblast differentiation even in the absence of Wnt/β-
catenin signalling in the context of aging associated changes in ROS 
production. The TGFβ and MAPK pathways were upregulated in 
DD derived fibroblasts (Krause et al. 2011) and  
NOX4 was upregulated in DD tissue in this study. NOX4 
expression was induced by TGFβ1 and Wnt3a and NOX4 was 
required for αSMA induction through TGFβ1 or Wnt3a. These 
results support the hypothesis that the signalling cascade described 
for aortic smooth muscle cells and kidney fibroblasts (Martin-
Garrido et al. 2011, Bondi et al. 2010) is also present in DD 
fibroblasts. Namely that TGFβ/smad signalling leads to the 
upregulation of NOX4 which in turn induces αSMA expression. 
Figure 66. Proposed signalling cascade that leads to αSMA expression and myofibroblast differentiation. 
In this study Wnt3a induced the expression of αSMA in patient cells. But inhibition of 
GSK3β or NXN (both Wnt/β-catenin signalling inhibitors) attenuated the upregulation of 
αSMA through TGFβ1 or Wnt3a. The inhibition of GSK3β in cells from asthma patients 
attenuated myofibroblast differentiation (Michalik et al. 2012). Michalik and colleges used 
lithium in their study. Lithium is a GSK3β inhibitor that is implemented in drugs for the 
treatment of psychiatric diseases. In these patients’ lithium treatment coincided with the 
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remission of asthmatic symptoms (Nasr and Atkins 1977). More experiments are needed in 
order to unravel the signalling cascade that leads to myofibroblast differentiation in DD. 
4.3.4 Other Genes Deregulated in DD 
Among the other genes up- or downregulated in DD were a number of genes associated with 
the immune system, pointing to the possible infiltration of disease tissue by immune cells, 
e.g. macrophages (also see CD44 above). 
HLA-DRB5 belongs to the HLA class II beta chain paralogues of DRB1. DRB5 encodes the 
beta chain of a heterodimer consisting of an alpha (DRA) and a beta (DRB) chain, both 
anchored in the membrane. It presents peptides derived from extracellular proteins and is 
expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). 
DRB1 is expressed at a level five times higher than DRB5. The DRB5*1010 allele is linked 
with the *1501 allele of DRB1. HLA-DRB1*1010 has been associated with multiple 
sclerosis (MS) (Winchester et al. 1975). DRB5 e.g. attenuates MS severity (Caillier et al. 
2008). The *1501 allele of HLA-DRB1 was also associated with DD (Brown et al. 2008).  
Mason et al. (2011) found HLA-DRB5 to by differentially expressed in muscle tissue of 
healthy persons (N = 225). They proposed that bimodal expression (0.2% of the genes 
expressed in muscle) indicates important genes pointing to disease susceptibility. 
Interestingly, of the eight genes identified to have bimodal expression in their study six were 
found to be differentially expressed in this study (GSTM1: -2.69, HLA-DRB1: +2.30, 
ERAP2: +1.58, HLA-DRB5: +8.70, MAOA: -6.60, and THNSL2: -1.66).  
CADM1 (fold change: +9.99) was described as a tumour suppressor gene in lung cancer 
(Kuramochi et al. 2001, Murakami et al. 2002). It encodes a member of the immunoglobulin 
(Ig) superfamily and shows significant homology in its extracellular domain with those of 
other Ig superfamily cell adhesion molecules (Masuda et al. 2002). It is expressed by cells of 
the immune system e.g. is expressed by human lung mast cells and promotes their interaction 
with airway smooth muscle cells (Hollins et al. 2008). 
RASL11B (fold change: 17.83) is a member of the small GTPase protein family similar to 
RAS proteins. It is highly expressed in primary macrophages and coronary artery smooth 
muscle cells after TGFβ1 treatment (Stolle et al. 2007). 
The gene MAFB locates to 20q11.2-q13.1, a chromosomal region that was found to be 
significantly associated with DD (Dolmans et al. 2011). Its expression was upregulated ~5 
fold in DD primary tissue compared to controls and upregulated ~7 fold in disease tissue 
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compared with control tissue from the same patient. In contrast its expression was 
significantly downregulated ~7 fold in disease tissue derived fibroblasts treated with TGFβ1. 
Another gene from the same family, MAF locates to chromosome 16q23.2; a region that 
showed suggestive association with DD. MAF was not differentially expressed in DD and 
control tissue. The MAFB gene contains no introns. The encoded protein is a basic leucine 
zipper (bZIP) transcription factor. MAFB expression is regulated by the transcription factor 
TFE3 (Zanocco-Marani et al. 2009). Which was downregulated in DD (fold change: -1.79). 
MAFB is phosphorylated by GSK3β (Rocques et al. 2007). Transcriptional activation of 
MAF and MAFB in multiple myeloma (MM) leaded to upregulation of SFRP2 and 
downregulation of DKK1 (Zhan et al. 2006). Therefore MAFB may influence Wnt/β-catenin 
signalling by (indirectly) regulating two of its repressors. Another gene upregulated by 
MAFB expression in MM was secreted phosphoprotein 1 (SPP1), which itself induces β-
catenin signalling via Akt activation and subsequent GSK3β inactivation (Robertson and 
Chellaiah 2010). SPP1 was downregulated in DD with a fold change of -19.56. 
G0S2 (fold change: -15.68) was the strongest downregulated gene in the whole genome 
expression analysis (with both detection P-values = 0). It belongs to the genes involved in 
the G0/G1 switch, the switch from the G0 to the G1 phases of the cell cycle (Russell and 
Fordyke 1991). It shows highest expression in white and brown adipose tissue but it is also 
expressed in 3T3 fibroblasts (Zandbergen et al. 2005). There it is upregulated in growth 
arrested (confluent) 3T3 cells. Downregulation of G0S2 is either due to the higher fat 
content in control tissue or it also could reflect the high proliferating rate in DD fibroblasts. 
To exclude the first possibility one could compare the expression of G0S2 in fibroblast cell 
lines. Satish et al. (2008) compared the whole genome expression of DD tissue derived 
fibroblasts to control fibroblasts and found G0S2 to be downregulated four fold in disease 
fibroblasts. 
In the table of genes downregulated in DD a large number of genes involved in adipose 
metabolism stand out. This is likely caused by the higher fat content in control tissue 
compared to DD tissue (figure 40). On the other hand keratins and other genes expressed in 
keratinocytes were upregulated in DD tissue. Outgrowth of keratinocytes from cultivated DD 
tissue samples was often observed, although all visible (epi-) dermal tissue was removed 
prior to cell culture. In the disease process the skin becomes attached to the nodules and gets 
invaginated into the underlying tissue. Some DD tissue samples therefore contain 
keratinocytes while keratinocytes will be few in the control tissue. Whether these 
keratinocytes are trapped accidentally or play an active part in the pathology of DD is not 
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known. Neighbouring skin and fat tissue was suspected to play a role in the pathogenesis of 
DD (Shih et al. 2009), but evidence for involved mechanisms is scarce. Spatial proximity of 
fascia, fat and skin in the palm suggest that interactions between these tissues take place both 
in normal and disease situations. 
     
Figure 67. Pictures of one DD (A) and two control (B and C) tissue samples. The disease sample was hard 
and collagen rich. The depicted sample was about 1.3 cm long. The control samples contain more fat 
(arrow in B, yellow tissue). Control sample in C was not used for whole genome expression analysis. Fat 
tissue proved to be a very difficult tissue to isolate sufficient amounts of RNA for array analysis from. 
Therefore control samples consisting mainly of fat were not included in the whole genome expression 
analysis. Still the used control tissues had a higher fat content than DD tissue. Most control tissue 
samples were so tiny that only small amounts of total RNA were isolated.
A      B   C 
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5 Conclusions 
DD is a progressive aging associated disease with a strong genetic basis. Although the 
underlying cause of this disease remains to be identified genetic association and expression 
analysis highlighted the Wnt/β-catenin pathway as a likely key player. Upregulation of the 
Wnt/β-catenin pathway in disease compared to control tissue shows that this pathway clearly 
is involved in the pathology of DD. At the same time genetic association of at least six 
chromosomal regions that contain Wnt/β-catenin signalling components suggests that these 
genes may harbour variants that contribute to the aetiology of DD. These assumed genetic 
variants most likely have no negative effect on development. And according to evolutionary 
theories of aging there was possibly no selection against them. The disease manifests itself 
only when changes in e.g. connective tissue composition or hormone signalling occur due to 
aging (and other factors such as disease, medicamentation, life style habits or (repetitive) 
hand trauma). The aging process is therefore likely to play a crucial role. 
One future goal is the identification of disease-causing variants. This can be accomplished 
for example by next generation sequencing or exon sequencing of associated regions. For 
these approaches either a subgroup of very early or severely affected patients or several 
patients from one family could be selected. 
As stated in the introduction, the aging process is characterised by conserved features 
because it is determined by conserved processes in most animals (e.g. reproduction and 
damage repair). That is not only true between different (model) organisms, but also between 
different aging associated diseases. The Wnt/β-catenin signalling pathway is involved in 
several aging associated diseases. The same applies for mitochondrial dysfunction and 
oxidative stress. When investigating aging associated diseases one has therefore to bear in 
mind which mechanisms are shared over different aging associated diseases. To identify 
these pathways and study their function is one approach to eventually access healthy aging in 
humans. 
DD is particularly well suited to investigate the molecular mechanisms of aging associated 
diseases. Unlike many other aging associated diseases, e.g. neurodegenerative diseases, the 
abnormal tissue is easily accessible as it is removed during surgery. In support of genetic 
association studies one can thus perform expressions studies with primary tissue (as was 
done in this study). Additionally, questions, resulting from these analyses can be directly 
investigated in vitro in primary cells from DD patients. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 150 - 
 
6 References 
Adams JC, Monk R, Taylor AL, Ozbek S, Fascetti N, Baumgartner S, Engel J. 
Characterisation of Drosophila thrombospondin defines an early origin of pentameric 
thrombospondins. J Mol Biol. 2003 Apr 25;328(2):479-94. 
 
Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP Jr. QSulf1 
remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote 
Wnt signaling. J Cell Biol. 2003 Jul 21;162(2):341-51. Epub 2003 Jul 14. 
 
Ai Z, Fischer A, Spray DC, Brown AM, Fishman GI. Wnt-1 regulation of connexin43 in 
cardiac myocytes. J Clin Invest. 2000 Jan;105(2):161-71. 
 
An HS, Southworth SR, Jackson WT, Russ B. Cigarette smoking and Dupuytren's 
contracture of the hand. J Hand Surg Am. 1988 Nov;13(6):872-4. 
 
Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data 
quality control in genetic case-control association studies. Nat Protoc. 2010 Sep;5(9):1564-
73. 
 
van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. 
Development. 2009 Oct;136(19):3205-14. 
 
Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW 3rd, Kang 
L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neufer PD. 
Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin 
resistance in both rodents and humans. J Clin Invest. 2009 Mar;119(3):573-81. 
 
Andziak B, O'Connor TP, Buffenstein R. Antioxidants do not explain the disparate longevity 
between mice and the longest-living rodent, the naked mole-rat. Mech Ageing Dev. 2005 
Nov;126(11):1206-12. 
 
Arafa M, Steingold RF, Noble J. The incidence of Dupuytren's disease in patients with 
rheumatoid arthritis. J Hand Surg 1984;9B:165-6. 
 
Arber S, Caroni P. Thrombospondin-4, an extracellular matrix protein expressed in the 
developing and adult nervous system promotes neurite outgrowth. J Cell Biol. 1995 
Nov;131(4):1083-94. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 151 - 
 
Armstrong LC, Björkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P. 
Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-
independent mechanism. Mol Biol Cell. 2002 Jun;13(6):1893-905. 
 
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell 
surface receptor for hyaluronate.Cell. 1990 Jun 29;61(7):1303-13. 
 
Aström C, Rehn B, Lundström R, Nilsson T, Burström L, Sundelin G. Hand-arm vibration 
syndrome (HAVS) and musculoskeletal symptoms in the neck and the upper limbs in 
professional drivers of terrain vehicles--a cross sectional study. Appl Ergon. 2006 
Nov;37(6):793-9. 
 
Babior BM. NADPH oxidase: an update. Blood. 1999 Mar 1;93(5):1464-76. 
 
Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren's 
disease. Lancet. 1993 Jun 26;341(8861):1622-3. 
 
Barja, G. Mitochondrial oxygen radical generation and leak sites of production in states 4 
and 3, organ specificity, and relation to aging and longevity. J. Bioenerg. Biomembr. 1999; 
31: 347–366. 
 
Bayat A, McGrouther DA. Management of Dupuytren's disease--clear advice for an elusive 
condition. Ann R Coll Surg Engl. 2006 Jan;88(1):3-8. 
 
Bergamini E, Cavallini G, Donati A, Gori Z. The role of autophagy in aging: its essential 
part in the anti-aging mechanism of caloric restriction. Ann N Y Acad Sci. 2007 
Oct;1114:69-78. 
 
Bergenudd H, Lindgärde F, Nilsson BE. Prevalence of Dupuytren's contracture and its 
correlation with degenerative changes of the hands and feet and with criteria of general 
health. J Hand Surg Br. 1993 Apr;18(2):254-7. 
 
Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions 
of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-77. 
 
Bias WB, Nyberg LM Jr, Hochberg MC, Walsh PC. Peyronie's disease: a newly recognized 
autosomal-dominant trait. Am J Med Genet. 1982 Jun;12(2):227-35. 
 
Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD Jr, Turnbull DM. Mitochondrial 
function in Parkinson's disease. Lancet. 1989 Jul 1;2(8653):49. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 152 - 
 
 
Blüher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in 
adipose tissue. Science. 2003 Jan 24;299(5606):572-4. 
 
Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. 
Mech Ageing Dev. 2004 Oct-Nov;125(10-11):811-26. 
 
Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL. NAD(P)H 
oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc 
Nephrol. 2010 Jan;21(1):93-102. 
 
Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin MA, Morio B, Vidal H, Rieusset 
J. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-
induced insulin-resistant mice. J Clin Invest. 2008 Feb;118(2):789-800. 
 
Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life 
Sci. 1995;56(14):1151-71. 
 
Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. Beta-catenin regulates the expression of 
the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033–
1038. 
 
Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA. Increased Wnt 
signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007 Aug 
10;317(5839):807-10. 
 
Browning BL and Browning SR. A unified approach to genotype imputation and haplotype 
phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 2009. 
84:210-223. 
 
Brenner P, Krause-Bergmann A, Van VH. Dupuytren contracture in North Germany. 
Epidemiological study of 500 cases. Unfallchirurg. 2001 Apr;104(4):303-11. 
 
Brenner P and Rayan GM. Morbus Dupuytren - Ein chirurgisches Therapiekonzept. 
Springer, Wien, 2002 
 
Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's 
contracture. J Bone Joint Surg Br. 1997 Mar;79(2):206-10. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 153 - 
 
Brookes PS, Levonen AL, Shiva S, Sarti P, Darley-Usmar VM. Mitochondria: regulators of 
signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med. 2002 Sep 
15;33(6):755-64. 
 
Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process. 
Nature. 1996 Nov 7;384(6604):33. 
 
Brown JJ, Ollier W, Thomson W, Bayat A.Positive association of HLA-DRB1*15 with 
Dupuytren's disease in Caucasians. Tissue Antigens. 2008 Aug;72(2):166-70. 
 
Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's 
contracture. J Bone Joint Surg Br. 1997 Mar;79(2):206-10. 
 
Burke FD, Proud G, Lawson IJ, McGeoch KL, Miles JN. An assessment of the effects of 
exposure to vibration, smoking, alcohol and diabetes on the prevalence of Dupuytren's 
disease in 97,537 miners. J Hand Surg Eur Vol. 2007 Aug;32(4):400-6. 
 
Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 
1997 Dec 15;11(24):3286-305. 
 
Caillier SJ, Briggs F, Cree BA, Baranzini SE, Fernandez-Viña M, Ramsay PP, Khan O, 
Royal W 3rd, Hauser SL, Barcellos LF, Oksenberg JR. Uncoupling the roles of HLA-DRB1 
and HLA-DRB5 genes in multiple sclerosis. J Immunol. 2008 Oct 15;181(8):5473-80. 
 
Cannizzo ES, Clement CC, Sahu R, Follo C, Santambrogio L. Oxidative stress, inflamm-
aging and immunosenescence. J Proteomics. 2011 Jun 21. 
 
Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors 
for Peyronie's disease. J Clin Epidemiol. 1998 Jun;51(6):511-5. 
 
Carthy JM, Garmaroudi FS, Luo Z, McManus BM. Wnt3a induces myofibroblast 
differentiation by upregulating TGF-β signaling through SMAD2 in a β-catenin-dependent 
manner. PLoS One. 2011;6(5):e19809. Epub 2011 May 18. 
 
Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in 
monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol. 
2004 Jan;24(1):23-8. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 154 - 
 
Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE.FGF-20 and 
DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and 
development. EMBO J. 2005 Jan 12;24(1):73-84. 
 
Charlesworth B. Patterns of age-specific means and genetic variances of mortality rates 
predicted by the mutation-accumulation theory of ageing. J Theor Biol. 2001 May 
7;210(1):47-65. 
 
Chen YW, Zhao P, Borup R, Hoffman EP. Expression profiling in the muscular dystrophies: 
identification of novel aspects of molecular pathophysiology. J Cell Biol. 2000 Dec 
11;151(6):1321-36. 
 
Cheng, J.H., She, H., Han, Y.P., Wang, J., Xiong, S., Asahina, K., and Tsukamoto, H. 
(2008). Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am. J. 
Physiol. Gastrointest. Liver Physiol. 294,G39–G49. 
 
Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, Alman BA. beta-Catenin 
stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and 
causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S 
A. 2002 May 14;99(10):6973-8. 
 
Cheon SS, Nadesan P, Poon R, Alman BA. Growth factors regulate beta-catenin-mediated 
TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of 
wound healing. Exp Cell Res. 2004 Feb 15;293(2):267-74. 
 
Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, 
Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C. Aberrant Wnt/beta-
catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003 
May;162(5):1495-502. 
 
Chiquet-Ehrismann R, Hagios C, Schenk S. The complexity in regulating the expression of 
tenascins. Bioessays. 1995 Oct;17(10):873-8. 
 
Cho HY, Choi HJ, Sun HJ, Yang JY, An JH, Cho SW, Kim SW, Kim SY, Kim JE, Shin CS. 
Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control 
of serum amyloid P promoter exhibit low bone mass but did not result in disturbed 
phosphate homeostasis. Bone. 2010 Aug;47(2):263-71. 
 
Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic 
statistical analysis in genetic case-control studies. Nat Protoc. 2011 Feb;6(2):121-33. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 155 - 
 
Coert JH, Nérin JP, Meek MF. Results of partial fasciectomy for Dupuytren disease in 261 
consecutive patients. Ann Plast Surg. 2006 Jul;57(1):13-7. 
 
Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR. 
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes 
involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000 Mar 
28;97(7):3260-5. 
 
O'Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, Mateyak MK, Sedivy JM. A 
large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem. 2003 
Apr 4;278(14):12563-73. 
 
Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. Assessment of growth parameters 
and life span of GHR/BP gene-disrupted mice. Endocrinology. 2000 Jul;141(7):2608-13. 
 
Crawford HC, Fingleton BM, Rudolph-Owen LA, Heppner Goss KJ, Rubinfeld B, Polakis P, 
Matrisian LM. The metalloproteinase matrilysin is a target of beta-catenin transactivation in 
intestinal tumors. Oncogene 1999;18:2883–2891. 
 
Critchley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren's disease in epilepsy: result 
of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry. 1976 
May;39(5):498-503. 
 
Couto-Gonzalez I, Brea-Garcia B, Taboada-Suárez A, González-Álvarez E. Aggressive 
Dupuytren's diathesis in a young woman. BMJ Case Rep. 2010 Sep 20;2010. doi:pii: 
bcr1220092592. 10.1136/bcr.12.2009.2592. 
 
Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. NAD(P)H 
oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac 
fibroblasts into myofibroblasts. Circ Res. 2005 Oct 28;97(9):900-7. 
 
Cui J, Randell E, Renouf J, Sun G, Han FY, Younghusband B, Xie YG. Gender dependent 
association of thrombospondin-4 A387P polymorphism with myocardial infarction. 
Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):e183-4. 
 
Dahl G, Locovei S. Pannexin: to gap or not to gap, is that a question? IUBMB Life. 2006 
Jul;58(7):409-19. 
 
Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene 
network. Semin Cancer Biol. 2006 Aug;16(4):253-64. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 156 - 
 
Demers M, Rose AA, Grosset AA, Biron-Pain K, Gaboury L, Siegel PM, St-Pierre Y Am J. 
Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis 
of breast cancer cells. Pathol. 2010 Jun;176(6):3023-31. Epub 2010 Apr 9. 
 
Denkler K. Surgical complications associated with fasciectomy for dupuytren's disease: a 20-
year review of the English literature. Eplasty. 2010 Jan 27;10:e15. 
 
Desai SS, Hentz VR. The treatment of Dupuytren disease. J Hand Surg Am. 2011 
May;36(5):936-42. 
 
Desnoyers L, Arnott D, Pennica D. WISP-1 binds to decorin and biglycan. J Biol Chem. 
2001 Dec 14;276(50):47599-607. Epub 2001 Oct 11. 
 
Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999 
Dec;55(4):997-1004. 
 
Dolmans GH, Werker PM, Hennies HC, Furniss D, Festen EA, Franke L, Becker K, van der 
Vlies P, Wolffenbuttel BH, Tinschert S, Toliat MR, Nothnagel M, Franke A, Klopp N, 
Wichmann HE, Nürnberg P, Giele H, Ophoff RA, Wijmenga C; the Dutch Dupuytren Study 
Group, the German Dupuytren Study Group, the LifeLines Cohort Study, and the BSSH–
GODD Consortium.Wnt Signaling and Dupuytren's Disease. N Engl J Med. 2011 Jul 6. 
 
McDonald, JH. Handbook of Biological Statistics 2009 (2nd ed.). Sparky House Publishing, 
Baltimore, Maryland. 
 
Doonan R, McElwee JJ, Matthijssens F, Walker GA, Houthoofd K, Back P, Matscheski A, 
Vanfleteren JR, Gems D. Against the oxidative damage theory of aging: superoxide 
dismutases protect against oxidative stress but have little or no effect on life span in 
Caenorhabditis elegans. Genes Dev. 2008 Dec 1;22(23):3236-41. 
 
Dron M, Dandoy-Dron F, Guillo F, Benboudjema L, Hauw JJ, Lebon P, Dormont D, Tovey 
MG. Characterization of the human analogue of a Scrapie-responsive gene. J Biol Chem. 
1998 Jul 17;273(29):18015-8. 
 
Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby 
beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res. 2009 
Jan 1;81(1):178-86. 
 
Dwyer MA, Joseph JD, Wade HE, Eaton ML, Kunder RS, Kazmin D, Chang CY, 
McDonnell DP. WNT11 expression is induced by estrogen-related receptor alpha and beta-
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 157 - 
 
catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res. 2010 
Nov 15;70(22):9298-308. 
 
Early P. Population studies in Dupuytren’s contracture. J Bone Joint Surg 1962;44B:602–13. 
 
Ekblom P, Aufderheide E. Stimulation of tenascin expression in mesenchyme by epithelial-
mesenchymal interactions. Int J Dev Biol. 1989 Mar;33(1):71-9. 
 
Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest. 2001 
Jul;108(2):169-73. 
 
Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. 
Functional interaction between beta-catenin and FOXO in oxidative stress signaling. 
Science. 2005 May 20;308(5725):1181-4. 
 
Esteves TC, Brand MD. The reactions catalysed by the mitochondrial uncoupling proteins 
UCP2 and UCP3. Biochim Biophys Acta. 2005 Aug 15;1709(1):35-44. 
 
Falter E, Herndl E, Mühlbauer W. [Dupuytren's contracture. When operate? Conservative 
preliminary treatment?]. Fortschr Med. 1991 Apr 5;109(10):223-6. 
 
Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochondrial 
Ca2+ and ROS. Front Biosci. 2009 Jan 1;14:1197-218. 
 
Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. 
Genomic targets of the human c-Myc protein. Genes Dev. 2003 May 1;17(9):1115-29. Epub 
2003 Apr 14. 
 
De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res 
Brain Res Rev. 2000 Aug;33(1):1-12. 
 
Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. Lifespan extension and delayed 
immune and collagen aging in mutant mice with defects in growth hormone production. Proc 
Natl Acad Sci U S A. 2001 Jun 5;98(12):6736-41. 
 
Freedman LP. Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest 
and differentiation. J Nutr. 1999 Feb;129(2S Suppl):581S-586S. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 158 - 
 
Friedman DB, Johnson TE. A mutation in the age-1 gene in Caenorhabditis elegans 
lengthens life and reduces hermaphrodite fertility. Genetics. 1988 Jan;118(1):75-86. 
 
De la Fuente M. Role of neuroimmunomodulation in aging. Neuroimmunomodulation. 
2008;15(4-6):213-23. 
 
De la Fuente M, Miquel J. An update of the oxidation-inflammation theory of aging: the 
involvement of the immune system in oxi-inflamm-aging. Curr Pharm Des. 
2009;15(26):3003-26. 
 
Fuerer C, Nusse R, Ten Berge D. Wnt signalling in development and disease. Max Delbrück 
Center for Molecular Medicine meeting on Wnt signaling in Development and Disease. 
EMBO Rep. 2008 Feb;9(2):134-8. 
 
Fuerer C, Habib SJ, Nusse R. A study on the interactions between heparan sulfate 
proteoglycans and Wnt proteins. Dev Dyn. 2010 Jan;239(1):184-90. 
 
Fujino G, Noguchi T, Takeda K, and Ichijo H. Thioredoxin and protein kinases in redox 
signaling. Semin Cancer Biol 26: 26, 2006. 
 
Funato Y, Michiue T, Asashima M, Miki H. The thioredoxin-related redox-regulating 
protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat Cell 
Biol. 2006 May;8(5):501-8. 
 
Funato Y, Miki H. Nucleoredoxin, a novel thioredoxin family member involved in cell 
growth and differentiation. Antioxid Redox Signal. 2007 Aug;9(8):1035-57. 
 
Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-
hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. 1989 Nov 
18;2(8673):1176-8. 
 
Gerber RA, Perry R, Thompson R and Bainbridge C. Dupuytren’s contracture: a 
retrospective database analysis to assess clinical management and costs in England. BMC 
Musculoskeletal Disorders 2011, 12:73 
 
Ghosh S, Lertwattanarak R, Lefort N, Molina-Carrion M, Joya-Galeana J, Bowen BP, 
Garduno-Garcia JD, Abdul-Ghani M, Richardson A, Defronzo RA, Mandarino L, Van 
Remmen H, Musi N.Reduction in Reactive Oxygen Species Production by Mitochondria 
From Elderly Subjects With Normal and Impaired Glucose Tolerance. Diabetes. 2011 Jun 
15. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 159 - 
 
Giepmans BN, Verlaan I, Hengeveld T, Janssen H, Calafat J, Falk MM, Moolenaar WH.Gap 
junction protein connexin-43 interacts directly with microtubules. Curr Biol. 2001a Sep 
4;11(17):1364-8. 
 
Giepmans BN, Hengeveld T, Postma FR, Moolenaar WH.Interaction of c-Src with gap 
junction protein connexin-43. Role in the regulation of cell-cell communication. J Biol 
Chem. 2001b Mar 16;276(11):8544-9. 
 
van Gijn ME, Daemen MJ, Smits JF, Blankesteijn WM. The wnt-frizzled cascade in 
cardiovascular disease. Cardiovasc Res. 2002 Jul;55(1):16-24. 
 
Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. 
Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24. 
 
Girodet PO, Ozier A, Trian T, Begueret H, Ousova O, Vernejoux JM, Chanez P, Marthan R, 
Berger P, Tunon de Lara JM. Mast cell adhesion to bronchial smooth muscle in asthma 
specifically depends on CD51 and CD44 variant 6. Allergy. 2010 Aug;65(8):1004-12. 
 
Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a 
member of a new family of secreted proteins and functions in head induction. Nature. 1998 
Jan 22;391(6665):357-62. 
 
Gloy J, Hikasa H, Sokol SY. Frodo interacts with Dishevelled to transduce Wnt signals. Nat 
Cell Biol. 2002 May;4(5):351-7. 
 
Godtfredsen NS, Lucht H, Prescott E, Sørensen TI, Grønbaek M. A prospective study linked 
both alcohol and tobacco to Dupuytren's disease. J Clin Epidemiol. 2004 Aug;57(8):858-63. 
 
Goldspink G, Fernandes K, Williams PE, Wells DJ. Age-related changes in collagen gene 
expression in the muscles of mdx dystrophic and normal mice. Neuromuscul Disord. 1994 
May;4(3):183-91. 
 
Gombert WM, Krumm A. Targeted deletion of multiple CTCF-binding elements in the 
human C-MYC gene reveals a requirement for CTCF in C-MYC expression. PLoS One. 
2009 Jul 1;4(7):e6109. 
 
González-Sancho JM, Aguilera O, García JM, Pendás-Franco N, Peña C, Cal S, García de 
Herreros A, Bonilla F, Muñoz A. The Wnt antagonist DICKKOPF-1 gene is a downstream 
target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene. 2005 
Feb 3;24(6):1098-103. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 160 - 
 
Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple 
transcription factors. J Biol Chem. 2006 Aug 11;281(32):22429-33. 
 
O'Gorman DB, Wu Y, Seney S, Zhu RD, Gan BS. Wnt expression is not correlated with 
beta-catenin dysregulation in Dupuytren's Disease. J Negat Results Biomed. 2006 Aug 
30;5:13. 
 
Gradl D, Kuhl M, Wedlich D. The Wnt/Wg signal transducer beta-catenin controls 
fibronectin expression. Mol Cell Biol 1999;19:5576–5587. 
 
Groth S, Schulze M, Kalthoff H, Fändrich F, Ungefroren H. Adhesion and Rac1-dependent 
regulation of biglycan gene expression by transforming growth factor-beta. Evidence for 
oxidative signaling through NADPH oxidase. J Biol Chem. 2005 Sep 30;280(39):33190-9. 
 
Gudmundsson KG, Arngrímsson R, Sigfússon N, Björnsson A, Jónsson T. Epidemiology of 
Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J 
Clin Epidemiol. 2000 Mar 1;53(3):291-6. 
 
Gudmundsson KG, Arngrímsson R, Sigfússon N, Jónsson T. Increased total mortality and 
cancer mortality in men with Dupuytren's disease: a 15-year follow-up study. J Clin 
Epidemiol. 2002 Jan;55(1):5-10. 
 
Guğmundsson KG, Arngrímsson R, Sigfússon N, Jónsson T. Prevalence of joint complaints 
amongst individuals with Dupuytren's disease--from the Reykjavík study. Scand J 
Rheumatol. 1999;28(5):300-4. 
 
Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol. 2000 Feb 
7;148(3):399-404. 
 
Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP 
genotyping assay using microarray technology. Nat Genet. 2005 May;37(5):549-54. 
 
Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, Liu 
ET. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res. 2000 
Nov 1;60(21):5922-8. 
 
Haertel-Wiesmann M, Liang Y, Fantl WJ, Williams LT. Regulation of cyclooxygenase-2 
and periostin by Wnt-3 in mouse mammary epithelial cells. J Biol Chem. 2000 Oct 
13;275(41):32046-51. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 161 - 
 
Hakstian RW. Long-term results of extensive fasciectomy. Br J Plast Surg. 1966 
Apr;19(2):140-9. 
 
The International HapMap Consortium. Integrating common and rare genetic variation in 
diverse human populations. Nature 467, 52-58. 2010. 
 
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, 
Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998 Sep 
4;281(5382):1509-12. 
 
Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C: Alphasmooth muscle actin 
expression upregulates fibroblast contractile activity. Mol Biol Cell 2001, 12:2730–2741 
 
Hinz B: Masters and servants of the force: the role of matrix adhesions in myofibroblast 
force perception and transmission. Eur J Cell Biol 2006, 85:175–181 
 
Hinz B, Pittet P, Smith-Clerc J, Chaponnier C, Meister JJ: Myofibroblast development is 
characterized by specific cell-cell adherens junctions. Mol Biol Cell 2004, 15:4310–4320 
 
Hoang B, Moos M Jr, Vukicevic S, Luyten FP. Primary structure and tissue distribution of 
FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal 
morphogenesis. J Biol Chem. 1996 Oct 18;271(42):26131-7. 
 
Hollins F, Kaur D, Yang W, Cruse G, Saunders R, Sutcliffe A, Berger P, Ito A, Brightling 
CE, Bradding P. Human airway smooth muscle promotes human lung mast cell survival, 
proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and 
IL-6. J Immunol. 2008 Aug 15;181(4):2772-80. 
 
Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox 
Signal 2: 811–820, 2000. 
 
Holzenberger M, Dupont J, Ducos B, Leneuve P, Géloën A, Even PC, Cervera P, Le Bouc 
Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003 
Jan 9;421(6919):182-7. 
 
Honda Y, Honda S. The daf-2 gene network for longevity regulates oxidative stress 
resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans. FASEB 
J. 1999 Aug;13(11):1385-93. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 162 - 
 
Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence MJ, Holcombe RF, 
Waterman ML. Beta-cateninsensitive isoforms of lymphoid enhancer factor-1 are selectively 
expressed in colon cancer. Nat Genet 2001;28:53–57. 
 
Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B, Gan BS. Elevated levels 
of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease 
cells are regulated by tension in vitro. BMC Musculoskelet Disord. 2003 Jul 16;4:16. 
 
Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, 
Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their 
activities. Nature. 1999 Apr 1;398(6726):431-6. 
 
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, 
Rodzvilla J; CORD I Study Group.Akelman E, Bear B, Belsky MR, Blazar P, Britton EN, 
Costas B, Frazier JL, Hentz V, Hotchkiss RN, Hurst LC, Badalamente MA, Kaplan FT, 
Lubahn J, McPherson S, Meals R, Peimer CA, Roeshot D. Injectable collagenase clostridium 
histolyticum for Dupuytren's contracture. N Engl J Med. 2009 Sep 3;361(10):968-79. 
 
Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, 
Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during 
tissue remodeling after myocardial infarction. Lab Invest. 2001 Jul;81(7):1015-24. 
 
International HapMap Consortium. The International Hap-Map Project. Nature. 
2003;426:789 – 96. 
 
International HapMap Consortium. A haplotype map of the human genome. Nature. 
2005;437:1299 – 320. 
 
Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM, Smith JC, Krumlauf R. Wise, a 
context-dependent activator and inhibitor of Wnt signalling. Development. 2003 
Sep;130(18):4295-305. 
 
Jamora C, Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat Cell Biol. 
2002 Apr;4(4):E101-8. 
 
Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N.Signals leading 
to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 
2000 Jan;6(1):41-8. 
 
Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia. 2008 
Oct;51(10):1771-80. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 163 - 
 
 
Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and 
regulation during embryonic development and tissue remodeling. Dev Dyn. 2000 
Jun;218(2):235-59. 
 
Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice 
as long as wild type. Nature. 1993 Dec 2;366(6454):461-4. 
 
Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G. daf-2, an insulin receptor-like gene that 
regulates longevity and diapause in Caenorhabditis elegans. Science. 1997 Aug 
15;277(5328):942-6. 
 
Kirkwood TB, Austad SN. Why do we age? Nature. 2000 Nov 9;408(6809):233-8. 
 
Klapholz-Brown Z, Walmsley GG, Nusse YM, Nusse R, Brown PO. Transcriptional 
program induced by Wnt protein in human fibroblasts suggests mechanisms for cell 
cooperativity in defining tissue microenvironments. PLoS One. 2007 Sep 26;2(9):e945. 
 
Kim J, Lee JH, Iyer VR. Global identification of Myc target genes reveals its direct role in 
mitochondrial biogenesis and its E-box usage in vivo. PLoS One. 2008 Mar 12;3(3):e1798. 
 
Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ. 
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol 
Genet. 2010 Oct 15;19(20):3919-35. 
 
Kim KA, Zhao J, Andarmani S, et al. R-Spondin proteins: a novel link to betacatenin 
activation. Cell Cycle 2006;5:23-6. 
 
Kim KA, Wagle M, Tran K, Zhan X, Dixon MA, Liu S, Gros D, Korver W, Yonkovich S, 
Tomasevic N, Binnerts M, Abo A. R-Spondin family members regulate the Wnt pathway by 
a common mechanism. Mol Biol Cell. 2008 Jun;19(6):2588-96. 
 
Koch W, Hoppmann P, de Waha A, Schömig A, Kastrati A. Polymorphisms in 
thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis 
of available evidence. Hum Mol Genet. 2008 Apr 15;17(8):1120-6. Epub 2008 Jan 4. 
 
Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y, Smith IM, Wu R, Zhai Y, 
Cho KR, Fearon ER. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in 
human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer 
Cell 2002;1:145–155. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 164 - 
 
 
Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, 
Seeger W, Schaefer L, Günther A, Eickelberg O. WNT1-inducible signaling protein-1 
mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic 
pulmonary fibrosis. J Clin Invest. 2009 Apr;119(4):772-87. 
 
Korswagen HC. Regulation of the Wnt/beta-catenin pathway by redox signaling. Dev Cell. 
2006 Jun;10(6):687-8. 
 
Krause C, Kloen P, Ten Dijke P. Elevated transforming growth factor beta and mitogen-
activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. 
Fibrogenesis Tissue Repair. 2011 Jun 28;4(1):14. 
 
Krause KH. Tissue distribution and putative physiological function of NOX family NADPH 
oxidases. Jpn J Infect Dis. 2004 Oct;57(5):S28-9. 
 
Kraytsberg Y, Simon DK, Turnbull DM, Khrapko K. Do mtDNA deletions drive premature 
aging in mtDNA mutator mice? Aging Cell. 2009 Aug;8(4):502-6. 
 
Ku HH, Sohal RS. Comparison of mitochondrial pro-oxidant generation and anti-oxidant 
defenses between rat and pigeon: possible basis of variation in longevity and metabolic 
potential. Mech Ageing Dev. 1993 Nov;72(1):67-76. 
 
Kumar NM, Gilula NB. The gap junction communication channel. Cell. 1996 Feb 
9;84(3):381-8. 
 
Kuramochi M, Fukuhara H, Nobukuni T et al. TSLC1 is a tumorsuppressor gene in human 
non-small-cell lung cancer. Nat Genet 2001; 
27: 427–30. 
 
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, 
Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai 
R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling 
ageing. Nature. 1997 Nov 6;390(6655):45-51. 
 
Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and 
subcortical glucose consumption measured by PET in patients with Huntington's disease. 
Brain. 1990 Oct;113 ( Pt 5):1405-23. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 165 - 
 
Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T. The heparanome--the 
enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol. 2007 Apr 
30;129(2):290-307. Epub 2007 Feb 8. 
 
Lambert AJ, Boysen HM, Buckingham JA, Yang T, Podlutsky A, Austad SN, Kunz TH, 
Buffenstein R, Brand MD. Low rates of hydrogen peroxide production by isolated heart 
mitochondria associate with long maximum lifespan in vertebrate homeotherms. Aging Cell. 
2007 Oct;6(5):607-18. Epub 2007 Jun 27. 
 
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing 
and analysis of the human genome. Nature. 2001;409:860 – 921. 
 
Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic Parkinsonism in humans due to a 
product of meperidine-analog synthesis. Science 219:979–980. 
 
Larson D, Jerosch-Herold C. Clinical effectiveness of post-operative splinting after surgical 
release of Dupuytren's contracture: a systematic review. BMC Musculoskelet Disord. 2008 
Jul 21;9:104. 
 
Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992 Apr;6(7):2397-404. 
 
Lawler J, Duquette M, Whittaker CA, Adams JC, McHenry K, DeSimone DW. 
Identification and characterization of thrombospondin-4, a new member of the 
thrombospondin gene family. J Cell Biol. 1993 Feb;120(4):1059-67. 
 
Lee HY, Choi CS, Birkenfeld AL, Alves TC, Jornayvaz FR, Jurczak MJ, Zhang D, Woo 
DK, Shadel GS, Ladiges W, Rabinovitch PS, Santos JH, Petersen KF, Samuel VT, Shulman 
GI. Targeted expression of catalase to mitochondria prevents age-associated reductions in 
mitochondrial function and insulin resistance. Cell Metab. 2010 Dec 1;12(6):668-74. 
 
Lee SS, Kennedy S, Tolonen AC, Ruvkun G. DAF-16 target genes that control C. elegans 
life-span and metabolism. Science. 2003 Apr 25;300(5619):644-7. 
 
Lescher B, Haenig B, Kispert A. sFRP-2 is a target of the Wnt-4 signaling pathway in the 
developing metanephric kidney. Dev Dyn. 1998 Dec;213(4):440-51. 
 
Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, Kim JW, Yustein JT, Lee 
LA, Dang CV. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial 
biogenesis. Mol Cell Biol. 2005 Jul;25(14):6225-34. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 166 - 
 
Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. 
Am J Ind Med. 1996 May;29(5):521-32. 
 
Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of beta-
catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002; 108: 837–847. 
 
Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, Malide D, Rovira II, Schimel D, 
Kuo CJ, Gutkind JS, Hwang PM, Finkel T. Augmented Wnt signaling in a mammalian 
model of accelerated aging. Science. 2007 Aug 10;317(5839):803-6. 
 
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402–8. 
 
Loeb LA, Wallace DC, Martin GM. The mitochondrial theory of aging and its relationship to 
reactive oxygen species damage and somatic mtDNA mutations. Proc Natl Acad Sci U S A. 
2005 Dec 27;102(52):18769-70. 
 
Loewenstein WR. Junctional intercellular communication: the cell-to-cell membrane 
channel. Physiol Rev. 1981 Oct;61(4):829-913. 
 
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev 
Cell Dev Biol. 2004;20:781-810. 
 
Loos B, Puschkin V, Horch RE. 50 years experience with Dupuytren's contracture in the 
Erlangen University Hospital--a retrospective analysis of 2919 operated hands from 1956 to 
2006. BMC Musculoskelet Disord. 2007 Jul 4;8:60. 
 
Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, Kovacic H. 
Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. 
Mol Cell Biol. 2003 Aug;23(15):5401-8. 
 
Louro ID, Bailey EC, Li X, South LS, McKie-Bell PR, Yoder BK, Huang CC, Johnson MR, 
Hill AE, Johnson RL, Ruppert JM.Comparative gene expression profile analysis of GLI and 
c-MYC in an epithelial model of malignant transformation. Cancer Res. 2002 Oct 
15;62(20):5867-73. 
 
Lowell BB, Shulman GI. (2005). Mitochondrial dysfunction and type 2 diabetes. Science 
307:384–7. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 167 - 
 
Luck JV. Dupuytren's contracture; a new concept of the pathogenesis correlated with 
surgical management. J Bone Joint Surg Am. 1959 Jun;41-A(4):635-64. 
 
Luo Y, Radice GL. Cadherin-mediated adhesion is essential for myofibril continuity across 
the plasma membrane but not for assembly of the contractile apparatus. J Cell Sci. 2003 Apr 
15;116(Pt 8):1471-9. 
 
De Magalhães JP, Church GM. Cells discover fire: employing reactive oxygen species in 
development and consequences for aging. Exp Gerontol. 2006 Jan;41(1):1-10. 
 
Magnaldo T, Bernerd F, Darmon M.Galectin-7, a human 14-kDa S-lectin, specifically 
expressed in keratinocytes and sensitive to retinoic acid. Dev Biol. 1995 Apr;168(2):259-71. 
 
Mäkelä EA, Jaroma H, Harju A, Anttila S, Vainio J. Dupuytren's contracture: the long-term 
results after day surgery. J Hand Surg Br. 1991 Aug;16(3):272-4. 
 
Mammucari C, Rizzuto R. Signaling pathways in mitochondrial dysfunction and aging. 
Mech Ageing Dev. 2010 Jul-Aug;131(7-8):536-43. 
 
Mansfield N J, Marshall J M. Symptoms of musculoskeletal disorders in stage rally drivers 
and co-drivers. Br J Sports Med 2001;35:314–320 
 
Maravic M, Landais P. Dupuytren’s disease in France – 1831 to 2001 – from description to 
economic burden. J Hand Surg [Br] 2005. 30B(5). 
 
Marchand A, Atassi F, Gaaya A, Leprince P, Le Feuvre C, Soubrier F, Lompré AM, Nadaud 
S. The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans. 
Aging Cell. 2011 Apr;10(2):220-32. 
 
Martin GM, Austad SN, Johnson TE. Genetic analysis of ageing: role of oxidative damage 
and environmental stresses. Nat Genet. 1996 May;13(1):25-34. 
 
Martin-Garrido A, Brown DI, Lyle AN, Dikalova A, Seidel-Rogol B, Lassègue B, San 
Martín A, Griendling KK. NADPH oxidase 4 mediates TGF-β-induced smooth muscle α-
actin via p38MAPK and serum response factor. Free Radic Biol Med. 2011 Jan 
15;50(2):354-62. 
 
Martínez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the 
telomere-binding proteins. Nat Rev Cancer. 2011 Mar;11(3):161-76. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 168 - 
 
Masmejean EH, Chavane H, Chantegret A, Issermann JJ, Alnot JY. The wrist of the formula 
1 driver. Br J Sports Med. 1999 Aug;33(4):270-3. 
 
Mason CC, Hanson RL, Ossowski V, Bian L, Baier LJ, Krakoff J, Bogardus C. Bimodal 
distribution of RNA expression levels in human skeletal muscle tissue. BMC Genomics. 
2011 Feb 7;12:98. 
 
Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, Murakami Y. 
The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem. 2002 
Aug 23;277(34):31014-9. Epub 2002 Jun 5. 
 
Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, 
Walter C, Glinka A, Niehrs C. Kremen proteins are Dickkopf receptors that regulate 
Wnt/beta-catenin signalling. Nature. 2002 Jun 6;417(6889):664-7. Epub 2002 May 26. 
 
Mao DY, Watson JD, Yan PS, Barsyte-Lovejoy D, Khosravi F, Wong WW, Farnham PJ, 
Huang TH, Penn LZ.Analysis of Myc bound loci identified by CpG island arrays shows that 
Max is essential for Myc-dependent repression. Curr Biol. 2003 May 13;13(10):882-6. 
 
Medawar, P. B. An Unsolved Problem of Biology (Lewis, London, 1952). 
 
Melchior-Becker A, Dai G, Ding Z, Schäfer L, Schrader J, Young MF, Fischer JW. 
Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast 
phenotype. J Biol Chem. 2011 May 13;286(19):17365-75. 
 
Meng H, Zhang X, Lee SJ, Strickland DK, Lawrence DA, Wang MM. Low density 
lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) 
enhancement of Notch3 signaling. J Biol Chem. 2010 Jul 23;285(30):23047-55. Epub 2010 
May 14. 
 
Mercurio S, Latinkic B, Itasaki N, Krumlauf R, Smith JC. Connective-tissue growth factor 
modulates WNT signalling and interacts with the WNT receptor complex. Development. 
2004 May;131(9):2137-47. 
 
Michaeloudes C, Sukkar MB, Khorasani NM, Bhavsar PK, Chung KF. TGF-β regulates 
Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am 
J Physiol Lung Cell Mol Physiol. 2011 Feb;300(2):L295-304. 
 
Michalik M, Wójcik KA, Jakieła B, Szpak K, Pierzchalska M, Sanak M, Madeja Z, Czyż J. 
Lithium Attenuates TGF-β(1)-Induced Fibroblasts to Myofibroblasts Transition in Bronchial 
Fibroblasts Derived from Asthmatic Patients. J Allergy (Cairo). 2012;2012:206109. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 169 - 
 
 
Misenheimer TM, Mosher DF. Biophysical characterization of the signature domains of 
thrombospondin-4 and thrombospondin-2. J Biol Chem. 2005 Dec 16;280(50):41229-35. 
Epub 2005 Oct 24. 
 
Mitra A, Goldstein RY. Dupuytren's contracture in the black population: a review. Ann Plast 
Surg. 1994 Jun;32(6):619-22. 
 
Moon RT, Kohn AD, Ferrari GVD, Kaykas A. WNT and beta-catenin signalling: diseases 
and therapies. Nat Rev Genet 2004;5:691-701. 
 
Morgan KG, Gangopadhyay SS. Invited review: cross-bridge regulation by thin filament-
associated proteins. J Appl Physiol. 2001 Aug;91(2):953-62. 
 
Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and 
characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J 
Biol Chem. 2002 Dec 20;277(51):49175-85. Epub 2002 Oct 3. 
 
Morrish F, Giedt C, Hockenbery D. c-MYC apoptotic function is mediated by NRF-1 target 
genes. Genes Dev. 2003 Jan 15;17(2):240-55. 
 
Mroue RM, El-Sabban ME, Talhouk RS. Connexins and the gap in context. Integr Biol 
(Camb). 2011 Apr;3(4):255-66. 
 
Muley A, Majumder S, Kolluru GK, Parkinson S, Viola H, Hool L, Arfuso F, Ganss R, 
Dharmarajan A, Chatterjee S. Secreted frizzled-related protein 4: an angiogenesis inhibitor. 
Am J Pathol. 2010 Mar;176(3):1505-16. 
 
Murakami Y. Functional cloning of a tumor suppressor gene, TSLC1, in human non-small 
cell lung cancer. Oncogene 2002; 21: 6936–48. 
 
Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H, Kenyon 
C. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis 
elegans. Nature. 2003 Jul 17;424(6946):277-83. 
 
Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell 
adhesion an adaptive state? J Clin Invest. 2001 Apr;107(7):785-90. 
 
Naito AT, Shiojima I, Komuro I. Wnt signaling and aging-related heart disorders. Circ Res. 
2010 Nov 26;107(11):1295-303. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 170 - 
 
 
Narouz-Ott L, Maurer P, Nitsche DP, Smyth N, Paulsson M. Thrombospondin-4 binds 
specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-
terminal domains. J Biol Chem. 2000 Nov 24;275(47):37110-7. 
 
Nasr SJ, Atkins RW. Coincidental improvement in asthma during lithium treatment. Am J 
Psychiatry. 1977 Sep;134(9):1042-3. 
 
Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 
2004 Mar 5;303(5663):1483-7. 
 
Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, Oliveira-
Emilio HC, Carpinelli AR, Curi R. Diabetes associated cell stress and dysfunction: role of 
mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007 Aug 
15;583(Pt 1):9-24. 
 
Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, Sugano S, Akiyama T. 
DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. 
Oncogene. 2004 Nov 4;23(52):8520-6. 
 
Nusse R. Wnt signaling in disease and in development. Cell Res. 2005 Jan;15(1):28-32. 
 
Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J 
Bone Joint Surg Br. 1984 May;66(3):322-5. 
 
Nör JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 
induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death 
pathway. J Vasc Res. 2000 May-Jun;37(3):209-18. 
 
Ochi K, Derfoul A, Tuan RS. A predominantly articular cartilage-associated gene, SCRG1, 
is induced by glucocorticoid and stimulates chondrogenesis in vitro. Osteoarthritis Cartilage. 
2006 Jan;14(1):30-8. Epub 2005 Sep 26. 
 
Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, Ruvkun G. The Fork 
head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in 
C. elegans. Nature. 1997 Oct 30;389(6654):994-9. 
 
Onumah OE, Jules GE, Zhao Y, Zhou L, Yang H, Guo Z. Overexpression of catalase delays 
G0/G1- to S-phase transition during cell cycle progression in mouse aortic endothelial cells. 
Free Radic Biol Med. 2009 Jun 15;46(12):1658-67. 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 171 - 
 
 
Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, 
Cano A, de Herreros AG, Lafarga M, Muñoz A. Vitamin D(3) promotes the differentiation 
of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin 
signaling. J Cell Biol. 2001 Jul 23;154(2):369-87. 
 
Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, Narayan D. Microarray gene 
analysis and expression profiles of Dupuytren's contracture. Ann Plast Surg 2003, 50:618-
622. 
 
Pandur P, Läsche M, Eisenberg LM, Kühl M. Wnt-11 activation of a non-canonical Wnt 
signalling pathway is required for cardiogenesis. Nature. 2002 Aug 8;418(6898):636-41. 
 
Papaconstantinou J. Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and 
longevity determination. Mol Cell Endocrinol. 2009 Feb 5;299(1):89-100. 
 
Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. 2006 Jul 
15;71(2):247-58.  
 
Parisi MS, Gazzerro E, Rydziel S, Canalis E.Expression and regulation of CCN genes in 
murine osteoblasts. Bone. 2006 May;38(5):671-7. 
 
Park JB. Phagocytosis induces superoxide formation and apoptosis in macrophages. Exp 
Mol Med. 2003 Oct 31;35(5):325-35. 
 
Park JE, Chang WY, Cho M. Induction of matrix metalloproteinase-9 by galectin-7 through 
p38 MAPK signaling in HeLa human cervical epithelial adenocarcinoma cells. Oncol Rep. 
2009 Dec;22(6):1373-9. 
 
Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji 
H, McLaughlin M, Veenstra TD, Nusse R, McCrea PD, Artandi SE. Telomerase modulates 
Wnt signalling by association with target gene chromatin. Nature. 2009 Jul 2;460(7251):66-
72. 
 
Patti ME, Butti AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, 
Costello M, Saccone R, et al (2003). Coordinated reduction of genes of oxidative 
metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and 
NRF1. Proc Natl Acad Sci USA 100:8466–71. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 172 - 
 
Peña-Silva RA, Miller JD, Chu Y, Heistad DD. Serotonin produces monoamine oxidase-
dependent oxidative stress in human heart valves. Am J Physiol Heart Circ Physiol. 2009 
Oct;297(4):H1354-60. 
 
Pendás-Franco N, Aguilera O, Pereira F, González-Sancho JM, Muñoz A. Vitamin D and 
Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. 
Anticancer Res. 2008 Sep-Oct;28(5A):2613-23. 
 
Pendás-Franco N, García JM, Peña C, Valle N, Pálmer HG, Heinäniemi M, Carlberg C, 
Jiménez B, Bonilla F, Muñoz A, González-Sancho JM. DICKKOPF-4 is induced by 
TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion 
and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene. 2008 Jul 
24;27(32):4467-77. 
 
Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, 
Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, 
Hillan KJ, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective 
tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly 
expressed in human colon tumors. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14717-22. 
 
Pérez VI, Bokov A, Van Remmen H, Mele J, Ran Q, Ikeno Y, Richardson A. Is the 
oxidative stress theory of aging dead? Biochim Biophys Acta. 2009 Oct;1790(10):1005-14. 
 
Perls TT, Alpert L, Fretts RC. Middle-aged mothers live longer. Nature. 1997 Sep 
11;389(6647):133. 
 
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. (2004). Impaired mitochondrial 
activity in the insulin-resistant offspring of patients with type 2 diabetes. New Eng J Med 
350:664–71. 
 
Pruim RJ*, Welch RP*, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, 
Abecasis GR, Willer CJ. (2010) LocusZoom: Regional visualization of genome-wide 
association scan results. Bioinformatics 2010 September 15; 26(18): 2336.2337. 
 
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de 
Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and 
population-based linkage analyses. Am J Hum Genet. 2007 Sep;81(3):559-75. 
 
Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF.Comparison of gene expression profiles 
between Peyronie's disease and Dupuytren's contracture. Urology. 2004 Aug;64(2):399-404. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 173 - 
 
Rao TP, Kühl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ 
Res. 2010 Jun 25;106(12):1798-806. 
 
Rayan GM. Clinical presentation and types of Dupuytren's disease. Hand Clin. 1999 
Feb;15(1):87-96, vii. 
 
Rhee SG, Chae HZ, and Kim K. Peroxiredoxins: a historical overview and speculative 
preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 
38:1543–1552, 2005. 
 
Rigoulet M, Yoboue ED, Devin A. Mitochondrial ROS generation and its regulation: 
mechanisms involved in H(2)O(2) signaling. Antioxid Redox Signal. 2011 Feb 1;14(3):459-
68. 
 
van Rijssen AL, Gerbrandy FS, Ter Linden H, Klip H, Werker PM. A comparison of the 
direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's 
disease: a 6-week follow-up study. J Hand Surg Am. 2006 May-Jun;31(5):717-25. 
 
Robertson BW, Chellaiah MA. Osteopontin induces beta-catenin signaling through 
activation of Akt in prostate cancer cells. Exp Cell Res. 2010 Jan 1;316(1):1-11. 
 
Rocques N, Abou Zeid N, Sii-Felice K, Lecoin L, Felder-Schmittbuhl MP, Eychène A, 
Pouponnot C. GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol 
Cell. 2007 Nov 30;28(4):584-97. 
 
Rozen WM, Edirisinghe Y, Crock J (2012) Late Complications of Clinical Clostridium 
Histolyticum Collagenase Use in Dupuytren's Disease. PLoS ONE 7(8): e43406. 
doi:10.1371/journal.pone.0043406 
 
Russell L, Forsdyke DR. A human putative lymphocyte G0/G1 switch gene containing a 
CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA 
Cell Biol. 1991 Oct;10(8):581-91. 
 
Sanz A, Fernández-Ayala DJ, Stefanatos RK, Jacobs HT. Mitochondrial ROS production 
correlates with, but does not directly regulate lifespan in Drosophila. Aging (Albany NY). 
2010 Apr;2(4):200-23. 
 
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial 
complex I deficiency in Parkinson's disease. Lancet. 1989 Jun 3;1(8649):1269. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 174 - 
 
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. 
Nat Protocols 2008;3:1101–8. 
 
Sgrò CM, Partridge L. A delayed wave of death from reproduction in Drosophila. Science. 
1999 Dec 24;286(5449):2521-4. 
 
Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling 
inhibitor. J Biol Chem. 2005 Jul 22;280(29):26770-5. 
 
Shafer SL, Towler DA. Transcriptional regulation of SM22alpha by Wnt3a: convergence 
with TGFbeta(1)/Smad signaling at a novel regulatory element. J Mol Cell Cardiol. 2009 
May;46(5):621-35. 
 
Shih B, Brown JJ, Armstrong DJ, Lindau T, Bayat A. Differential gene expression analysis 
of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison 
to control tissue. Hand (N Y). 2009 Sep;4(3):294-301. 
 
Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. 
Nat Rev Rheumatol. 2010 Dec;6(12):715-26. 
 
Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M, Saruta T. Extracellular 
matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and 
migration. Circ Res. 2004 Apr 30;94(8):1067-74. Epub 2004 Mar 18. 
 
Shin SY, Kim CG, Jho EH, Rho MS, Kim YS, Kim YH, Lee YH. Hydrogen peroxide 
negatively modulates Wnt signaling through downregulation of beta-catenin. Cancer Lett. 
2004 Aug 30;212(2):225-31. 
 
Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC. Matricellular protein CCN3 
(NOV) regulates actin cytoskeleton reorganization. J Biol Chem. 2009 Oct 
23;284(43):29935-44. 
 
Singh D, Solan JL, Taffet SM, Javier R, Lampe PD. Connexin 43 interacts with zona 
occludens-1 and -2 proteins in a cell cycle stage-specific manner. J Biol Chem. 2005 Aug 
26;280(34):30416-21. Epub 2005 Jun 26. 
 
Slattery D. Review: Dupuytren's disease in Asia and the migration theory of Dupuytren's 
disease. ANZ J Surg. 2010 Jul-Aug;80(7-8):495-9. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 175 - 
 
Smith SP, Devaraj VS, Bunker TD. The association between frozen shoulder and 
Dupuytren's disease. J Shoulder Elbow Surg. 2001 Mar-Apr;10(2):149-51. 
 
Sohal RS, Sohal BH, Orr WC. Mitochondrial superoxide and hydrogen peroxide generation, 
protein oxidative damage, and longevity in different species of flies. Free Radic Biol Med. 
1995 Oct;19(4):499-504. 
 
Steemers FJ, Chang W, Lee G, Barker DL, Shen R, Gunderson KL. Whole-genome 
genotyping with the singlebase extension assay. Nat Methods. 2006;3:31 – 3. 
 
Stenina OI, Desai SY, Krukovets I, Kight K, Janigro D, Topol EJ, Plow EF. 
Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. 
Circulation. 2003 Sep 23;108(12):1514-9. Epub 2003 Sep 2. 
 
Stolle K, Schnoor M, Fuellen G, Spitzer M, Cullen P, Lorkowski S.Cloning, genomic 
organization, and tissue-specific expression of the RASL11B gene. Biochim Biophys Acta. 
2007 Jul-Aug;1769(7-8):514-24. Epub 2007 Jun 6. 
 
Sugimura R, Li L. Noncanonical Wnt signaling in vertebrate development, stem cells, and 
diseases. Birth Defects Res C Embryo Today. 2010 Dec;90(4):243-56. 
 
Surendran K, Schiavi S, Hruska KA. Wnt-dependent beta-catenin signaling is activated after 
unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the 
progression of renal fibrosis. J Am Soc Nephrol. 2005 Aug;16(8):2373-84. 
 
Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's 
disease. Med Hypotheses. 2004;63(1):8-20. 
 
Tahara EB, Navarete FD, Kowaltowski AJ. Tissue-, substrate-, and site-specific 
characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med. 
2009 May 1;46(9):1283-97. 
 
Takada R, Satomi Y, Kurata T, Ueno N, Norioka S, Kondoh H, Takao T, Takada S. 
Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell. 
2006 Dec;11(6):791-801. 
 
Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-
type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human 
colorectal cancers. Oncogene 2002;21:5861–5867. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 176 - 
 
Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Puré E, Henson PM, Noble PW. 
Resolution of lung inflammation by CD44. Science. 2002 Apr 5;296(5565):155-8. 
 
Terman A, Gustafsson B, Brunk UT. The lysosomal-mitochondrial axis theory of postmitotic 
aging and cell death. Chem Biol Interact. 2006 Oct 27;163(1-2):29-37. 
 
Tolwinski, N. S. & Wieschaus, E. Rethinking WNT signaling. Trends Genet. 20, 177–181 
(2004). 
 
Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-
regulation of connective tissue remodeling. Nat Rev Mol Cell Biol 2002, 3:349–363 
 
Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedman M, 
Metivier J, Cannata R, O'Donnell CJ, Kottke-Marchant K, Murugesan G, Plow EF, Stenina 
O, Daley GQ. Single nucleotide polymorphisms in multiple novel thrombospondin genes 
may be associated with familial premature myocardial infarction. Circulation. 2001 Nov 
27;104(22):2641-4. 
 
Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, 
Bohlooly-Y M, Gidlöf S, Oldfors A, Wibom R, Törnell J, Jacobs HT, Larsson NG. 
Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. 
2004 May 27;429(6990):417-23. 
 
Tubiana R. Evaluation of deformities in Dupuytren's disease. Ann Chir Main. 1986;5(1):5-
11. 
 
Tunn S, Gurr E, Delbrück A, Buhr T, Flory J. The distribution of unsulphated and sulphated 
glycosaminoglycans in palmar fascia from patients with Dupuytren's disease and healthy 
subjects. J Clin Chem Clin Biochem. 1988 Jan;26(1):7-14. 
 
Turner N, Bruce CR, Beale SM, Hoehn KL, So T, Rolph MS, Cooney GJ Excess lipid 
availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against 
a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.  
Diabetes. 2007 Aug;56(8):2085-92. 
 
Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen 
SD. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-
bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC 
Biochem. 2006 Jan 17;7:2. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 177 - 
 
Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway 
in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003 Oct 
16;22(46):7218-21. 
 
Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richards RS, McFarlane RM, Alman B, 
Howard JC. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix 
interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene. 2003 Jun 
12;22(24):3680-4. 
 
Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of beta-
catenin-independent Wnt signaling. Dev Cell. 2003 Sep;5(3):367-77. 
 
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the 
human genome. Science. 2001;291:1304 – 51. 
 
Wei CJ, Francis R, Xu X, Lo CW.Connexin43 associated with an N-cadherin-containing 
multiprotein complex is required for gap junction formation in NIH3T3 cells. J Biol Chem. 
2005 May 20;280(20):19925-36. Epub 2005 Feb 28. 
 
Werner S, Grose R: Regulation of wound healing by growth factors and cytokines. Physiol 
Rev 2003, 83:835–870 
 
Wessel J, Topol EJ, Ji M, Meyer J, McCarthy JJ. Replication of the association between the 
thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J. 2004 
May;147(5):905-9. 
 
van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, 
Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete 
G, Pals S, Eilers M, Medema R, Clevers H. The beta-catenin/TCF-4 complex imposes a 
crypt progenitor phenotype on colorectal cancer cells. Cell. 2002 Oct 18;111(2):241-50. 
 
Whitelock JM, Iozzo RV. Heparan sulfate: a complex polymer charged with biological 
activity. Chem Rev. 2005 Jul;105(7):2745-64. 
 
Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. 
Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. 
Am J Pathol. 1999 Feb;154(2):515-23. 
 
Wilbrand S, Ekbom A, Gerdin B. Cancer incidence in patients treated surgically for 
Dupuytren's contracture. J Hand Surg Br. 2000 Jun;25(3):283-7. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 178 - 
 
Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt 
protein in human embryonic carcinoma cells. BMC Dev Biol. 2002 Jul 2;2:8. 
 
Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR 3rd, 
Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 
2003 May 22;423(6938):448-52. 
 
Williams GC. Pleiotropy, natural selection and the evolution of senescence. Evolution 11, 
398–411 (1957). 
 
Williams H, Johnson JL, Jackson CL, White SJ, George SJ. MMP-7 mediates cleavage of N-
cadherin and promotes smooth muscle cell apoptosis. Cardiovasc Res. 2010 Jul 1;87(1):137-
46. 
 
Winchester R, Ebers G, Fu SM, Espinosa L, Zabriskie J, Kunkel HG.B-cell alloantigen Ag 
7a in multiple sclerosis. Lancet. 1975 Oct 25;2(7939):814. 
 
Woodruff MJ, Waldram MA. A clinical grading system for Dupuytren's contracture. J Hand 
Surg Br. 1998 Jun;23(3):303-5. 
 
Wurster-Hill DH, Brown F, Park JP, Gibson SH. Cytogenetic studies in Dupuytren 
contracture. Am J Hum Genet. 1988 Sep;43(3):285-92. 
 
Xiao NM, Zhang YM, Zheng Q, Gu J. Klotho is a serum factor related to human aging. Chin 
Med J (Engl). 2004 May;117(5):742-7. 
 
Xu X, Li WE, Huang GY, Meyer R, Chen T, Luo Y, Thomas MP, Radice GL, Lo CW. J 
Modulation of mouse neural crest cell motility by N-cadherin and connexin 43 gap junctions. 
Cell Biol. 2001 Jul 9;154(1):217-30. 
 
Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, 
Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ, Williams LT. 
Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin 
signaling is activated in human colon tumors. Proc Natl Acad Sci U S A. 2001 Dec 
18;98(26):14973-8. 
 
Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt 
signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008 
May;149(5):2341-51. 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 179 - 
 
Yoon JC, Ng A, Kim BH, Bianco A, Xavier RJ, Elledge SJ. Wnt signaling regulates 
mitochondrial physiology and insulin sensitivity. Genes Dev. 2010 Jul 15;24(14):1507-18. 
 
Zandbergen F, Mandard S, Escher P, Tan NS, Patsouris D, Jatkoe T, Rojas-Caro S, Madore 
S, Wahli W, Tafuri S, Müller M, Kersten S. The G0/G1 switch gene 2 is a novel PPAR 
target gene. Biochem J. 2005 Dec 1;392(Pt 2):313-24. 
 
Zanocco-Marani T, Vignudelli T, Parenti S, Gemelli C, Condorelli F, Martello A, Selmi T, 
Grande A, Ferrari S. TFE3 transcription factor regulates the expression of MAFB during 
macrophage differentiation. Exp Cell Res. 2009 Jul 1;315(11):1798-808. 
 
Zerajic D, Finsen V. Dupuytren's disease in Bosnia and Herzegovina. An epidemiological 
study. BMC Musculoskelet Disord. 2004 Mar 29;5:10. 
 
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer 
J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, 
Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. The molecular classification of 
multiple myeloma. Blood. 2006 Sep 15;108(6):2020-8. 
 
Zhang DY, Wang HJ, Tan YZ. Wnt/β-Catenin Signaling Induces the Aging of Mesenchymal 
Stem Cells through the DNA Damage Response and the p53/p21 Pathway. PLoS One. 
2011;6(6):e21397. 
 
Zhu X, Ding M, Yu ML, Feng MX, Tan LJ, Zhao FK. Identification of galectin-7 as a 
potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC 
Cancer. 2010 Jun 15;10:290. 
 
 
 
 
Molecular Genetics of Dupuytren´s Disease 
Kerstin Becker  - 180 - 
 
7 Appendix 
7.1 Questionnaires and Informed Consent Forms 
 
 
Figure 68. Latest version of the questionnaire filled out by Dupuytren patients participating in the study. 
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Figure 69. First version of the questionnaire filled out by Dupuytren patients participating in the Study 
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Figure 70. Informed consent form filled out by Dupuytren patients participating in the Study. 
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Figure 71. Questionnaire and informed consent form fillt out by control persons participating in the 
Dupuytren Study. 
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7.2 Primer Sequences 
Table 30. Primer for sequencing of the SFRP4 gene. 
primer name primer sequence product size (bp) 
SFRP4_1_F TGCATTTGCAAAGTAGTGACG 542 
SFRP4_1_R CAGAGTTTGTAACTCTCAAGTT  
SFRP4_2_F GAAGGCTTGAGTCCACACTGATAC 379 
SFRP4_2_R CTCTGTGGTCTCTTTCTGTCTGGA  
SFRP4_3-1_F GGTGATGTCACCGCTTCTGCAC 456 
SFRP4_3-1_R CACAGCGCCACTAGGATGGAGAGG  
SFRP4_3-2_F GCGCTTTCTGTCTGCCGGGGTCG 556 
SFRP4_3-2_R CAGTTCTCGATTGGCAGCCACAGC  
SFRP4_4+5_F CCAGCTGGGTGAACAGACCAAATC 356 
SFRP4_4+5_R CCAGCTTTGTAATGAACCAAGTCTC  
SFRP4_6_F CTTTAAGAGAGGCTCAGAAGTTG 351 
SFRP4_6_R CTGAGATTGAGGTCTTCCTAACAGTG  
SFRP4_7_F GCAGATCAGCAGATCATCTCAATAC 333 
SFRP4_7_R GAAATCTGTTATGTGCACTTACATC  
SFRP4_8-1_F CACATTAGCTGAGCACCATAAAGGG 521 
SFRP4_8-1_R GTTACTCTGAATGCAATGCAATAAGCC  
SFRP4_8-2_F GCAGCATTTTTCTTAAGGCTATGC 389 
SFRP4_8-2_R CCTTCTGCAGACCATAAACACATAAAG  
SFRP4_8-3_F GCTTCTAAGAAGGAACAGTAGTGG 610 
SFRP4_8-3_R GATTAAAGTATCCCAACTGTCAAG  
SFRP4_8-4_F CTTTGCCTAAATACATGTGAGAGGAG 634 
SFRP4_8-4_R CAAATGTATCCCAAGGTACTAATGAAG  
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Table 31. Primer for sequencing of the EPDR1 gene. 
primer name primer sequence product size (bp) 
EPDR1_1_F TGAGGTTTTATGGTCTGTTGACATTC 297 
EPDR1_1_R GATTCTGAATTAGGACTATGCCAAC  
EPDR1_2_F GAATCGCCAGTATGTGCAGTTTG 348 
EPDR1_2_R CATTGTGTAATTACTGTCATTGGCAAAC  
EPDR1_3-1_F CTTGCCCCTCCCTGTGTGATTACC 468 
EPDR1_3-1_R CGTCCTGGCATCGCGGTCAGCCTT  
EPDR1_3-2_F GAGCCGGCGGGAGCCACTCTGATC 457 
EPDR1_3-2_R GCAAGGGGCCGGAAAGAGTTACAG  
EPDR1_4_F CCTGCAAGAGGTACAGGTCATCG 426 
EPDR1_4_R GTGCCTCTCTAGCAGATGTCTCTAG  
EPDR1_5_F GATTGCCTAGCTAGTAATTTCTTTC 471 
EPDR1_5_R CCTGCAGACCTAAGTGGAGGCT  
EPDR1_6-1_F ACCACCATAAGAAAAAATATGAACTTC 448 
EPDR1_6-1_R TCTGTAAACAGAGCTTGAGTAGTCA  
EPDR1_6-2_F CAGCTGGAGATGGATATGAGACTAG 404 
EPDR1_6-2_R GGGCATTCTCTGCAGGGAATTTAAGA  
EPDR1_6-3_F AGAAGTTTGCCTTGGCAGCAAGTATT 420 
EPDR1_6-3_R GCACATACATCAATACTCTTGCATAG  
EPDR1_6-4_F GGCAGTTTAGAGAATCCTAATGTCT 450 
EPDR1_6-4_R GTACCCAAGGAGCTCACAGCCAAGAT  
EPDR1_6-5_F GTTGCACCTTGCATCTTGAGCATGCAT 373 
EPDR1_6-5_R AATATAGGTGTCACACATTTCTCCTGG  
EPDR1_6-6_F CTATTCTAGATGCTTCTACTGTTATG 356 
EPDR1_6-6_R AAATGGATCAAGAATGACTTGGAAGC  
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Table 32. Primer for qPCR. 
primer name primer sequence product size (bp) 
ACTA2_F ccgcaaatgcttctaaaacac 70 
ACTA2_R tccacaggacattcacagttg  
APP_F tggaagaggtggttcgagtt 60 
APP_R acttgtcaacggcatcagg  
ATP5B_F cagcagattttggcaggtg 70 
ATP5B_R cttcaatgggtcccaccata  
CASP3_F ctggttttcggtgggtgt 88 
CASP3_R ccactgagttttcagtgttctcc  
CAT_F ccatcgcagttcggttct 64 
CAT_R gggtcccgaactgtgtca  
CDH1_F cgactaggggactcgagaga 73 
CDH1_R accaccagcaacgtgatttc  
COX8A_F ggaagcttgggatcatgga 95 
COX8A_R ggtctccaggtgtgacagg  
EIF2C2_F AGAACGAGCGGGGGACAAGCA 121 
EIF2C2_R GTGCAGCGCACGTAGGTGTGA  
EIF3H_F GATGCGGAGCCTTCGCCATGT 95 
EIF3H_R CCAGGAGTGCCCGGGTAACG  
EPDR1_F agaggaaggcgctgatcc 90 
EPDR1_R tggtggcttggtcaatctg  
FZD4_F ttcacaccgctcatccagta 76 
FZD4_R tgcacattggcacataaaca  
GSK3B_F AGGTCCTGGGAACTCCAACAAGGG 118 
GSK3B_R GGAGTTCGGGGTCGGAAGACCTT  
MAFB_F agggaagctgccaagctc 67 
MAFB_R atttgaccataagacaaggctgt  
MAOA_F aacccaaaacagaatcttacgc 113 
MAOA_R cccgaaatggatatgttttcc  
MnSOD_F tgtgctttctcgtcttcagc 61 
MnSOD_R gagcccagataccccaaag  
PCDH18_F aaccacgtgccagagaattt 77 
PCDH18_R gaaagaagctgagagacctgct  
RPL19_F GGGCCCGAGCGAGCTCTTTCCTT 102 
RPL19_R TTCTTGCCACAGCGGAGGACACT  
RSPO2_F ccatccgggtactatggaca 74 
RSPO2_R gaatcacagttttctattctgcatctt  
SFRP4_F gcctgaagccatcgtcac 68 
SFRP4_R ccatcatgtctggtgtgatgt  
SOD1_F ccatgttcatgagtttggagataa 73 
SOD1_R tctggatagaggattaaagtgagga  
THBS4_F gctccagcttctacgtggtc 125 
THBS4_R ccctggacctgtcttagacttc  
WNT2_F tttggcagggtcctactcc 87 
WNT2_R cctggtgatggcaaatacaa  
WNT7B_F CCATCTGCCAGAGTCGGCCCGATG 110 
WNT7B_R GGCAGAGCAGTTCCAGCGTCCGAAG  
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7.3 GWAS detailed Results 
Table 33. GWAS detailed results 186 cases compared with 1618 controls. 
            
CHR SNP POSITION UNADJ GC QQ BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
1 rs1890024 162,115,263-162,116,263 1.30E-10 1.14E-09 7.49E-02 9.26E-05 9.26E-05 9.26e-08 9.26E-05 1.72E-06 2.41E-05 
1 rs12126332 162,600,414-162,601,414 3.90E-07 1.86E-06 0.0001672 0.0002785 0.0002785 0.0002785 0.0002784 2.31E-03 3.25E-02 
1 rs6674453 19,433,112-19,434,112 1.74E-07 8.82E-07 0.0001434 0.0001246 0.0001246 0.0001246 0.0001246 1.21e-06 1.70E-02 
1 rs7554574 81,460,797-81,461,797 1.71E-06 7.26E-06 0.0002022 0.001219 0.001219 0.001219 0.001218 8.41e-06 0.0001182 
1 rs11586072 81,986,661-81,987,661 6.67e-06 1.52E-02 0.0004135 1 1 0.9915 0.9915 0.01611 0.2264 
1 rs10913320 177,364,005-177,365,005 4.16E-10 3.34E-09 8.05E-02 2.98E-04 2.98E-04 2.98E-04 2.98E-04 5.13E-06 7.21E-05 
1 rs6540808 214,103,271-214,104,271 3.47E-07 1.67E-06 0.000163 0.0002478 0.0002477 0.0002477 0.0002477 2.12E-03 2.98E-02 
1 rs1833040 216,771,072-216,772,072 5.21E-03 1.21E-02 0.0004023 1 1 0.9759 0.9759 0.01294 0.1818 
1 rs11117808 217,396,292-217,397,292 3.37E-03 8.09E-03 0.0003771 1 1 0.9098 0.9097 0.008908 0.1252 
1 rs17047589 218,475,630-218,476,630 1.93E-04 5.74E-04 0.0002903 0.1377 0.1377 0.1287 0.1286 0.0006621 0.009307 
1 rs16849180 229,044,392-229,045,392 7.34E-10 5.64E-09 8.19E-02 5.25E-04 5.25E-04 5.25E-04 5.25E-04 8.89E-06 1.25e-07 
2 rs17046473 24,906,139-24,907,139 1.21E-08 7.48E-08 0.000107 8.62E-03 8.62e-06 8.62E-03 8.62e-06 1.12e-07 1.57E-03 
2 rs13392392 42,053,778-42,054,778 3.80E-10 3.07E-09 7.63E-02 2.72E-04 2.72E-04 2.71E-04 2.71E-04 4.94E-06 6.94E-05 
2 rs4510173 160,660,607-160,661,607 2.45E-06 1.01E-05 0.0002106 0.001749 0.001748 0.001747 0.001747 1.16E-02 0.0001628 
2 rs12617336 162,848,812-162,849,812 5.45E-09 3.59E-08 9.31E-02 3.89E-03 3.89E-03 3.89E-03 3.89E-03 5.81E-05 8.17E-04 
2 rs2060198 166,244,730-166,245,730 9.07E-04 2.40E-03 0.0003365 0.6482 0.648 0.477 0.4769 0.00269 0.03781 
2 rs41376445 171,427,778-171,428,778 2.02E-05 7.12E-05 0.0002442 0.01441 0.0144 0.0143 0.0143 8.23e-05 0.001157 
2 rs10803852 171,665,209-171,666,209 3.35E-03 8.05E-03 0.0003757 1 1 0.9088 0.9087 0.008903 0.1252 
2 rs7601760 177,647,997-177,648,997 3.17E-11 3.10E-10 7.21E-02 2.27E-05 2.27E-05 2.27E-05 2.27E-05 4.36E-07 6.13E-06 
2 rs6731229 239,315,047-239,316,047 4.75e-14 4.50E-10 7.35E-02 3.40E-05 3.40E-05 3.40E-05 3.40E-05 6.41E-07 9.00E-06 
3 rs17582553 21,985,331-21,986,331 1.39E-12 1.73E-11 6.51E-02 9.96E-07 9.96E-07 1.03E-06 1.03E-06 2.12E-08 2.98E-07 
3 rs11718264 109,472,195-109,473,195 1.41E-06 6.07E-06 0.0001966 0.001004 0.001004 0.001004 0.001003 7.12E-03 0.0001001 
3 rs16856504 109,950,602-109,951,602 1.06e-07 3.30E-04 0.0002777 0.07575 0.07573 0.07295 0.07293 0.0003796 0.005336 
 
CHR: chromosom; SNP: single nucleotide polymorphism identifier; POSITION: chromosomal localisation of the SNP (base pair position); UNADJ: unadjusted P-value, GC: ; QQ: ; BONF: P-value after 
Bonferroni correction; HOLM: P-value after Holm-Bonferroni correction; SIDAK: P-value after Šidák correction; FDR: . 
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Table 33 continued. 
            
CHR SNP POSITION UNADJ GC QQ BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
4 rs16839778 7,174,191-7,175,191 7.36E-08 3.98E-07 0.0001266 5.26E-02 5.26E-02 5.26E-02 5.26E-02 5.78E-04 8.12E-03 
4 rs10213406 7,906,827-7,907,827 1.11E-05 4.11e-08 0.0002358 0.007955 0.007953 0.007923 0.007921 4.71E-02 0.0006616 
4 rs6825629 12,572,878-12,573,878 3.92E-10 3.16E-09 7.77E-02 2.8e-07 2.8e-07 2.8e-07 2.8e-07 5.00E-06 7.03E-05 
5 rs36791 109,329,695-109,330,695 8.24E-04 2.2e-06 0.0003337 0.589 0.5888 0.4451 0.445 0.002465 0.03464 
5 rs17131910 109,630,471-109,631,471 3.81E-06 1.53E-05 0.0002148 0.002724 0.002723 0.00272 0.002719 1.77E-02 0.0002486 
6 rs478791 10,774,946-10,775,946 1.77E-03 4.45E-03 0.0003533 1 1 0.7169 0.7168 0.004988 0.07011 
6 rs6936890 10,784,763-10,785,763 9.68E-03 2.15e-05 0.000447 1 1 0.999 0.999 0.02163 0.304 
6 rs9366776 31,256,130-31,257,130 7.40E-03 1.68E-02 0.0004205 1 1 0.995 0.995 0.01758 0.2471 
6 rs2068204 33,058,218-33,059,218 9.89E-06 3.69E-05 0.0002302 0.007071 0.007069 0.007046 0.007044 4.29E-02 0.0006024 
6 rs929052 36,714,194-36,715,194 2.07E-08 1.23E-07 0.000114 1.48E-02 1.48E-02 1.48E-02 1.48E-02 1.80E-04 2.53E-03 
6 rs12661480 37,962,808-37,963,808 3.28E-04 9.39E-04 0.0003043 0.2347 0.2346 0.2092 0.2091 0.001076 0.01513 
7 rs10085558 37,984,780-37,985,780 5.11E-05 1.68E-04 0.0002609 0.03653 0.03652 0.03587 0.03586 0.0001953 0.002746 
7 rs16879765 37,988,595-37,989,595 8.54E-04 2.27E-03 0.0003351 0.6102 0.61 0.4568 0.4566 0.002542 0.03574 
7 rs2044830 38,023,904-38,024,904 3.76E-03 8.95E-03 0.0003883 1 1 0.9317 0.9316 0.009655 0.1357 
7 rs17171240 38,024,074-38,025,074 8.07E-03 1.82E-02 0.0004274 1 1 0.9969 0.9969 0.01885 0.265 
8 rs13260434 3,225,724-3,226,724 4.60E-03 1.08E-02 0.0003925 1 1 0.9626 0.9626 0.0117 0.1644 
8 rs2623668 3,644,185-3,645,185 1.66E-04 4.99E-04 0.0002861 0.1185 0.1185 0.1118 0.1117 0.0005781 0.008126 
8 rs11777623 75,897,198-75,898,198 6.25E-14 9.83E-13 6.23E-02 4.47E-08 4.47E-08 7.94E-08 7.93E-08 9.92E-10 1.40E-08 
8 rs10875382 136,800,559-136,801,559 6.66E-07 3.05E-06 0.0001784 0.0004762 0.0004761 0.0004761 0.000476 3.72e-06 5.23e-05 
9 rs7032394 2,159,878-2,160,878 2.04E-05 7.19e-08 0.000247 0.01457 0.01456 0.01446 0.01446 8.23e-05 0.001157 
9 rs7032831 2,160,192-2,161,192 3.03E-05 1.04E-04 0.000254 0.02168 0.02168 0.02145 0.02144 0.0001191 0.001675 
            
CHR: chromosom; SNP: single nucleotide polymorphism identifier; POSITION: chromosomal localisation of the SNP (base pair position); UNADJ: unadjusted P-value, GC: ; QQ: ; BONF: P-value after 
Bonferroni correction; HOLM: P-value after Holm-Bonferroni correction; SIDAK: P-value after Šidák correction; FDR: . 
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Table 33 continued. 
 
CHR SNP POSITION UNADJ GC QQ BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
9 rs10963171 17,635,927-17,636,927 1.12e-11 6.99E-08 0.0001056 8.00E-03 8.00E-03 8.00E-03 8.00E-03 1.05E-04 1.48e-06 
9 rs7851959 20,307,666-20,308,666 4.04E-10 3.25E-09 7.91E-02 2.89E-04 2.89E-04 2.89E-04 2.89E-04 5.07E-06 7.12E-05 
9 rs35517812 110,970,886-110,971,886 8.37E-03 1.88E-02 0.000433 1 1 0.9975 0.9975 0.0193 0.2713 
9 rs7849991 111,278,442-111,279,442 9.46E-03 2.11E-02 0.0004428 1 1 0.9988 0.9988 0.02134 0.2999 
9 rs10759289 111,280,824-111,281,824 8.91E-03 1.99e-05 0.0004358 1 1 0.9983 0.9983 0.02041 0.2869 
9 rs10759290 111,280,841-111,281,841 6.42E-03 1.47E-02 0.0004107 1 1 0.9899 0.9898 0.01562 0.2195 
9 rs7863555 123,185,097-123,186,097 2.58E-12 3.05e-14 6.79E-02 1.84E-06 1.84E-06 1.83E-06 1.83E-06 3.76E-08 5.29E-07 
10 rs16924545 24,597,740-24,598,740 2.36E-12 2.81E-11 6.65E-02 1.69E-06 1.69E-06 1.67E-06 1.67E-06 3.51E-08 4.94E-07 
10 rs745947 106,532,460-106,533,460 5.03E-04 1.39E-03 0.0003169 0.3597 0.3596 0.3021 0.302 0.001585 0.02227 
10 rs1349624 106,830,602-106,831,602 5.00E-06 1.96E-05 0.0002176 0.003576 0.003575 0.003569 0.003568 2.29E-02 0.0003222 
10 rs12415432 129,743,645-129,744,645 3.89e-16 5.32E-12 6.37E-02 2.78e-10 2.78e-10 3.17E-07 3.17E-07 6.05E-09 8.50E-08 
11 rs501560 111,395,783-111,396,783 2.06E-03 5.13E-03 0.0003575 1 1 0.7701 0.7699 0.005742 0.08071 
11 rs10891927 116,080,697-116,081,697 5.12E-03 1.19E-02 0.0003995 1 1 0.9742 0.9741 0.01278 0.1797 
11 rs11216534 117,628,968-117,629,968 1.21e-10 6.30E-07 0.0001322 8.65E-02 8.65E-02 8.65E-02 8.64E-02 9.10E-04 1.28E-02 
11 rs11216674 117,879,639-117,880,639 5.67E-04 1.56E-03 0.0003211 0.4053 0.4052 0.3333 0.3332 0.001762 0.02477 
11 rs12225323 117,920,077-117,921,077 3.03E-04 8.71E-04 0.0003015 0.2164 0.2163 0.1946 0.1945 0.001002 0.01408 
12 rs12321570 69,161,743-69,162,743 1.16E-11 1.22E-10 6.93E-02 8.29E-06 8.29E-06 8.25E-06 8.25E-06 1.66E-07 2.33e-09 
15 rs9806619 47,471,900-47,472,900 7.49e-09 2.85e-08 0.0002218 0.005353 0.005352 0.005339 0.005337 3.37E-02 0.0004732 
15 rs16960559 48,379,619-48,380,619 4.17E-05 1.39E-04 0.0002567 0.02978 0.02977 0.02934 0.02934 0.0001619 0.002275 
15 rs8029891 50,439,732-50,440,732 1.55E-06 6.64e-09 0.000198 0.001107 0.001107 0.001106 0.001106 7.80E-03 0.0001096 
15 rs6493942 57,962,582-57,963,582 2.00E-09 1.42E-08 8.89E-02 1.43E-03 1.43E-03 1.43E-03 1.43E-03 2.23E-05 3.14E-04 
15 rs16944662 62,127,757-62,128,757 1.25E-06 5.45E-06 0.0001938 0.000894 0.0008938 0.0008936 0.0008934 6.43E-03 9.04e-05 
15 rs4390546 63,208,686-63,209,686 9.51E-06 3.55E-05 0.0002274 0.006795 0.006794 0.006772 0.006771 4.17E-02 0.000586 
15 rs1385951 65,215,457-65,216,457 5.76E-22 3.76E-20 4.27E-02 4.12E-16 4.12E-16 INF INF 1.33E-17 1.87E-16 
15 rs11856313 73,859,989-73,860,989 2.30E-11 2.30E-10 7.07E-02 1.65E-05 1.65E-05 1.64E-05 1.64E-05 3.23E-07 4.54E-06 
            
CHR: chromosom; SNP: single nucleotide polymorphism identifier; POSITION: chromosomal localisation of the SNP (base pair position); UNADJ: unadjusted P-value, GC: ; QQ: ; BONF: P-value after 
Bonferroni correction; HOLM: P-value after Holm-Bonferroni correction; SIDAK: P-value after Šidák correction; FDR: . 
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Table 33 continued. 
 
CHR SNP POSITION UNADJ GC QQ BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
16 rs1833203 53,390,957-53,391,957 5.61E-08 3.10E-07 0.0001238 4.01E-02 4.01E-02 4.01E-02 4.01E-02 4.51E-04 6.33E-03 
16 rs2077576 78,338,264-78,339,264 2.51E-03 6.17E-03 0.0003617 1 1 0.8339 0.8338 0.006931 0.09743 
16 rs2738694 78,518,357-78,519,357 4.40E-16 1.01E-14 5.25E-02 3.14E-10 3.14E-10 INF INF 8.27E-12 1.16E-10 
16 rs8052047 79,812,854-79,813,854 2.41E-209 5.29E-193 3.50E-03 1.72E-203 1.72E-203 INF INF 5.75E-204 8.08E-203 
16 rs41338245 80,834,241-80,835,241 3.20E-04 9.16e-07 0.0003029 0.2284 0.2283 0.2042 0.2041 0.001052 0.01479 
16 rs804902 81,104,465-81,105,465 2.09E-08 1.25E-07 0.0001154 1.50E-02 1.50E-02 1.50E-02 1.50E-02 1.80E-04 2.53E-03 
16 rs8058531 83,103,555-83,104,555 1.60E-07 8.16E-07 0.0001406 0.0001145 0.0001145 0.0001145 0.0001145 1.13E-03 1.59E-02 
17 rs3744171 76,993,397-76,994,397 6.21E-05 2.02E-04 0.0002637 0.04441 0.0444 0.04344 0.04343 0.000235 0.003303 
23 rs6421524 2,010,440-2,011,440 3.69E-03 8.80E-03 0.0003841 1 1 0.9284 0.9283 0.009575 0.1346 
23 rs5982585 2,357,640-2,358,640 9.34E-04 2.47e-06 0.0003379 0.6675 0.6673 0.487 0.4869 0.002758 0.03877 
23 rs311100 2,660,593-2,661,593 6.47e-07 1.76E-03 0.0003225 0.4624 0.4622 0.3702 0.3701 0.001994 0.02803 
23 rs7889262 32,007,938-32,008,938 2.96e-07 8.53E-04 0.0002987 0.2115 0.2115 0.1907 0.1906 0.0009885 0.01389 
23 rs553369 154,962,939-154,963,939 1.96E-04 5.82E-04 0.0002931 0.1398 0.1398 0.1305 0.1305 0.0006658 0.009359 
            
CHR: chromosom; SNP: single nucleotide polymorphism identifier; POSITION: chromosomal localisation of the SNP (base pair position); UNADJ: unadjusted P-value, GC: ; QQ: ; BONF: P-value after 
Bonferroni correction; HOLM: P-value after Holm-Bonferroni correction; SIDAK: P-value after Šidák correction; FDR: . 
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7.4 Whole Genome Expression Analysis detailed Results 
Table 34. Wnt/β-catenin signalling pathway components. 
          
SYMBOL 
case 
Signal 
case 
STDEV case Pval 
Control 
Signal 
control 
STDEV 
control 
Pval DiffScore 
Fold 
change CHR 
WNT11 24.7 17.5 0.0079 87.5 31.4 0 33.94 -3.54 11 
RSPO3 131.7 176.3 0 420.6 196.9 0 17.40 -3.19 6 
SOX8 77.5 62.1 0 226.1 136.2 0 14.78 -2.92 16 
TLE1 42.2 24.8 0.0026 105.3 21.3 0 38.15 -2.50 9 
TCF7L1 50.4 24.1 0 111.2 39.8 0 22.82 -2.21 2 
FRAT1 9.1 3.5 0.0017 16.7 8.8 0.0002 9.72 -1.83 10 
TCF7L2 55.6 33.9 0 99.7 30.8 0 13.99 -1.79 10 
SFRP1 1548.9 1440.2 0 2567.3 971.6 0 5.59 -1.66 8 
SOX9 158.8 142.6 0 256.2 227.0 0 2.37 -1.61 17 
LRP5 164.9 82.6 5.55E-05 258.3 64.9 8.68E-07 10.80 -1.57 11 
TLE3 41.7 19.9 0.0026 64.9 32.7 0 5.92 -1.55 15 
LRP1 126.2 43.6 0 194.1 63.6 0 11.95 -1.54 12 
VEGFA 19.3 8.1 0.1214 29.2 12.1 0.0832 9.23 -1.51 6 
MARK2 10.9 6.7 0.0082 16.1 7.9 0.0006 2.63 -1.47 11 
VEGFB 817.5 132.6 0.0370 1192.8 281.2 0.0305 11.15 -1.46  
BTRC 6.9 4.4 0.0099 10.0 3.9 0.0072 2.00 -1.44 10 
TGFBR3 1763.6 731.5 0 2497.2 398.4 0 11.97 -1.42 1 
SOX13 148.9 65.4 0 195.8 80.6 0 3.43 -1.32 1 
WNT2 23.6 13.1 0.0079 30.4 30.0 0.0013 1.02 -1.29 7 
MAP4K1 14.8 7.0 0.0004 18.9 13.4 0.0001 1.53 -1.28 19 
TLE2 176.6 78.6 0 218.6 96.7 0 2.11 -1.24 19 
MAP4K2 201.7 54.1 0 244.6 35.0 0 7.07 -1.21 11 
SOX10 27.6 25.2 0.0053 32.6 34.7 0.0013 0.48 -1.18 22 
PIN1 909.3 191.2 0 1060.0 184.8 0 5.24 -1.17 19 
MAP3K7IP1 29.2 11.4 0.0231 34.0 8.7 0.0013 4.67 -1.16 22 
TCF15 7.6 4.4 0.0303 8.8 5.5 0.0250 0.77 -1.15 20 
WNT16 6.5 2.4 0.0099 7.4 3.7 0.0173 0.66 -1.13 7 
PPARD 18.2 5.1 0.0013 20.5 8.1 0.0018 0.56 -1.13 6 
LRP6 16.4 7.0 0.0105 18.4 13.0 0.0092 0.58 -1.12 12 
SRC 87.5 28.9 0.1364 92.0 34.9 0.0617 0.75 -1.05 20 
NR5A2 17.3 8.0 0.0199 18.1 6.1 0.0096 0.43 -1.05 1 
CCND1 2075.3 628.2 0 2171.5 990.7 0 0.31 -1.05 11 
UBB 6503.8 981.1 0 6796.1 1076.2 0 1.17 -1.04 17 
DVL3 287.0 79.4 0 298.6 85.3 0 0.38 -1.04 3 
WNT2B 10.7 4.8 0.0006 11.1 6.3 0.0005 0.11 -1.03 1 
TCF25 704.1 196.3 0 721.1 179.7 0 0.23 -1.02 16 
AKT1 818.8 224.1 9.99E-05 832.7 129.4 0.0031 -0.53 -1.02 14 
SOX14 8.2 3.6 0.0224 8.3 4.3 0.0264 0.05 -1.01 3 
UBC 8910.0 647.0 7.50E-06 8820.6 699.1 2.44E-05 -0.98 1.01 12 
MAP4K3 55.7 18.5 0 54.9 19.4 0 -0.09 1.01 2 
          
Given is a selection of genes involved in or affected by the Wnt/β-catenin canonical pathway and 
expressed in DD (case) and control connective tissue. Signal: detection signal mean, STDEV: standard 
derivation from signal mean (N = 12), Pval: detection p-value. Genes are sorted by expression fold 
change, genes with the lowest fold change at the top. 
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Table 34 continued. 
          
SYMBOL 
case 
Signal 
case 
STDEV case Pval 
Control 
Signal 
control 
STDEV 
control 
Pval DiffScore 
Fold 
change CHR 
AXIN1 147.6 16.3 0.0113 144.0 20.2 0.0098 -0.11 1.03 16 
RUVBL2 149.5 45.4 0 143.0 74.8 0 -0.28 1.05 19 
DVL1 8.3 6.4 0.0446 7.9 6.2 0.0572 -0.50 1.06 1 
NFKB1 1008.7 149.0 0 917.0 147.4 0 -3.25 1.10 4 
APPL1 35.4 9.6 0.0040 32.0 7.8 0.0013 -1.48 1.10 3 
NLK 7.3 4.6 0.0316 6.6 5.3 0.0290 -0.39 1.11 17 
EP300 173.9 47.1 0 157.1 56.4 0 -1.17 1.11 22 
HDAC1 728.3 128.1 0 657.0 115.7 0 -2.94 1.11 1 
TGFBRAP1 124.0 61.9 0 110.1 56.8 0 -0.75 1.13 2 
ILK 763.6 163.5 0.0025 674.2 110.8 0.0224 -2.01 1.13 11 
MAP3K7IP2 6.1 3.1 0.0064 5.3 2.3 0.0048 -1.07 1.16 6 
RARA 135.4 50.9 0.1332 112.9 50.0 0.0321 0.14 1.20 17 
TCFL5 258.9 76.2 0 211.4 37.5 0 -5.11 1.22 20 
CSNK1A1 77.9 17.9 1.05E-06 63.4 10.5 1.05E-06 -4.67 1.23 5 
TGFBR2 1419.2 430.7 1.95E-07 1125.5 261.7 8.23E-08 -3.64 1.26 3 
DVL2 139.1 16.1 0 109.5 16.2 0 -22.59 1.27 17 
JUN 1040.6 541.8 0 770.2 233.2 0 -3.53 1.35 1 
WNT5B 53.0 25.2 0.3166 36.9 18.3 0.4120 -2.75 1.43 12 
MMP7 383.4 473.6 0 266.0 362.8 0 -0.95 1.44 11 
MAP3K7 204.4 63.4 3.47E-06 141.2 25.4 7.81E-06 -10.42 1.45 6 
TCF3 143.1 41.6 0 98.4 31.3 0 -11.47 1.46 19 
WISP2 1426.6 1009.7 0 977.0 473.6 0 -2.81 1.46 20 
TCF20 79.1 8.0 0.0010 53.8 9.8 0.0009 -13.92 1.47 22 
FRAT2 239.0 38.2 0 162.1 37.9 0 -26.00 1.47 10 
CDH5 697.2 307.5 0 469.7 113.6 0 -7.71 1.48 16 
APPL2 719.3 209.0 0 468.8 143.2 0 -14.69 1.53 12 
TCF4 798.8 159.5 0 519.0 89.5 0 -28.63 1.54 18 
GSK3B 165.1 70.8 0 106.5 34.4 0 -8.77 1.55 3 
PPP2R4 140.4 58.7 0.0060 90.3 16.7 0.0150 -4.42 1.55 9 
BCL9 89.7 27.4 0 56.9 9.9 0 -18.23 1.58 1 
CD44 2037.1 313.5 3.05E-09 1251.3 504.8 0 -12.80 1.63 11 
SOX17 55.8 19.3 0 33.6 13.9 0.0013 -13.26 1.66 8 
AXIN2 486.7 113.7 0 291.9 90.3 0 -23.78 1.67 17 
RSPO2 23.4 14.0 0.0008 13.9 5.7 0.4638 -5.89 1.68 8 
TGFB1I1 152.3 72.8 0 87.0 44.1 8.68E-07 -7.27 1.75 16 
SOX18 1485.9 1002.7 0 847.8 337.6 0 -5.91 1.75 20 
WNT5A 44.2 30.6 0.0026 24.5 13.5 0.0040 -5.59 1.80 3 
CDH1 266.5 381.4 0 141.1 204.6 0 -1.65 1.89 16 
TLE4 109.6 29.8 2.17E-05 57.7 11.0 7.03E-05 -22.80 1.90 9 
SOX7 101.7 77.9 5.55E-05 52.8 21.9 8.68E-05 -4.40 1.92 8 
SOX12 16.6 14.0 0.0105 8.6 4.0 0.0237 -4.95 1.93 20 
MAP4K5 112.1 32.3 4.25E-05 57.8 22.7 0.0004 -18.93 1.94 14 
WNT4 11.6 14.1 0.0171 5.9 5.9 0.0329 -2.48 1.97 1 
MYC 217.4 100.7 3.47E-06 109.5 20.9 1.39E-05 -14.92 1.99 8 
          
Given is a selection of genes involved in or affected by the Wnt/β-catenin canonical pathway and 
expressed in DD (case) and control connective tissue. Signal: detection signal mean, STDEV: standard 
derivation from signal mean (N = 12), Pval: detection p-value. Genes are sorted for expression fold 
change, genes with the lowest fold change at the top. 
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Table 34 continued. 
          
SYMBOL 
case 
Signal 
case 
STDEV case Pval 
Control 
Signal 
control 
STDEV 
control 
Pval DiffScore 
Fold 
change CHR 
SOX15 119.3 68.1 0 59.9 37.4 0 -9.24 1.99 17 
CTNNB1 61.2 28.3 0.0038 30.4 9.7 0.0096 -5.05 2.01  
TP53 45.0 23.7 0.0026 22.2 19.6 0.0053 -8.70 2.03 17 
TCF12 242.6 74.5 3.96E-05 112.9 17.6 0.0005 -22.13 2.15 15 
KREMEN1 40.1 21.5 0.0002 17.6 9.1 0.0004 -9.21 2.28 22 
APP 1185.6 448.2 0 512.3 174.1 2.44E-08 -21.62 2.31 21 
WNT3 23.7 15.8 0.0079 9.6 8.5 0.0224 -9.77 2.47 17 
UBD 36.5 30.5 0.0026 14.0 11.4 0.0119 -7.65 2.61 6 
VEGFC 123.6 34.4 0 47.4 19.0 0 -38.21 2.61 4 
MAP4K4 295.7 74.2 0.0009 111.8 18.9 0.0053 -30.38 2.65 2 
SFRP4 1557.9 506.2 4.25E-05 581.9 730.9 0.0009 -16.71 2.68 7 
TGFBR1 6.4 3.5 0.0369 2.2 5.0 0.1594 -7.32 2.87 9 
DKK3 1502.4 343.6 0.0016 491.0 453.5 0.0164 -22.09 3.06 11 
CDH3 67.8 48.4 0 22.0 32.8 0.0040 -9.66 3.08 16 
SOX4 110.6 44.0 0 31.4 15.0 0.0013 -32.88 3.52 6 
TGFBI 9670.5 5813.0 0 2352.2 1504.2 0 -20.69 4.11 5 
WNT7B 10.7 12.9 0.1201 2.5 2.6 0.3283 -4.58 4.19 22 
TGFB3 1300.1 494.9 0 261.9 143.4 0 -39.82 4.96 14 
SFRP2 1486.9 763.0 0 257.5 180.4 0 -29.56 5.78 4 
GJA1 1005.3 595.5 0 173.6 80.7 0 -24.88 5.79 6 
DKK2 21.9 15.4 0.0001 3.6 2.7 0.1156 -18.96 6.06 4 
LEF1 58.6 36.5 3.47E-06 8.6 3.3 0.0115 -23.18 6.79 4 
CDH2 174.7 175.7 0 17.4 7.5 0.0092 -12.30 10.03 18 
TGFB2 133.2 93.5 0 12.0 9.9 0.0145 -22.42 11.12 1 
SOX21 27.2 58.7 0.0053 1.8 3.3 0.2240 -3.18 15.25 13 
WISP1 125.6 75.7 0.0001 0.3 5.3 0.4437 -28.66 380.60 8 
          
Given is a selection of genes involved in or affected by the Wnt/β-catenin canonical pathway and 
expressed in DD (case) and control connective tissue. Signal: detection signal mean, STDEV: standard 
derivation from signal mean (N = 12), Pval: detection p-value. Genes are sorted for expression fold 
change, genes with the lowest fold change at the top. 
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